Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16080280,maximum plasma concentrations,"For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],3.36,2,DB00586,Diclofenac
,16080280,"C(max, 0-12)","For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],3.36,3,DB00586,Diclofenac
,16080280,"C(max, 12-24)","For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],3.73,4,DB00586,Diclofenac
,16080280,"C(max, 0-24)","For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],3.84,5,DB00586,Diclofenac
,16080280,areas under the plasma concentration-time curve (AUC),"For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],31.11,6,DB00586,Diclofenac
,16080280,AUC(0-12,"For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],31.11,7,DB00586,Diclofenac
,16080280,AUC(12.24),"For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],34.83,8,DB00586,Diclofenac
,16080280,AUC(0-24),"For the test preparation, maximum plasma concentrations of 3.36 ng/ml (C(max, 0-12)), 3.73 ng/ml (C(max, 12-24)) and 3.84 ng/ml (C(max, 0-24)) as well as areas under the plasma concentration-time curve (AUC) of 31.11 ng x h/ml (AUC(0-12), 34.83 ng x h/ml (AUC(12.24)) and 65.94 ng x h/ml (AUC(0-24)) were determined.",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],65.94,9,DB00586,Diclofenac
,16080280,"C(max, 0-12)","For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],1.55,10,DB00586,Diclofenac
,16080280,"C(max, 12-24","For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],1.45,11,DB00586,Diclofenac
,16080280,"C(max, 0-24)","For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[ng] / [ml],1.57,12,DB00586,Diclofenac
,16080280,AUC(0-12),"For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],13.28,13,DB00586,Diclofenac
,16080280,AUC(12-24),"For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],12.68,14,DB00586,Diclofenac
,16080280,AUC(0-24),"For the reference preparation, these values were 1.55 ng/ml (C(max, 0-12)), 1.45 ng/ml (C(max, 12-24) and 1.57 ng/ml (C(max, 0-24)) as well as 13.28 ng x h/ml (AUC(0-12)), 12.68 ng x h/ml (AUC(12-24)) and 25.96 ng x h/ml (AUC(0-24)).",Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080280/),[h·ng] / [ml],25.96,15,DB00586,Diclofenac
,30903395,entrapment efficiency,Stable diclofenac sodium-loaded hydroxyethyl starch nanoparticles (nanodiclo) of size 170 ± 5 nm and entrapment efficiency 72 ± 3% were prepared.,"Effect of formulation parameters on pharmacokinetics, pharmacodynamics, and safety of diclofenac nanomedicine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30903395/),%,72,267,DB00586,Diclofenac
,26724224,total clearance,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],16.00,1309,DB00586,Diclofenac
,26724224,total clearance,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],6.72,1310,DB00586,Diclofenac
,26724224,half-life,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),h,1.64,1311,DB00586,Diclofenac
,26724224,half-life,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),h,2.71,1312,DB00586,Diclofenac
,26724224,Area under the plasma concentration versus time curve (AUClast),"Area under the plasma concentration versus time curve (AUClast) in the hypothermic group was increased (33.2±11-77.8±18hng/mL, p<0.01).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[hng] / [ml],33.2,1313,DB00586,Diclofenac
,26724224,Area under the plasma concentration versus time curve (AUClast),"Area under the plasma concentration versus time curve (AUClast) in the hypothermic group was increased (33.2±11-77.8±18hng/mL, p<0.01).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[hng] / [ml],77.8,1314,DB00586,Diclofenac
,26724224,total clearance,"Moreover, mild hypothermia reduced the total clearance of diclofenac (10.33±1.53-7.20±1.66mL/min/kg, p<0.01), indicating that the CYP2C9 activity was compromised in reduced temperature.",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],10.33,1315,DB00586,Diclofenac
,26724224,total clearance,"Moreover, mild hypothermia reduced the total clearance of diclofenac (10.33±1.53-7.20±1.66mL/min/kg, p<0.01), indicating that the CYP2C9 activity was compromised in reduced temperature.",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],7.20,1316,DB00586,Diclofenac
,24607446,steady state drug flux,Ex vivo permeation across excised rabbit cornea showed an improved steady state drug flux (0.00052 mg cm(-2)min(-1)) and permeability co-efficient (1.7 × 10(-4)cmmin(-1)) for the RD-SOM compared to pure drug and a marketed eye drop preparation.,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),[mg] / [(cm)^2],0.00052,1715,DB00586,Diclofenac
,24607446,permeability co-efficient,Ex vivo permeation across excised rabbit cornea showed an improved steady state drug flux (0.00052 mg cm(-2)min(-1)) and permeability co-efficient (1.7 × 10(-4)cmmin(-1)) for the RD-SOM compared to pure drug and a marketed eye drop preparation.,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),1/[cmmin],1.7 × 10(-4),1716,DB00586,Diclofenac
,24607446,Cmax,In the case of a typical eye drop formulation a lower Cmax was obtained (1.97 ug/mL).,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),[ug] / [ml],1.97,1717,DB00586,Diclofenac
,23777257,Km,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,33,1718,DB00586,Diclofenac
,23777257,Vmax,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),1/[min],0.20,1719,DB00586,Diclofenac
,23777257,inhibition constant,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,37,1720,DB00586,Diclofenac
,23777257,maximum plasma concentration,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,10.5,1721,DB00586,Diclofenac
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00586,Diclofenac
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00586,Diclofenac
,29105796,area under the curve (AUC),Celecoxib showed the highest area under the curve (AUC) [146.50 ± 2.75 μg/mL*h] of all NSAID's.,Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105796/),[μg] / [h·ml],146.50,2654,DB00586,Diclofenac
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,2.39,4552,DB00586,Diclofenac
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,3.59,4553,DB00586,Diclofenac
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],62.7,4554,DB00586,Diclofenac
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],41.7,4555,DB00586,Diclofenac
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,5.0,5290,DB00586,Diclofenac
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.6,5291,DB00586,Diclofenac
,1681957,systemic clearance,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.0,5292,DB00586,Diclofenac
,19239400,C(max),"The mean C(max) and T(max), for the test and reference formulations were 1.95 microg/ml, 1.89 microg/ml and 0.39 h, 0.43 h respectively.",Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[μg] / [ml],1.95,7952,DB00586,Diclofenac
,19239400,T(max),"The mean C(max) and T(max), for the test and reference formulations were 1.95 microg/ml, 1.89 microg/ml and 0.39 h, 0.43 h respectively.",Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[μg] / [ml],1.89,7953,DB00586,Diclofenac
,19239400,T(max),"The mean C(max) and T(max), for the test and reference formulations were 1.95 microg/ml, 1.89 microg/ml and 0.39 h, 0.43 h respectively.",Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),h,0.39,7954,DB00586,Diclofenac
,19239400,T(max),"The mean C(max) and T(max), for the test and reference formulations were 1.95 microg/ml, 1.89 microg/ml and 0.39 h, 0.43 h respectively.",Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),h,0.43,7955,DB00586,Diclofenac
,19239400,AUC,AUC values from 0 to last measurable time point 't' observed for test and reference formulations were 3.37 microg.h/ml and 3.28 microg.h/ml respectively.,Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[h·μg] / [ml],3.37,7956,DB00586,Diclofenac
,19239400,AUC,AUC values from 0 to last measurable time point 't' observed for test and reference formulations were 3.37 microg.h/ml and 3.28 microg.h/ml respectively.,Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[h·μg] / [ml],3.28,7957,DB00586,Diclofenac
,19239400,AUC 0 - infinity,The mean AUC 0 - infinity for test and reference formulations was 3.57 microg.h/ml and 3.52 microg.h/ml.,Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[h·μg] / [ml],3.57,7958,DB00586,Diclofenac
,19239400,AUC 0 - infinity,The mean AUC 0 - infinity for test and reference formulations was 3.57 microg.h/ml and 3.52 microg.h/ml.,Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239400/),[h·μg] / [ml],3.52,7959,DB00586,Diclofenac
,7582384,bioavailability,"The dispersible formulation showed a relative extent of bioavailability between 78% and 99% (90% CI) for the AUC0-infinity, being the 90% CI for the Cmax 63%-129%.",Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582384/),%,78,9582,DB00586,Diclofenac
,7582384,bioavailability,"The dispersible formulation showed a relative extent of bioavailability between 78% and 99% (90% CI) for the AUC0-infinity, being the 90% CI for the Cmax 63%-129%.",Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582384/),%,99,9583,DB00586,Diclofenac
,11996501,flow-rate,"Samples were eluted with a mobile phase containing 100 mM sodium dihydrogenphosphate (pH 3.1)-acetonitrile (30:70, v/v), and the flow-rate of the mobile phase was 0.05 ml/min.",Determination of diclofenac in rat bile and its interaction with cyclosporin A using on-line microdialysis coupled to liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996501/),[ml] / [min],0.05,9819,DB00586,Diclofenac
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],0.1,10506,DB00586,Diclofenac
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],2.0,10507,DB00586,Diclofenac
,22491166,shelf lives,The obtained shelf lives of all formulations ranged from 3.38-4.92 years.,"Stability, bioavailability, and ulcerative activity of diclofenac sodium-mastic controlled release tablets. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491166/),years,3.38-4.92,10839,DB00586,Diclofenac
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,1.11,15134,DB00586,Diclofenac
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,0.99,15135,DB00586,Diclofenac
,29368187,IC50,"EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively.",Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368187/),μM,2.23,15169,DB00586,Diclofenac
,29368187,IC50,"EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively.",Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368187/),μM,48.04,15170,DB00586,Diclofenac
,11902803,Plasma,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,1.0,16784,DB00586,Diclofenac
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,1.6,16785,DB00586,Diclofenac
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,2.0,16786,DB00586,Diclofenac
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,4.2,16787,DB00586,Diclofenac
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,3.9,16788,DB00586,Diclofenac
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,20.9,16789,DB00586,Diclofenac
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,4.2,16790,DB00586,Diclofenac
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,3.9,16791,DB00586,Diclofenac
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,20.9,16792,DB00586,Diclofenac
,11902803,Permeability-surface area (PS),Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],0.02-0.40,16793,DB00586,Diclofenac
,11902803,permeation clearances (CL(PI)),Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],0.02-0.40,16794,DB00586,Diclofenac
,11902803,fractions,Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],41.8 to 0.10,16795,DB00586,Diclofenac
,26642661,flow rate,"Chromatographic separation of DIC, PAP and the IS was achieved on a Zorbax SB C18 5-µm column (150 mm x 4.6 mm) using methanol-water (55:45, v/v) as mobile phase at a flow rate of 0.8 mL/min.",PHARMACOKINETICS OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE AFTER ORAL ADMINISTRATION OF TABLETS TO RABBITS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642661/),[ml] / [min],0.8,17050,DB00586,Diclofenac
,21660124,total run time,Samples were injected in an online-SPE-LC-ESI-MS/MS setup allowing a total run time of only 126 s for a full gradient separation.,Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),s,126,17849,DB00586,Diclofenac
,21660124,peak width (FWHM,DCF eluted at stable retention times (±0.33%) with narrow peak width (FWHM 3.3 ± 0.15 s).,Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),s,3.3,17850,DB00586,Diclofenac
,21660124,limit of detection,"The method displays excellent analytical performance, with a limit of detection of 6 fmol on column, a linear range of over four orders of magnitude and a negligible carry over of 0.12 ± 0.03% for DCF.",Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),fmol,6,17851,DB00586,Diclofenac
,21660124,carry over,"The method displays excellent analytical performance, with a limit of detection of 6 fmol on column, a linear range of over four orders of magnitude and a negligible carry over of 0.12 ± 0.03% for DCF.",Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),%,0.12,17852,DB00586,Diclofenac
,25557368,Cmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),[μg] / [ml],2.06,21178,DB00586,Diclofenac
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,1,21179,DB00586,Diclofenac
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,159.72,21180,DB00586,Diclofenac
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),[μg] / [ml],2.01,21181,DB00586,Diclofenac
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,352.76,21182,DB00586,Diclofenac
,25557368,relative bioavailability,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,352.76,21183,DB00586,Diclofenac
,26816910,Cmax,"Mean Cmax after administration of Dynapar QPS(®) and diclofenac emulgel were 175.93 and 40.04 ng/ml, respectively.",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[ng] / [ml],175.93,21721,DB00586,Diclofenac
,26816910,Cmax,"Mean Cmax after administration of Dynapar QPS(®) and diclofenac emulgel were 175.93 and 40.04 ng/ml, respectively.",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[ng] / [ml],40.04,21722,DB00586,Diclofenac
,26816910,Tmax,Tmax of diclofenac was almost half with QPS compared to emulgel (5.24 hrs versus 9.53 hrs respectively).,Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),h,5.24,21723,DB00586,Diclofenac
,26816910,Tmax,Tmax of diclofenac was almost half with QPS compared to emulgel (5.24 hrs versus 9.53 hrs respectively).,Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),h,9.53,21724,DB00586,Diclofenac
,26816910,AUC0-t,"The mean AUC0-t and AUC0-∞ after administration of Dynapar QPS(®) was higher as compared to diclofenac emulgel (AUC0-t: 1224.19 versus 289.78 ng.h/ml, respectively; AUC0-∞: 1718.21 versus 513.83 ng.h/ml, respectively).",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[h·ng] / [ml],1224.19,21725,DB00586,Diclofenac
,26816910,AUC0-t,"The mean AUC0-t and AUC0-∞ after administration of Dynapar QPS(®) was higher as compared to diclofenac emulgel (AUC0-t: 1224.19 versus 289.78 ng.h/ml, respectively; AUC0-∞: 1718.21 versus 513.83 ng.h/ml, respectively).",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[h·ng] / [ml],289.78,21726,DB00586,Diclofenac
,26816910,AUC0-∞,"The mean AUC0-t and AUC0-∞ after administration of Dynapar QPS(®) was higher as compared to diclofenac emulgel (AUC0-t: 1224.19 versus 289.78 ng.h/ml, respectively; AUC0-∞: 1718.21 versus 513.83 ng.h/ml, respectively).",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[h·ng] / [ml],1718.21,21727,DB00586,Diclofenac
,26816910,AUC0-∞,"The mean AUC0-t and AUC0-∞ after administration of Dynapar QPS(®) was higher as compared to diclofenac emulgel (AUC0-t: 1224.19 versus 289.78 ng.h/ml, respectively; AUC0-∞: 1718.21 versus 513.83 ng.h/ml, respectively).",Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26816910/),[h·ng] / [ml],513.83,21728,DB00586,Diclofenac
,24342124,AUC,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],139.70,22350,DB00586,Diclofenac
,24342124,Cmax,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],42.99,22351,DB00586,Diclofenac
,24342124,CLoral,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.08,22352,DB00586,Diclofenac
,24342124,Cmax,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],7.80,22353,DB00586,Diclofenac
,24342124,AUC,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],56.46,22354,DB00586,Diclofenac
,24342124,Vd/F,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [kg],7.55,22355,DB00586,Diclofenac
,24342124,CLoral,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.58,22356,DB00586,Diclofenac
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[μg] / [ml],20,23157,DB00586,Diclofenac
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[counts] / [ml],10,23158,DB00586,Diclofenac
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0053,23159,DB00586,Diclofenac
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0096,23160,DB00586,Diclofenac
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.024,23161,DB00586,Diclofenac
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.055,23162,DB00586,Diclofenac
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.0,23163,DB00586,Diclofenac
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,<,23164,DB00586,Diclofenac
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.01,23165,DB00586,Diclofenac
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.34,23166,DB00586,Diclofenac
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.85,23167,DB00586,Diclofenac
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0,23168,DB00586,Diclofenac
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.87,23169,DB00586,Diclofenac
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.99,23170,DB00586,Diclofenac
,17069941,half-life,"In cow, diclofenac was detectable in liver, kidney and intestine up to 71 h post-treatment; in plasma, half-life was 12.2 h.",Diclofenac disposition in Indian cow and goat with reference to Gyps vulture population declines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17069941/),h,12.2,23691,DB00586,Diclofenac
,32043623,elimination half-life (t1/2β ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),h,2.27,25343,DB00586,Diclofenac
,32043623,total body clearance (ClT ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [h·kg],0.56,25344,DB00586,Diclofenac
,32043623,total body clearance (ClT ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [kg],1.66,25345,DB00586,Diclofenac
,32043623,volume of distribution at steady state (Vdss ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [h·kg],0.56,25346,DB00586,Diclofenac
,32043623,volume of distribution at steady state (Vdss ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [kg],1.66,25347,DB00586,Diclofenac
,32043623,area under the curve (AUC),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[h·μg] / [ml],8.91,25348,DB00586,Diclofenac
,10320184,Mini,"Minimal respiratory rates were significantly slower after the administration of diclofenac (P < 0.001), occurring at 197+/-51.9 (60-360) min; arterial desaturations occurred in two patients without oxygen therapy.",Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: potential for opioid-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320184/),min,197,25880,DB00586,Diclofenac
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],9.24,28553,DB00586,Diclofenac
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],8.81,28554,DB00586,Diclofenac
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],10.43,28555,DB00586,Diclofenac
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,36.75,28556,DB00586,Diclofenac
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,34.88,28557,DB00586,Diclofenac
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,35.50,28558,DB00586,Diclofenac
,2775450,MRT,"One, a newly developed sustained release formulation, had a MRT of 5.5 hours, and showed surprisingly small variation coefficients [AUC ss (72-84 hrs) +/- 26%; Cmax ss (72-84 hrs) +/- 19%] after 7 administered doses; accordingly, the maximum concentrations were within a very narrow time window [tmax ss (72-84 hrs) range: 1.5-2.5 hours after administration].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,5.5,31677,DB00586,Diclofenac
,2775450,AUC ss,"One, a newly developed sustained release formulation, had a MRT of 5.5 hours, and showed surprisingly small variation coefficients [AUC ss (72-84 hrs) +/- 26%; Cmax ss (72-84 hrs) +/- 19%] after 7 administered doses; accordingly, the maximum concentrations were within a very narrow time window [tmax ss (72-84 hrs) range: 1.5-2.5 hours after administration].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,72-84,31678,DB00586,Diclofenac
,2775450,Cmax ss,"One, a newly developed sustained release formulation, had a MRT of 5.5 hours, and showed surprisingly small variation coefficients [AUC ss (72-84 hrs) +/- 26%; Cmax ss (72-84 hrs) +/- 19%] after 7 administered doses; accordingly, the maximum concentrations were within a very narrow time window [tmax ss (72-84 hrs) range: 1.5-2.5 hours after administration].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,72-84,31679,DB00586,Diclofenac
,2775450,tmax ss,"One, a newly developed sustained release formulation, had a MRT of 5.5 hours, and showed surprisingly small variation coefficients [AUC ss (72-84 hrs) +/- 26%; Cmax ss (72-84 hrs) +/- 19%] after 7 administered doses; accordingly, the maximum concentrations were within a very narrow time window [tmax ss (72-84 hrs) range: 1.5-2.5 hours after administration].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,72-84,31680,DB00586,Diclofenac
,2775450,tmax ss,"One, a newly developed sustained release formulation, had a MRT of 5.5 hours, and showed surprisingly small variation coefficients [AUC ss (72-84 hrs) +/- 26%; Cmax ss (72-84 hrs) +/- 19%] after 7 administered doses; accordingly, the maximum concentrations were within a very narrow time window [tmax ss (72-84 hrs) range: 1.5-2.5 hours after administration].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,1.5-2.5,31681,DB00586,Diclofenac
,2775450,AUC 0-12 hrs,"Due to the selected release profiles with this formulation, there was no danger of cumulation in spite of administration every 12 hours [AUC 0-12 hrs, mean value = 1555 ng/ml x h; AUC ss 72-84 hrs, mean value = 1750 ng/ml x h].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),[ng] / [h·ml],1555,31682,DB00586,Diclofenac
,2775450,AUC ss,"Due to the selected release profiles with this formulation, there was no danger of cumulation in spite of administration every 12 hours [AUC 0-12 hrs, mean value = 1555 ng/ml x h; AUC ss 72-84 hrs, mean value = 1750 ng/ml x h].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),h,72-84,31683,DB00586,Diclofenac
,2775450,AUC ss,"Due to the selected release profiles with this formulation, there was no danger of cumulation in spite of administration every 12 hours [AUC 0-12 hrs, mean value = 1555 ng/ml x h; AUC ss 72-84 hrs, mean value = 1750 ng/ml x h].",The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775450/),[ng] / [h·ml],1750,31684,DB00586,Diclofenac
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00586,Diclofenac
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00586,Diclofenac
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00586,Diclofenac
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00586,Diclofenac
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00586,Diclofenac
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00586,Diclofenac
,11867967,peak plasma drug concentration (C(max)),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[μg] / [ml],48.48,32035,DB00586,Diclofenac
,11867967,T(max),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),h,2,32036,DB00586,Diclofenac
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],114.18,32037,DB00586,Diclofenac
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],194.13,32038,DB00586,Diclofenac
,8011009,plateau time of concentrations above minimum effective concentrations (MEC),"Area under the curve (AUC), maximum plasma concentrations (Cmax), time of maximum plasma concentration (tmax), time of delay of first measurable concentrations (tlag) and plateau time of concentrations above minimum effective concentrations (MEC) of 50 ng/ml (tMEC(50)) and 100 ng/ml (tMEC(100)), respectively, were evaluated as pharmacokinetic characteristics.",[The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011009/),[ng] / [ml],100,32157,DB00586,Diclofenac
,8011009,relative bioavailabilities,Mean (median) relative bioavailabilities of diclofenac of the test formulation (comparison: postprandial vs. fasting conditions) were determined for the test formulation as 96% (103%) and for the reference product as 70% (83%).,[The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011009/),%,96,32158,DB00586,Diclofenac
,8011009,relative bioavailabilities,Mean (median) relative bioavailabilities of diclofenac of the test formulation (comparison: postprandial vs. fasting conditions) were determined for the test formulation as 96% (103%) and for the reference product as 70% (83%).,[The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011009/),%,70,32159,DB00586,Diclofenac
,8011009,maximum plasma concentrations,Mean +/- SD (median) maximum plasma concentrations of the test formulation were determined as 695 +/- 313 (677) ng/ml (fasting) and as 452 +/- 163 (456) ng/ml (postprandial).,[The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011009/),[ng] / [ml],695,32160,DB00586,Diclofenac
,8011009,maximum plasma concentrations,Mean +/- SD (median) maximum plasma concentrations of the test formulation were determined as 695 +/- 313 (677) ng/ml (fasting) and as 452 +/- 163 (456) ng/ml (postprandial).,[The bioavailability of enteric coated diclofenac formulations. 2. Bioavailability following single administration of a multiple-unit formulation in comparison to a single-unit formulation under fasting and non-fasting conditions]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011009/),[ng] / [ml],452,32161,DB00586,Diclofenac
,19204082,influx clearances,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g·min],0.276,32373,DB00586,Diclofenac
,19204082,influx clearances,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g·min],0.0345,32374,DB00586,Diclofenac
,19204082,efflux rate constants,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),1/[min],0.406,32375,DB00586,Diclofenac
,19204082,efflux rate constants,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),1/[min],0.0337,32376,DB00586,Diclofenac
,19204082,placental tissue/plasma concentration ratio,"By taking into account protein binding, the placental tissue/plasma concentration ratio in humans for diclofenac was estimated to be 0.108 ml/g of cotyledon and was smaller than that of antipyrine.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g],0.108,32377,DB00586,Diclofenac
,24633464,absolute oral bioavailability,The absolute oral bioavailability of aceclofenac was approximately 15 %.,Absolute bioavailability and metabolism of aceclofenac in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633464/),%,15,33628,DB00586,Diclofenac
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.28,35122,DB00586,Diclofenac
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.38,35123,DB00586,Diclofenac
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.45,35124,DB00586,Diclofenac
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,1.07,35125,DB00586,Diclofenac
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.90,35126,DB00586,Diclofenac
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.70,35127,DB00586,Diclofenac
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.18,35128,DB00586,Diclofenac
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.32,35129,DB00586,Diclofenac
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.28,35130,DB00586,Diclofenac
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.43,35131,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),[ng] / [g],36,35674,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),[ng] / [g],42,35675,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),ng,2,35676,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),ng,2.8,35677,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),ng,3.9,35678,DB00586,Diclofenac
,23338668,concentration,The median diclofenac concentration was approximately 10-20-fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups.,Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338668/),ng,4.1,35679,DB00586,Diclofenac
,19161451,IC50 ratios,Robenacoxib selectively inhibited COX-2 in vitro as evidenced from COX-1:COX-2 IC50 ratios of 27:1 in purified enzyme preparations and >967:1 in isolated cell assays.,Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),,27:1,36368,DB00586,Diclofenac
,19161451,IC50 ratios,Robenacoxib selectively inhibited COX-2 in vitro as evidenced from COX-1:COX-2 IC50 ratios of 27:1 in purified enzyme preparations and >967:1 in isolated cell assays.,Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),:,967,36369,DB00586,Diclofenac
<,19161451,dissociation t(1/2),"Binding to COX-1 was rapid and readily reversible (dissociation t(1/2) << 1 min), whilst COX-2 binding was slowly reversible (t(1/2) = 25 min).",Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),min,1,36370,DB00586,Diclofenac
,19161451,t(1/2),"Binding to COX-1 was rapid and readily reversible (dissociation t(1/2) << 1 min), whilst COX-2 binding was slowly reversible (t(1/2) = 25 min).",Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),min,25,36371,DB00586,Diclofenac
,19161451,clearance,"After intravenous dosing, clearance was 2.4 mL/min/kg and volume of distribution at steady-state was 306 mL/kg.",Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),[ml] / [kg·min],2.4,36372,DB00586,Diclofenac
,19161451,volume of distribution at steady-state,"After intravenous dosing, clearance was 2.4 mL/min/kg and volume of distribution at steady-state was 306 mL/kg.",Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),[ml] / [kg],306,36373,DB00586,Diclofenac
,19161451,MRT,Robenacoxib was preferentially distributed into inflammatory exudate; the AUC for exudate was 2.9 times higher than for blood and the MRT in exudate (15.9 h) was three times longer than in blood (5.3 h).,Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),h,15.9,36374,DB00586,Diclofenac
,19161451,MRT,Robenacoxib was preferentially distributed into inflammatory exudate; the AUC for exudate was 2.9 times higher than for blood and the MRT in exudate (15.9 h) was three times longer than in blood (5.3 h).,Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161451/),h,5.3,36375,DB00586,Diclofenac
,26542632,flow rate,"Chromatographic separation was carried on Waters Spherisorb(®) S5 ODS2 C18 column (150 × 4.6 mm, 5 μm) using an isocratic mobile phase composed by water with triethylamine 0.3% (pH 4), methanol and acetonitrile grade (45:15:40, v/v/v) at a flow rate of 1 mL/min.",Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26542632/),[ml] / [min],1,37266,DB00586,Diclofenac
,26542632,total run time,"Both LASSBio-1736 and IS were eluted at 4.2 and 5 min, respectively, with a total run time of 8 min only.",Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26542632/),min,8,37267,DB00586,Diclofenac
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],213,38036,DB00586,Diclofenac
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],13,38037,DB00586,Diclofenac
,22307660,zeta potential,The LNEs of diclofenac acid with a mean size ranging from 200 to 240 nm and a zeta potential of -29.4 ± 1.04 mV (negatively charged LNEs) and 62.1 ± 3.5 (positively charged LNEs) emulsions were prepared by hot homogenization and ultrasonication process.,Formulation and pharmacokinetics of diclofenac lipid nanoemulsions for parenteral application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307660/),mv,-,38357,DB00586,Diclofenac
,22307660,zeta potential,The LNEs of diclofenac acid with a mean size ranging from 200 to 240 nm and a zeta potential of -29.4 ± 1.04 mV (negatively charged LNEs) and 62.1 ± 3.5 (positively charged LNEs) emulsions were prepared by hot homogenization and ultrasonication process.,Formulation and pharmacokinetics of diclofenac lipid nanoemulsions for parenteral application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307660/),mv,29.4,38358,DB00586,Diclofenac
,22307660,zeta potential,The LNEs of diclofenac acid with a mean size ranging from 200 to 240 nm and a zeta potential of -29.4 ± 1.04 mV (negatively charged LNEs) and 62.1 ± 3.5 (positively charged LNEs) emulsions were prepared by hot homogenization and ultrasonication process.,Formulation and pharmacokinetics of diclofenac lipid nanoemulsions for parenteral application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307660/),,62.1,38359,DB00586,Diclofenac
,10683715,mean time,"The rate of absorption with the sachets proved to be very fast, reaching peak values at 10 min in seven subjects and at 15 min in the remaining subjects: mean time was 13.68 min, with concentrations at 5 min being 38% of Cmax.",Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10683715/),min,13.68,39473,DB00586,Diclofenac
,10683715,time to peak concentration,The average time to peak concentration with the tablets was 53.10 min.,Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10683715/),min,53.10,39474,DB00586,Diclofenac
,10683715,AUC0-infinity,"The extent of absorption of the sachets and tablets was similar, with AUC0-infinity values of respectively 1362 and 1214 ng.",Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10683715/),ng,1362,39475,DB00586,Diclofenac
,10683715,AUC0-infinity,"The extent of absorption of the sachets and tablets was similar, with AUC0-infinity values of respectively 1362 and 1214 ng.",Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10683715/),ng,1214,39476,DB00586,Diclofenac
,19301941,maximum plasma concentration (C(max)),The maximum plasma concentration (C(max)) of ciprofloxacin increased from 2.48 +/- 0.33 microg/mL when administered alone to 3.91 +/- 0.8 microg/mL with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),[μg] / [ml],2.48,39915,DB00586,Diclofenac
,19301941,maximum plasma concentration (C(max)),The maximum plasma concentration (C(max)) of ciprofloxacin increased from 2.48 +/- 0.33 microg/mL when administered alone to 3.91 +/- 0.8 microg/mL with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),[μg] / [ml],3.91,39916,DB00586,Diclofenac
,19301941,Time to reach C(max) (t(max)),Time to reach C(max) (t(max)) with ciprofloxacin reduced from 2.02 +/- 0.3 hours when administered alone to 1.49 +/- 0.2 h with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),h,2.02,39917,DB00586,Diclofenac
,19301941,Time to reach C(max) (t(max)),Time to reach C(max) (t(max)) with ciprofloxacin reduced from 2.02 +/- 0.3 hours when administered alone to 1.49 +/- 0.2 h with co-administration of diclofenac.,"Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301941/),h,1.49,39918,DB00586,Diclofenac
,10072704,tmax,Peak anti-inflammatory effects with nimesulide were observed between 2 and 3 h post-treatment which correlates well with the tmax of 115 min.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),min,115,39988,DB00586,Diclofenac
,10072704,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 23 microgram ml-1 while t1/2 was derived as 4.2 h.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),[μg] / [ml],23,39989,DB00586,Diclofenac
,10072704,t1/2,Peak plasma concentration (Cmax) was 23 microgram ml-1 while t1/2 was derived as 4.2 h.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),h,4.2,39990,DB00586,Diclofenac
,10072704,Area Under Curve (AUC(0-6 h)),Area Under Curve (AUC(0-6 h)) was calculated as 83. 31 microgram ml-1 h-1.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),[μg] / [h·ml],83. 31,39991,DB00586,Diclofenac
,24320694,Cmax,"A comparative bioavailability study using a selected CPOP formulation (T) versus the innovator product (R) revealed that CPOP tablet maintained a less fluctuated DS plasma concentration for up to 24 h with a detected mean Cmax of 836.8 ± 142.4 and 445.0 ± 81.0 ng/mL for R and T, respectively.",Controlled porosity osmotic pump system for the delivery of diclofenac sodium: in-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24320694/),[ng] / [ml],836.8,42418,DB00586,Diclofenac
,24320694,Cmax,"A comparative bioavailability study using a selected CPOP formulation (T) versus the innovator product (R) revealed that CPOP tablet maintained a less fluctuated DS plasma concentration for up to 24 h with a detected mean Cmax of 836.8 ± 142.4 and 445.0 ± 81.0 ng/mL for R and T, respectively.",Controlled porosity osmotic pump system for the delivery of diclofenac sodium: in-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24320694/),[ng] / [ml],445.0,42419,DB00586,Diclofenac
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],2.29,46732,DB00586,Diclofenac
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],5.04,46733,DB00586,Diclofenac
,19774343,AUC(0-t) (area under the curve),"Iontophoretic delivery increased the AUC(0-t) (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery (0.86 +/- 0.04 and 2.0 +/- 0.06 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate, respectively).","""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],0.86,46767,DB00586,Diclofenac
,19774343,AUC(0-t) (area under the curve),"Iontophoretic delivery increased the AUC(0-t) (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery (0.86 +/- 0.04 and 2.0 +/- 0.06 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate, respectively).","""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],2.0,46768,DB00586,Diclofenac
,19774343,AUC(0-t),CD resulted in an AUC(0-t) of 5.2 +/- 0.69 and 24.6 +/- 1.97 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate which was approximately 6-12-fold higher than the passive and 2-4-fold higher than iontophoresis.,"""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],5.2,46769,DB00586,Diclofenac
,19774343,AUC(0-t),CD resulted in an AUC(0-t) of 5.2 +/- 0.69 and 24.6 +/- 1.97 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate which was approximately 6-12-fold higher than the passive and 2-4-fold higher than iontophoresis.,"""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],24.6,46770,DB00586,Diclofenac
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,137,47440,DB00586,Diclofenac
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,65,47441,DB00586,Diclofenac
,3768079,steady state plasma levels,"In man, upon daily topical administration of 3 times 2.5 g cream formulation (10 mg/cm2) the diclofenac steady state plasma levels were 20 to 40 nmol/l.(ABSTRACT TRUNCATED AT 250 WORDS)",[The percutaneous absorption of diclofenac]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768079/),[nM] / [l],20 to 40,47454,DB00586,Diclofenac
,1294333,gastric emptying time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,0.7,48203,DB00586,Diclofenac
,1294333,small intestinal transit time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,4,48204,DB00586,Diclofenac
,30336288,half-life,"In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.00 l/h kg and 0.02 ± 0.00 l/kg respectively (presented as geometric mean).",Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336288/),h,0.37,48650,DB00586,Diclofenac
,30336288,volume of distribution at steady state,"In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.00 l/h kg and 0.02 ± 0.00 l/kg respectively (presented as geometric mean).",Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336288/),[l] / [kg],0.02,48651,DB00586,Diclofenac
,24368338,recoveries,Enantiomer recoveries yielded 100.0 ± 15%.,HPLC method with solid-phase extraction for determination of (R)- and (S)-ketoprofen in plasma without caffeine interference: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368338/),%,100.0,49544,DB00586,Diclofenac
,3245235,peak plasma levels,"2. After a single 100 mg dose of diclofenac sodium to volunteers, the drug was absorbed rapidly and showed peak plasma levels of 10-12 nmol/g.",Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),[nM] / [g],10-12,51902,DB00586,Diclofenac
,3245235,maximum concentrations,The maximum concentrations of five metabolites were comparatively low (0.36-2.94 nmol/g).,Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),[nM] / [g],0.36-2.94,51903,DB00586,Diclofenac
,3245235,apparent terminal half-lives,"The mono- and dihydroxy metabolites (II-V) had apparent terminal half-lives similar to that of I (1-3 h), but the hydroxymethoxy metabolite (VI) had a half-life of about 80 h.",Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),h,1-3,51904,DB00586,Diclofenac
,3245235,half-life,"The mono- and dihydroxy metabolites (II-V) had apparent terminal half-lives similar to that of I (1-3 h), but the hydroxymethoxy metabolite (VI) had a half-life of about 80 h.",Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),h,80,51905,DB00586,Diclofenac
,3245235,Renal elimination,Renal elimination of VI within 96 h was about 1% of dose and that of I-VI was 36% (free plus conjugated).,Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),%,1,51906,DB00586,Diclofenac
,3245235,Renal elimination,Renal elimination of VI within 96 h was about 1% of dose and that of I-VI was 36% (free plus conjugated).,Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),%,36,51907,DB00586,Diclofenac
,3245235,steady-state trough concentrations,"3. Following daily treatment with 2 x 75 mg of an experimental sustained release formulation to patients for 6-10 months, steady-state trough concentrations of I-V in plasma were low (average values: 0.23-0.57 nmol/g).",Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),[nM] / [g],0.23-0.57,51908,DB00586,Diclofenac
,3245235,trough concentration,The mean trough concentration of VI was comparatively higher at 3.69 +/- 0.91 nmol/g presumably reflecting its accumulation.,Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245235/),[nM] / [g],3.69,51909,DB00586,Diclofenac
,9206268,plasma,A great difference in plasma drug concentration fluctuation index (FI) between CRP (0.476 +/- 0.0484) and CT (0.935 +/- 0.092) was observed (P < 0.05) during steady-state.,[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9206268/),,0.476,52442,DB00586,Diclofenac
,9206268,plasma,A great difference in plasma drug concentration fluctuation index (FI) between CRP (0.476 +/- 0.0484) and CT (0.935 +/- 0.092) was observed (P < 0.05) during steady-state.,[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9206268/),,0.935,52443,DB00586,Diclofenac
,9206268,area under the plasma drug concentration-time curve for a 0-12 h interval (AUC),The area under the plasma drug concentration-time curve for a 0-12 h interval (AUC) on day 5 of CRP (6.493 +/- 0.4169 micrograms.h.ml-1) and CT (7.551 +/- 0.4745 micrograms.h.ml-1) was shown to be not significantly different (P > 0.05).,[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9206268/),[h·μg] / [ml],6.493,52444,DB00586,Diclofenac
,9206268,area under the plasma drug concentration-time curve for a 0-12 h interval (AUC),The area under the plasma drug concentration-time curve for a 0-12 h interval (AUC) on day 5 of CRP (6.493 +/- 0.4169 micrograms.h.ml-1) and CT (7.551 +/- 0.4745 micrograms.h.ml-1) was shown to be not significantly different (P > 0.05).,[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9206268/),[h·μg] / [ml],7.551,52445,DB00586,Diclofenac
,9206268,relative bioavailability,The relative bioavailability in the human was about 86%.,[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9206268/),%,86,52446,DB00586,Diclofenac
,8887740,FH,The FH values of diclofenac were 0.664 in group A and 0.643 in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.664,54443,DB00586,Diclofenac
,8887740,FH,The FH values of diclofenac were 0.664 in group A and 0.643 in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.643,54444,DB00586,Diclofenac
,8887740,biliary excretion ratio (Fb),The biliary excretion ratio (Fb) of total diclofenac after intravenous administration was 27.0% in group A and 14.1% in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),%,27.0,54445,DB00586,Diclofenac
,8887740,biliary excretion ratio (Fb),The biliary excretion ratio (Fb) of total diclofenac after intravenous administration was 27.0% in group A and 14.1% in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),%,14.1,54446,DB00586,Diclofenac
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.192,54447,DB00586,Diclofenac
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.159,54448,DB00586,Diclofenac
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.174,54449,DB00586,Diclofenac
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.238,54450,DB00586,Diclofenac
,15120451,oral bioavailability,"The present work was aimed to study the effect of concomitant administration of Trikatu on the pharmacokinetics and pharmacodynamics of diclofenac sodium, a frequently prescribed non-steroidal anti-inflammatory drug, having a poor oral bioavailability (54 +/- 2%).","Pharmacokinetic and pharmacodynamic studies on interaction of ""Trikatu"" with diclofenac sodium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120451/),%,54,55916,DB00586,Diclofenac
,20187842,T(max),DPSGC 25 mg (Study 2) produced a shorter T(max) (0.45 h) and an equivalent C(max) (1125 ng/ml) to the 50-mg comparator drug.,Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187842/),h,0.45,56740,DB00586,Diclofenac
,20187842,C(max),DPSGC 25 mg (Study 2) produced a shorter T(max) (0.45 h) and an equivalent C(max) (1125 ng/ml) to the 50-mg comparator drug.,Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187842/),[ng] / [ml],1125,56741,DB00586,Diclofenac
,8996854,Tlag,"The Tlag for Voltaren was 0.8 +/- 0.2 h, significantly shorter than for Inflaban (1.7 +/- 0.2 h) indicating a faster rate of absorption from the upper gastrointestinal tract.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),h,0.8,57464,DB00586,Diclofenac
,8996854,Tlag,"The Tlag for Voltaren was 0.8 +/- 0.2 h, significantly shorter than for Inflaban (1.7 +/- 0.2 h) indicating a faster rate of absorption from the upper gastrointestinal tract.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),h,1.7,57465,DB00586,Diclofenac
,8996854,Cmax,"The Cmax obtained with Voltaren was significantly higher than that obtained with Inflaban (1,161 +/- 102 and 799 +/- 83, respectively).","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),,"1,161",57466,DB00586,Diclofenac
,8996854,Cmax,"The Cmax obtained with Voltaren was significantly higher than that obtained with Inflaban (1,161 +/- 102 and 799 +/- 83, respectively).","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),,799,57467,DB00586,Diclofenac
,8996854,Tmax,"Tmax for Voltaren and Inflaban was 4.2 +/- 0.5 and 4.5 +/- 0.4 h, respectively, whereas AUC0-26h values for both products were 5,423 +/- 562 and 5,237 +/- 520 ng x h/ml, respectively.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),h,4.2,57468,DB00586,Diclofenac
,8996854,Tmax,"Tmax for Voltaren and Inflaban was 4.2 +/- 0.5 and 4.5 +/- 0.4 h, respectively, whereas AUC0-26h values for both products were 5,423 +/- 562 and 5,237 +/- 520 ng x h/ml, respectively.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),h,4.5,57469,DB00586,Diclofenac
,8996854,AUC0-26h,"Tmax for Voltaren and Inflaban was 4.2 +/- 0.5 and 4.5 +/- 0.4 h, respectively, whereas AUC0-26h values for both products were 5,423 +/- 562 and 5,237 +/- 520 ng x h/ml, respectively.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),[h·ng] / [ml],"5,423",57470,DB00586,Diclofenac
,8996854,AUC0-26h,"Tmax for Voltaren and Inflaban was 4.2 +/- 0.5 and 4.5 +/- 0.4 h, respectively, whereas AUC0-26h values for both products were 5,423 +/- 562 and 5,237 +/- 520 ng x h/ml, respectively.","Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996854/),[h·ng] / [ml],"5,237",57471,DB00586,Diclofenac
,30287408,plasma concentrations,"Moreover, the plasma concentrations of aceclofenac 24 h after application of tested formulations (lecithin/sucrose palmitate vs. lecithin/polysorbate 80) combined with microneedles (173.37 ± 40.50 ng/ml vs. 259.23 ± 73.18 ng/ml) were significantly higher than those obtained through intact skin (105.69 ± 19.53 ng/ml vs. 88.38 ± 14.46 ng/ml).",Combined use of biocompatible nanoemulsions and solid microneedles to improve transport of a model NSAID across the skin: In vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30287408/),[ng] / [ml],173.37,57762,DB00586,Diclofenac
,30287408,plasma concentrations,"Moreover, the plasma concentrations of aceclofenac 24 h after application of tested formulations (lecithin/sucrose palmitate vs. lecithin/polysorbate 80) combined with microneedles (173.37 ± 40.50 ng/ml vs. 259.23 ± 73.18 ng/ml) were significantly higher than those obtained through intact skin (105.69 ± 19.53 ng/ml vs. 88.38 ± 14.46 ng/ml).",Combined use of biocompatible nanoemulsions and solid microneedles to improve transport of a model NSAID across the skin: In vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30287408/),[ng] / [ml],259.23,57763,DB00586,Diclofenac
,30287408,plasma concentrations,"Moreover, the plasma concentrations of aceclofenac 24 h after application of tested formulations (lecithin/sucrose palmitate vs. lecithin/polysorbate 80) combined with microneedles (173.37 ± 40.50 ng/ml vs. 259.23 ± 73.18 ng/ml) were significantly higher than those obtained through intact skin (105.69 ± 19.53 ng/ml vs. 88.38 ± 14.46 ng/ml).",Combined use of biocompatible nanoemulsions and solid microneedles to improve transport of a model NSAID across the skin: In vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30287408/),[ng] / [ml],105.69,57764,DB00586,Diclofenac
,30287408,plasma concentrations,"Moreover, the plasma concentrations of aceclofenac 24 h after application of tested formulations (lecithin/sucrose palmitate vs. lecithin/polysorbate 80) combined with microneedles (173.37 ± 40.50 ng/ml vs. 259.23 ± 73.18 ng/ml) were significantly higher than those obtained through intact skin (105.69 ± 19.53 ng/ml vs. 88.38 ± 14.46 ng/ml).",Combined use of biocompatible nanoemulsions and solid microneedles to improve transport of a model NSAID across the skin: In vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30287408/),[ng] / [ml],88.38,57765,DB00586,Diclofenac
,27430634,peak observed concentrations in the blood,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[μg] / [ml],1.26,58088,DB00586,Diclofenac
,27430634,AUCinf,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[h·μg] / [ml],3.48,58089,DB00586,Diclofenac
,27430634,terminal half-life,Concentrations of lumiracoxib then declined with a terminal half-life of 1.54 + 0.31 h.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),h,1.54,58090,DB00586,Diclofenac
,21235465,Cmax,"The mean Cmax and Tmax for the test and reference formulations were 2.14 µg/mL, 1.91 µg/mL and 0.49 h, 0.50 h respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[μg] / [ml],2.14,59042,DB00586,Diclofenac
,21235465,Tmax,"The mean Cmax and Tmax for the test and reference formulations were 2.14 µg/mL, 1.91 µg/mL and 0.49 h, 0.50 h respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[μg] / [ml],1.91,59043,DB00586,Diclofenac
,21235465,Tmax,"The mean Cmax and Tmax for the test and reference formulations were 2.14 µg/mL, 1.91 µg/mL and 0.49 h, 0.50 h respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),h,0.49,59044,DB00586,Diclofenac
,21235465,Tmax,"The mean Cmax and Tmax for the test and reference formulations were 2.14 µg/mL, 1.91 µg/mL and 0.49 h, 0.50 h respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),h,0.50,59045,DB00586,Diclofenac
,21235465,AUC(0-t),"The mean AUC(0-t) for test and reference formulations were 3.79 µg.h/mL, and 3.43 µg.h/mL respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[h·μg] / [ml],3.79,59046,DB00586,Diclofenac
,21235465,AUC(0-t),"The mean AUC(0-t) for test and reference formulations were 3.79 µg.h/mL, and 3.43 µg.h/mL respectively.",Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[h·μg] / [ml],3.43,59047,DB00586,Diclofenac
,21235465,AUC(0-γ),The mean AUC(0-γ) for test and reference formulation were 4.03 µg.h/mL and 3.65 µg.h/mL respectively.,Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[h·μg] / [ml],4.03,59048,DB00586,Diclofenac
,21235465,AUC(0-γ),The mean AUC(0-γ) for test and reference formulation were 4.03 µg.h/mL and 3.65 µg.h/mL respectively.,Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21235465/),[h·μg] / [ml],3.65,59049,DB00586,Diclofenac
,16602135,flow rate,"The analyte was separated on a reversed-phase column with acetonitrile and 0.05% trichloracetic acid in water (35:65, v/v) as mobile phase at a flow rate of 1 mL/min, and UV detection at 270 nm.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),[ml] / [min],1,59666,DB00586,Diclofenac
,16602135,retention times,"The retention times for lumiracoxib and niflumic acid (internal standard) were 16.9 and 10.4 min, respectively.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),min,16.9,59667,DB00586,Diclofenac
,16602135,retention times,"The retention times for lumiracoxib and niflumic acid (internal standard) were 16.9 and 10.4 min, respectively.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),min,10.4,59668,DB00586,Diclofenac
,11710578,recovery,"The recovery of diclofenac was 92%, the analysis lasted 7 min with a sensitivity of 5 ng/ml and intra- and inter-day RSDs of 3 and 8%, respectively.",High-performance liquid chromatographic determination of diclofenac in human plasma after solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11710578/),%,92,60620,DB00586,Diclofenac
,10219542,Area under the curve [AUC],"(Area under the curve [AUC]: 4.356 +/- 1.3 mcg/ml.hr in animals and 0.442 +/- 0.053 mcg/ml.hr in humans; Tmax was 8 hr in both the cases, whereas Cmax was 0.288 +/- 0.088 mcg/ml in animals and 0.034 +/- .008 mcg/ml in human volunteers.)",Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219542/),[mcg] / [h·ml],4.356,61920,DB00586,Diclofenac
,10219542,Area under the curve [AUC],"(Area under the curve [AUC]: 4.356 +/- 1.3 mcg/ml.hr in animals and 0.442 +/- 0.053 mcg/ml.hr in humans; Tmax was 8 hr in both the cases, whereas Cmax was 0.288 +/- 0.088 mcg/ml in animals and 0.034 +/- .008 mcg/ml in human volunteers.)",Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219542/),[mcg] / [h·ml],0.442,61921,DB00586,Diclofenac
,10219542,Tmax,"(Area under the curve [AUC]: 4.356 +/- 1.3 mcg/ml.hr in animals and 0.442 +/- 0.053 mcg/ml.hr in humans; Tmax was 8 hr in both the cases, whereas Cmax was 0.288 +/- 0.088 mcg/ml in animals and 0.034 +/- .008 mcg/ml in human volunteers.)",Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219542/),h,8,61922,DB00586,Diclofenac
,10219542,Cmax,"(Area under the curve [AUC]: 4.356 +/- 1.3 mcg/ml.hr in animals and 0.442 +/- 0.053 mcg/ml.hr in humans; Tmax was 8 hr in both the cases, whereas Cmax was 0.288 +/- 0.088 mcg/ml in animals and 0.034 +/- .008 mcg/ml in human volunteers.)",Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219542/),[mcg] / [ml],0.288,61923,DB00586,Diclofenac
,10219542,Cmax,"(Area under the curve [AUC]: 4.356 +/- 1.3 mcg/ml.hr in animals and 0.442 +/- 0.053 mcg/ml.hr in humans; Tmax was 8 hr in both the cases, whereas Cmax was 0.288 +/- 0.088 mcg/ml in animals and 0.034 +/- .008 mcg/ml in human volunteers.)",Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219542/),[mcg] / [ml],0.034,61924,DB00586,Diclofenac
,29505100,run time,A very small injection volume (3 μL) was applied and the run time was 2.0 min.,"Liquid chromatography-tandem MS/MS method for simultaneous quantification of paracetamol, chlorzoxazone and aceclofenac in human plasma: An application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505100/),min,2.0,62206,DB00586,Diclofenac
,17529891,total time for,"The peaks were monitored with an ultraviolet detector set at a wavelength of 312 nm, and total time for chromatographic separation was approximately 25 minutes.",Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529891/),min,25,63034,DB00586,Diclofenac
,22763809,flow rate,"The chromatographic analysis was performed on a Waters Alliance system with a Betasil C(18) column maintained at ambient room temperature and an isocratic mobile phase [acetonitrile-water-10 mm potassium dihydrogen phosphate (pH 3.0), 55:5:40, v/v/v] at a flow rate of 1.00 mL/min with a total run time of 10 min.",Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763809/),[ml] / [min],1.00,63304,DB00586,Diclofenac
,22763809,total run time,"The chromatographic analysis was performed on a Waters Alliance system with a Betasil C(18) column maintained at ambient room temperature and an isocratic mobile phase [acetonitrile-water-10 mm potassium dihydrogen phosphate (pH 3.0), 55:5:40, v/v/v] at a flow rate of 1.00 mL/min with a total run time of 10 min.",Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763809/),min,10,63305,DB00586,Diclofenac
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],3.6,65584,DB00586,Diclofenac
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],7.7,65585,DB00586,Diclofenac
,27320817,mean absorption time (MAT),"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.61,65797,DB00586,Diclofenac
,27320817,absorption half-life (t1/2ka),"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.51,65798,DB00586,Diclofenac
,27320817,bioavailability,"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),%,100,65799,DB00586,Diclofenac
,27320817,MAT,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,2.85,65800,DB00586,Diclofenac
,27320817,t1/2ka,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.53,65801,DB00586,Diclofenac
,27320817,bioavailability,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),%,70,65802,DB00586,Diclofenac
,12966366,50% inhibitory concentration,"Maximal plasma concentrations of diclofenac after oral administration of aceclofenac (0.39 micromol/L) or diclofenac (1.28 micromol/L) were sufficient for a greater than 97% inhibition of COX-2 (50% inhibitory concentration, 0.024 micromol/L) and a 46% (aceclofenac treatment) or 82% inhibition (diclofenac treatment) of COX-1 (50% inhibitory concentration, 0.43 micromol/L).",Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966366/),[μM] / [l],0.024,66075,DB00586,Diclofenac
,12966366,50% inhibitory concentration,"Maximal plasma concentrations of diclofenac after oral administration of aceclofenac (0.39 micromol/L) or diclofenac (1.28 micromol/L) were sufficient for a greater than 97% inhibition of COX-2 (50% inhibitory concentration, 0.024 micromol/L) and a 46% (aceclofenac treatment) or 82% inhibition (diclofenac treatment) of COX-1 (50% inhibitory concentration, 0.43 micromol/L).",Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966366/),[μM] / [l],0.43,66076,DB00586,Diclofenac
,2376240,elimination half-life,It has an intermediate elimination half-life of 17 h which does not depend on age or sex.,The pharmacokinetics of pirazolac in human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376240/),h,17,66914,DB00586,Diclofenac
,8292067,time of maximum plasma concentration (tmax),"Moreover, time of maximum plasma concentration (tmax), lag-time (tlag) and plateau time of concentrations above minimum effective concentrations (MEC) of 50 ng/ml (tMEC(50)) and 100 ng/ml (tMEC(100)), respectively were calculated.",[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),[ng] / [ml],50,67336,DB00586,Diclofenac
,8292067,lag-time (tlag),"Moreover, time of maximum plasma concentration (tmax), lag-time (tlag) and plateau time of concentrations above minimum effective concentrations (MEC) of 50 ng/ml (tMEC(50)) and 100 ng/ml (tMEC(100)), respectively were calculated.",[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),[ng] / [ml],50,67337,DB00586,Diclofenac
,8292067,plateau time of concentrations above minimum effective concentrations (MEC),"Moreover, time of maximum plasma concentration (tmax), lag-time (tlag) and plateau time of concentrations above minimum effective concentrations (MEC) of 50 ng/ml (tMEC(50)) and 100 ng/ml (tMEC(100)), respectively were calculated.",[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),[ng] / [ml],100,67338,DB00586,Diclofenac
,8292067,relative bioavailability,Mean relative bioavailability of the test formulation was calculated as 99%.,[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),%,99,67339,DB00586,Diclofenac
,8292067,Maximum plasma concentrations,Maximum plasma concentrations (mean +/- SD) were determined as 1159 +/- 632 ng/ml (test) and as 1481 +/- 637 ng/ml (reference).,[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),[ng] / [ml],1159,67340,DB00586,Diclofenac
,8292067,Maximum plasma concentrations,Maximum plasma concentrations (mean +/- SD) were determined as 1159 +/- 632 ng/ml (test) and as 1481 +/- 637 ng/ml (reference).,[Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292067/),[ng] / [ml],1481,67341,DB00586,Diclofenac
,34312763,Drug entrapment efficiency,"Drug entrapment efficiency for the PVA/Ca-alginate beads was calculated as 98%, and for Ca-alginate beads, it came out to a maximum of 74%.","Fabrication, Evaluation, In Vivo Pharmacokinetic and Toxicological Analysis of pH-Sensitive Eudragit S-100-Coated Hydrogel Beads: a Promising Strategy for Colon Targeting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312763/),%,98,68329,DB00586,Diclofenac
,34312763,Drug entrapment efficiency,"Drug entrapment efficiency for the PVA/Ca-alginate beads was calculated as 98%, and for Ca-alginate beads, it came out to a maximum of 74%.","Fabrication, Evaluation, In Vivo Pharmacokinetic and Toxicological Analysis of pH-Sensitive Eudragit S-100-Coated Hydrogel Beads: a Promising Strategy for Colon Targeting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34312763/),%,74,68330,DB00586,Diclofenac
,9570000,relative bioavailability,The sustained-release relative bioavailability is 90-99%.,"Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570000/),%,90-99,69728,DB00586,Diclofenac
,9570000,relative bioavailability,"However, the relative bioavailability of the suppository formulation is low (55%), since defecation may remove the drug from the absorption site before complete absorption.","Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570000/),%,55,69729,DB00586,Diclofenac
,15340127,AUC(0-t),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],108.0,70188,DB00586,Diclofenac
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70189,DB00586,Diclofenac
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70190,DB00586,Diclofenac
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70191,DB00586,Diclofenac
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70192,DB00586,Diclofenac
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70193,DB00586,Diclofenac
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70194,DB00586,Diclofenac
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70195,DB00586,Diclofenac
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70196,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.1,70197,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],110.2,70198,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],27.5,70199,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.0,70200,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,53.7,70201,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70202,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70203,DB00586,Diclofenac
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.0,70204,DB00586,Diclofenac
,8079650,recovery,The average recovery of diclofenac was 98.2% to 102.5%.,[High-performance liquid chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8079650/),%,98.2,70344,DB00586,Diclofenac
,8079650,recovery,The average recovery of diclofenac was 98.2% to 102.5%.,[High-performance liquid chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8079650/),%,102.5,70345,DB00586,Diclofenac
,8079650,detection limit,The detection limit of the method was 10 ng/ml.,[High-performance liquid chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8079650/),[ng] / [ml],10,70346,DB00586,Diclofenac
,8079650,T1/2,The serum drug concentration-time curve exhibited a 1-compartment open model and the mean T1/2 was 2.15 h.,[High-performance liquid chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8079650/),h,2.15,70347,DB00586,Diclofenac
,32898192,LOD,Linearity was found to be 0.999 over the drug concentration range of 50μg/mL to 0.05μg/mL with LLOQ and LOD of 0.05μg/mL and 0.025μg/mL respectively.,Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [ml],0.05,72803,DB00586,Diclofenac
,32898192,LOD,Linearity was found to be 0.999 over the drug concentration range of 50μg/mL to 0.05μg/mL with LLOQ and LOD of 0.05μg/mL and 0.025μg/mL respectively.,Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [ml],0.025,72804,DB00586,Diclofenac
,32898192,Cmax,The Cmax of the test and brand was found to be 8.629±1.251μg/mL and 8.478±0.913μg/mL.,Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [ml],8.629,72805,DB00586,Diclofenac
,32898192,Cmax,The Cmax of the test and brand was found to be 8.629±1.251μg/mL and 8.478±0.913μg/mL.,Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [ml],8.478,72806,DB00586,Diclofenac
,32898192,AUC0-t,"The AUC0-t and AUC0-∞ of the test and the reference were computed to be 20.890 ±2.2021μg/mL.h, 23.272 ±1.914 μg/mL.h and 19.850 ±2.911 μg/mL.h, 22.890 ± 2.110 μg/mL.h correspondingly.",Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [h·ml],20.890,72807,DB00586,Diclofenac
,32898192,AUC0-t,"The AUC0-t and AUC0-∞ of the test and the reference were computed to be 20.890 ±2.2021μg/mL.h, 23.272 ±1.914 μg/mL.h and 19.850 ±2.911 μg/mL.h, 22.890 ± 2.110 μg/mL.h correspondingly.",Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [h·ml],19.850,72808,DB00586,Diclofenac
,32898192,AUC0-∞,"The AUC0-t and AUC0-∞ of the test and the reference were computed to be 20.890 ±2.2021μg/mL.h, 23.272 ±1.914 μg/mL.h and 19.850 ±2.911 μg/mL.h, 22.890 ± 2.110 μg/mL.h correspondingly.",Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [h·ml],23.272,72809,DB00586,Diclofenac
,32898192,AUC0-∞,"The AUC0-t and AUC0-∞ of the test and the reference were computed to be 20.890 ±2.2021μg/mL.h, 23.272 ±1.914 μg/mL.h and 19.850 ±2.911 μg/mL.h, 22.890 ± 2.110 μg/mL.h correspondingly.",Pharmacokinetics and bioequivalence assessment of optimized directly compressible Aceclofenac (100 mg) tablet formulation in healthy human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32898192/),[μg] / [h·ml],22.890,72810,DB00586,Diclofenac
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,46,74425,DB00586,Diclofenac
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,33,74426,DB00586,Diclofenac
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,51,74427,DB00586,Diclofenac
,2387653,apparent half-lives,"The apparent half-lives of diclofenac and 4'-OH-diclofenac are, respectively 1.3 +/- 0.3 h and 4.3 +/- 1.0 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,1.3,75028,DB00586,Diclofenac
,2387653,apparent half-lives,"The apparent half-lives of diclofenac and 4'-OH-diclofenac are, respectively 1.3 +/- 0.3 h and 4.3 +/- 1.0 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,4.3,75029,DB00586,Diclofenac
,2387653,t 1/2,"When the t 1/2 values are derived from the renal excretion rate-time profiles, they are as follows: diclofenac 1.8 +/- 0.9 h, 3'-OH-, and 5-OH-diclofenac 2.3 +/- 1.0 h and 2.5 +/- 0.4 h, respectively, while those of 4'-OH- and 4',5-diOH-diclofenac are, respectively 3.6 +/- 0.5 h and 3.1 +/- 1.3 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,1.8,75030,DB00586,Diclofenac
,2387653,t 1/2,"When the t 1/2 values are derived from the renal excretion rate-time profiles, they are as follows: diclofenac 1.8 +/- 0.9 h, 3'-OH-, and 5-OH-diclofenac 2.3 +/- 1.0 h and 2.5 +/- 0.4 h, respectively, while those of 4'-OH- and 4',5-diOH-diclofenac are, respectively 3.6 +/- 0.5 h and 3.1 +/- 1.3 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,2.3,75031,DB00586,Diclofenac
,2387653,t 1/2,"When the t 1/2 values are derived from the renal excretion rate-time profiles, they are as follows: diclofenac 1.8 +/- 0.9 h, 3'-OH-, and 5-OH-diclofenac 2.3 +/- 1.0 h and 2.5 +/- 0.4 h, respectively, while those of 4'-OH- and 4',5-diOH-diclofenac are, respectively 3.6 +/- 0.5 h and 3.1 +/- 1.3 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,2.5,75032,DB00586,Diclofenac
,2387653,t 1/2,"When the t 1/2 values are derived from the renal excretion rate-time profiles, they are as follows: diclofenac 1.8 +/- 0.9 h, 3'-OH-, and 5-OH-diclofenac 2.3 +/- 1.0 h and 2.5 +/- 0.4 h, respectively, while those of 4'-OH- and 4',5-diOH-diclofenac are, respectively 3.6 +/- 0.5 h and 3.1 +/- 1.3 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,3.6,75033,DB00586,Diclofenac
,2387653,t 1/2,"When the t 1/2 values are derived from the renal excretion rate-time profiles, they are as follows: diclofenac 1.8 +/- 0.9 h, 3'-OH-, and 5-OH-diclofenac 2.3 +/- 1.0 h and 2.5 +/- 0.4 h, respectively, while those of 4'-OH- and 4',5-diOH-diclofenac are, respectively 3.6 +/- 0.5 h and 3.1 +/- 1.3 h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),h,3.1,75034,DB00586,Diclofenac
,2387653,renal clearance (Clr),"Diclofenac is excreted for 13.6 +/- 6.5%, its renal clearance (Clr) = 3.23 +/- 1.03 ml/min.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),[ml] / [min],3.23,75035,DB00586,Diclofenac
,2387653,Clr,The main metabolite excreted in the urine is 4'-OH-diclofenac (27.2 +/- 12% dose; Clr = 6.14 +/- 4.04 ml/min).,Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),[ml] / [min],6.14,75036,DB00586,Diclofenac
,2387653,total body clearance,"The total body clearance of the parent drug and the apparent total body clearance of the main metabolite are similar, 28.0 +/- 11.9 l/h and 27.5 +/- 10.9 l/h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),[l] / [h],28.0,75037,DB00586,Diclofenac
,2387653,apparent total body clearance,"The total body clearance of the parent drug and the apparent total body clearance of the main metabolite are similar, 28.0 +/- 11.9 l/h and 27.5 +/- 10.9 l/h.",Pharmacokinetics of rectal diclofenac and its hydroxy metabolites in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387653/),[l] / [h],27.5,75038,DB00586,Diclofenac
,3042958,terminal half-life,"Diclofenac significantly increased (P less than .05) the area under the curve in tissue-cage fluid of ceftriaxone and cefotiam-treated animals, and the terminal half-life of ceftriaxone in their sera (3.45 +/- 0.4 vs. 2.8 +/- 0.5 hr).",Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042958/),h,3.45,75141,DB00586,Diclofenac
,3042958,terminal half-life,"Diclofenac significantly increased (P less than .05) the area under the curve in tissue-cage fluid of ceftriaxone and cefotiam-treated animals, and the terminal half-life of ceftriaxone in their sera (3.45 +/- 0.4 vs. 2.8 +/- 0.5 hr).",Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042958/),h,2.8,75142,DB00586,Diclofenac
,22275128,flow-rate,"Chromatographic separation was achieved on a Thermo Hypurity C(18) , 50 × 4.6 mm, 5 µm column with a mobile phase consisting of 2 m m ammonium acetate buffer and methanol (pH 4.5 adjusted with glacial acetic acid; 15:85, v/v) at a flow-rate of 0.75 mL/min and the total run time was 1.75 min.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),[ml] / [min],0.75,75285,DB00586,Diclofenac
,22275128,total run time,"Chromatographic separation was achieved on a Thermo Hypurity C(18) , 50 × 4.6 mm, 5 µm column with a mobile phase consisting of 2 m m ammonium acetate buffer and methanol (pH 4.5 adjusted with glacial acetic acid; 15:85, v/v) at a flow-rate of 0.75 mL/min and the total run time was 1.75 min.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),min,1.75,75286,DB00586,Diclofenac
,22275128,dwell time,"Both the drug and IS were detected in negative-ion mode using multiple reaction monitoring m/z 240.0 → 196.3 and m/z 294.0 → 250.2, respectively, with a dwell time of 200 ms for each of the transitions.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),ms,200,75287,DB00586,Diclofenac
,22275128,recovery,The observed mean recovery was 73% for the drug.,A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),%,73,75288,DB00586,Diclofenac
,26067670,critical micelle concentration,"The critical micelle concentration of the MPEG-PCL-CS block polymer was 0.000692 g/L. DIC/MPEG-PCL-CS nanosuspension (mean particle size = 105 nm, zeta potential = 8 mV) was prepared and characterized by Fourier transform infrared spectroscopy, X-ray diffraction, and differential scanning calorimetry.",Chitosan grafted methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26067670/),[g] / [l],0.000692,75974,DB00586,Diclofenac
,26067670,zeta potential,"The critical micelle concentration of the MPEG-PCL-CS block polymer was 0.000692 g/L. DIC/MPEG-PCL-CS nanosuspension (mean particle size = 105 nm, zeta potential = 8 mV) was prepared and characterized by Fourier transform infrared spectroscopy, X-ray diffraction, and differential scanning calorimetry.",Chitosan grafted methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26067670/),mv,8,75975,DB00586,Diclofenac
,11556125,relative bioavailability,"After dose normalisation, a mean relative bioavailability of 99% (B), 142% (C) and 116% (D) was determined for the pellet formulation.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),%,99,77370,DB00586,Diclofenac
,11556125,relative bioavailability,"After dose normalisation, a mean relative bioavailability of 99% (B), 142% (C) and 116% (D) was determined for the pellet formulation.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),%,142,77371,DB00586,Diclofenac
,11556125,relative bioavailability,"After dose normalisation, a mean relative bioavailability of 99% (B), 142% (C) and 116% (D) was determined for the pellet formulation.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),%,116,77372,DB00586,Diclofenac
,11556125,maximum serum concentration,"For the test formulation, the highest mean maximum serum concentration (1595 ng/ml) was measured with a corresponding tmax of 0.8 h.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),[ng] / [ml],1595,77373,DB00586,Diclofenac
,11556125,tmax,"For the test formulation, the highest mean maximum serum concentration (1595 ng/ml) was measured with a corresponding tmax of 0.8 h.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),h,0.8,77374,DB00586,Diclofenac
,11556125,peak serum concentrations,"For the reference formulations, mean peak serum concentrations of 1285 ng/ml after 2.0 h (B), 370 ng/ml after 1.8 h (C) and 735 ng/ml after 1.9 h (D) were observed.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),[ng] / [ml],1285,77375,DB00586,Diclofenac
,11556125,peak serum concentrations,"For the reference formulations, mean peak serum concentrations of 1285 ng/ml after 2.0 h (B), 370 ng/ml after 1.8 h (C) and 735 ng/ml after 1.9 h (D) were observed.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),[ng] / [ml],370,77376,DB00586,Diclofenac
,11556125,peak serum concentrations,"For the reference formulations, mean peak serum concentrations of 1285 ng/ml after 2.0 h (B), 370 ng/ml after 1.8 h (C) and 735 ng/ml after 1.9 h (D) were observed.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),[ng] / [ml],735,77377,DB00586,Diclofenac
,11556125,lagtime,"Despite the enteric-coating of the pellets, a short lagtime of 0.4 h was determined for the test formulation.",[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11556125/),h,0.4,77378,DB00586,Diclofenac
,9876511,bioavailability,The in vivo availability study in six beagle dogs revealed that the formulated enteric-coated beads filled in hard gelatin capsules had a 197.54% bioavailability relative to that of the commercial Voltaren tablets.,Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),%,197.54,78288,DB00586,Diclofenac
,9876511,area under curve for 0-8 hr (AUC0-8 hr),The tablets showed a significantly lower (p < 0.05) area under curve for 0-8 hr (AUC0-8 hr) of 13.44 +/- 15.02 micrograms hr/ml compared to 26.55 +/- 5.19 micrograms hr/ml for the capsules.,Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),[h·μg] / [ml],13.44,78289,DB00586,Diclofenac
,9876511,area under curve for 0-8 hr (AUC0-8 hr),The tablets showed a significantly lower (p < 0.05) area under curve for 0-8 hr (AUC0-8 hr) of 13.44 +/- 15.02 micrograms hr/ml compared to 26.55 +/- 5.19 micrograms hr/ml for the capsules.,Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),[h·μg] / [ml],26.55,78290,DB00586,Diclofenac
,9876511,peak plasma concentration (Cmax),The capsules showed a nonsignificantly (p > 0.05) higher peak plasma concentration (Cmax) of 6.77 +/- 0.67 micrograms/ml compared to 5.88 +/- 7.38 micrograms/ml for the tablets.,Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),[μg] / [ml],6.77,78291,DB00586,Diclofenac
,9876511,peak plasma concentration (Cmax),The capsules showed a nonsignificantly (p > 0.05) higher peak plasma concentration (Cmax) of 6.77 +/- 0.67 micrograms/ml compared to 5.88 +/- 7.38 micrograms/ml for the tablets.,Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),[μg] / [ml],5.88,78292,DB00586,Diclofenac
,9876511,time to reach peak (Tmax),"The time to reach peak (Tmax) values were 2 +/- 1.48 and 2.25 +/- 1.08 hr for the capsules and tablets, respectively.",Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),h,2,78293,DB00586,Diclofenac
,9876511,time to reach peak (Tmax),"The time to reach peak (Tmax) values were 2 +/- 1.48 and 2.25 +/- 1.08 hr for the capsules and tablets, respectively.",Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876511/),h,2.25,78294,DB00586,Diclofenac
,8071813,ionization constants (pKas),Potentiometrically determined ionization constants (pKas) were in the range of 7.52 to 8.40 at 25 degrees C.,"Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071813/),,7.52 to 8.40,78659,DB00586,Diclofenac
,8071813,half-lives of hydrolysis,"In general, the esters were hydrolyzed rapidly in rat plasma at 37 degrees C, the half-lives of hydrolysis being in the range of 4.85 to 23.49 min.","Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071813/),min,4.85 to 23.49,78660,DB00586,Diclofenac
,9207985,half-life,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,85.54,80044,DB00586,Diclofenac
,9207985,liver clearance,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),[ml] / [g·min],0.52,80045,DB00586,Diclofenac
,9207985,extraction ratio,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,0.517,80046,DB00586,Diclofenac
,9207985,half-life,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,123.95,80047,DB00586,Diclofenac
,9207985,liver clearance,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),[ml] / [g·min],0.1164,80048,DB00586,Diclofenac
,9207985,extraction ratio,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),,0.116,80049,DB00586,Diclofenac
,29651912,Cmax,Diclofenac could significantly (p < 0.05) decrease the Cmax (from 66.93 ± 10.28 to 41.25 ± 8.06 ng/mL) and AUC0-t (from 765.84 ± 163.61 to 451.33 ± 110.88 μg × h/L) of celastrol in rats.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),[ng] / [ml],66.93,80435,DB00586,Diclofenac
,29651912,Cmax,Diclofenac could significantly (p < 0.05) decrease the Cmax (from 66.93 ± 10.28 to 41.25 ± 8.06 ng/mL) and AUC0-t (from 765.84 ± 163.61 to 451.33 ± 110.88 μg × h/L) of celastrol in rats.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),[ng] / [ml],41.25,80436,DB00586,Diclofenac
,29651912,AUC0-t,Diclofenac could significantly (p < 0.05) decrease the Cmax (from 66.93 ± 10.28 to 41.25 ± 8.06 ng/mL) and AUC0-t (from 765.84 ± 163.61 to 451.33 ± 110.88 μg × h/L) of celastrol in rats.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),[h·μg] / [l],765.84,80437,DB00586,Diclofenac
,29651912,AUC0-t,Diclofenac could significantly (p < 0.05) decrease the Cmax (from 66.93 ± 10.28 to 41.25 ± 8.06 ng/mL) and AUC0-t (from 765.84 ± 163.61 to 451.33 ± 110.88 μg × h/L) of celastrol in rats.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),[h·μg] / [l],451.33,80438,DB00586,Diclofenac
,29651912,efflux ratio,The efflux ratio of celastrol increased significantly (p < 0.05) from 3.12 to 4.55 with the treatment of diclofenac.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),,3.12,80439,DB00586,Diclofenac
,29651912,efflux ratio,The efflux ratio of celastrol increased significantly (p < 0.05) from 3.12 to 4.55 with the treatment of diclofenac.,Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29651912/),,4.55,80440,DB00586,Diclofenac
,24815417,half-time,Analgesia onset had an equilibration half-time of 0.496 h for acetaminophen and 0.23 h for diclofenac.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),h,0.496,81110,DB00586,Diclofenac
,24815417,half-time,Analgesia onset had an equilibration half-time of 0.496 h for acetaminophen and 0.23 h for diclofenac.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),h,0.23,81111,DB00586,Diclofenac
,24815417,maximum effect (EMAX ),The maximum effect (EMAX ) was 4.9.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),,4.9,81112,DB00586,Diclofenac
,24815417,concentration,The concentration resulting in 50% of EMAX (C50 ) was 1.23 mg·l(-1) for diclofenac and 13.3 mg·l(-1) for acetaminophen.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),[mg] / [l],1.23,81113,DB00586,Diclofenac
,24815417,concentration,The concentration resulting in 50% of EMAX (C50 ) was 1.23 mg·l(-1) for diclofenac and 13.3 mg·l(-1) for acetaminophen.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),[mg] / [l],13.3,81114,DB00586,Diclofenac
,24815417,peak placebo effect,A peak placebo effect of 6.8 occurred at 4 h.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),,6.8,81115,DB00586,Diclofenac
,15177307,area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)),There were no significant differences between subjects with moderate hepatic insufficiency and healthy subjects in the area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)): 29.2 +/- 6.7 microg h ml(-1) versus 28.7 +/- 6.3 mircrog h ml(-1).,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177307/),[h·μg] / [ml],29.2,81512,DB00586,Diclofenac
,15177307,area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)),There were no significant differences between subjects with moderate hepatic insufficiency and healthy subjects in the area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)): 29.2 +/- 6.7 microg h ml(-1) versus 28.7 +/- 6.3 mircrog h ml(-1).,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177307/),[h·mircrog] / [ml],28.7,81513,DB00586,Diclofenac
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.966,82028,DB00586,Diclofenac
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.503,82029,DB00586,Diclofenac
,32272615,Papp,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),[cm] / [s],0.115 × 10-6,82030,DB00586,Diclofenac
>,32272615,plasma protein binding,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),%,99.9,82031,DB00586,Diclofenac
,2907543,flow rate,"The drugs were eluted from a 5 microns C-8 reversed-phase column at ambient temperature with a mobile phase consisting of acetonitrile-water (50:50% v/v) adjusted to pH 3.3 with glacial acetic acid, at a flow rate of 2 mL min-1 with UV detection at 280 nm.",A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907543/),[ml] / [min],2,82036,DB00586,Diclofenac
,2907543,relative,Quantitation was achieved by the measurement of the peak-height ratio and the relative and absolute recoveries varied from 90 to 98%.,A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907543/),%,90 to 98,82037,DB00586,Diclofenac
,2907543,absolute recoveries,Quantitation was achieved by the measurement of the peak-height ratio and the relative and absolute recoveries varied from 90 to 98%.,A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907543/),%,90 to 98,82038,DB00586,Diclofenac
,2907543,Detection limits,Detection limits for diclofenac sodium in serum is 25 ng mL-1.,A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907543/),[ng] / [ml],25,82039,DB00586,Diclofenac
,25442263,ED30,"The derived theoretical ED30 for the antinociceptive effect (19.2 mg/kg) was significantly different from the observed experimental ED30 value (9.8 mg/kg); hence, the interaction between diclofenac and curcumin that mediates the antinociceptive effect was synergistic.",Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442263/),[mg] / [kg],19.2,82040,DB00586,Diclofenac
,25442263,ED30,"The derived theoretical ED30 for the antinociceptive effect (19.2 mg/kg) was significantly different from the observed experimental ED30 value (9.8 mg/kg); hence, the interaction between diclofenac and curcumin that mediates the antinociceptive effect was synergistic.",Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442263/),[mg] / [kg],9.8,82041,DB00586,Diclofenac
<,33564940,tensile strength,The tensile strength of ACE was < 1 MPa in contrast to the cocrystal tensile strength (3.5 MPa) which was ~1.98 times higher at 6000 psi.,"Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564940/),Mp,1,83310,DB00586,Diclofenac
,33564940,tensile strength,The tensile strength of ACE was < 1 MPa in contrast to the cocrystal tensile strength (3.5 MPa) which was ~1.98 times higher at 6000 psi.,"Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564940/),Mpa,3.5,83311,DB00586,Diclofenac
,33564940,AUC0-∞,The AUC0-∞ (37.87±1.3 μgh/ml) and Cmax (6.94±2.94 μg/ml) of the selected cocrystal C1 prepared by SAG were significantly enhanced (p < 0.05) and were ~3.43 and ~1.63-fold higher than that of ACE.,"Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564940/),[μgh] / [ml],37.87,83312,DB00586,Diclofenac
,33564940,Cmax,The AUC0-∞ (37.87±1.3 μgh/ml) and Cmax (6.94±2.94 μg/ml) of the selected cocrystal C1 prepared by SAG were significantly enhanced (p < 0.05) and were ~3.43 and ~1.63-fold higher than that of ACE.,"Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564940/),[μg] / [ml],6.94,83313,DB00586,Diclofenac
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],681.6,85784,DB00586,Diclofenac
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],1268.8,85785,DB00586,Diclofenac
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],229.6,85786,DB00586,Diclofenac
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],561.89,85787,DB00586,Diclofenac
,9793621,aqueous humor concentration peak,DCF was absorbed well through the cornea with the aqueous humor concentration peak being 757.8 ng/ml at 120 min.,Absorption of sodium diclofenac after ocular administration in rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793621/),[ng] / [ml],757.8,86220,DB00586,Diclofenac
,33991809,m/,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,310.1,88086,DB00586,Diclofenac
,33991809,m/,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,264.1,88087,DB00586,Diclofenac
,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,470.1,88088,DB00586,Diclofenac
>,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,276.1,88089,DB00586,Diclofenac
,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,296.0,88090,DB00586,Diclofenac
>,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,250.0,88091,DB00586,Diclofenac
more,33991809,extraction recovery,The extraction recovery was more than 80.54 %.,A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),%,80.54,88092,DB00586,Diclofenac
,16928785,EC(50),"In monkey hepatocytes, rifampin markedly induced DF 4'-hydroxylase activity, with values for EC(50) of 0.2 to 0.4 microM and E(max) of 2- to 5-fold over control.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2 to 0.4,88587,DB00586,Diclofenac
,16928785,EC(50),"Under similar treatment conditions, rifampin was previously shown to induce midazolam (MDZ) 1'-hydroxylation in rhesus monkey hepatocytes (EC(50) and E(max) values approximately 0.2 microM and approximately 2- to 3-fold, respectively), and markedly affected the in vivo pharmacokinetics of MDZ (>10-fold decreases in the i.pv.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2,88588,DB00586,Diclofenac
,2817851,Cumulative biliary excretion,"Cumulative biliary excretion of ceftriaxone over 6 h was significantly reduced in group 2 (5,291.6 +/- 2,017.5 micrograms in group 1 versus 1,379.1 +/- 567.1 micrograms in group 2).",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),μg,"5,291.6",89238,DB00586,Diclofenac
,2817851,Cumulative biliary excretion,"Cumulative biliary excretion of ceftriaxone over 6 h was significantly reduced in group 2 (5,291.6 +/- 2,017.5 micrograms in group 1 versus 1,379.1 +/- 567.1 micrograms in group 2).",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),μg,"1,379.1",89239,DB00586,Diclofenac
,2817851,clearance,"Indocyanine green clearance (20 mg/kg) increased in animals treated with ceftriaxone alone compared with the saline-treated control group (55.04 +/- 4.68 versus 33.29 +/- 7.52 ml/min per kg, respectively).",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),[ml] / [kg·min],55.04,89240,DB00586,Diclofenac
,2817851,clearance,"Indocyanine green clearance (20 mg/kg) increased in animals treated with ceftriaxone alone compared with the saline-treated control group (55.04 +/- 4.68 versus 33.29 +/- 7.52 ml/min per kg, respectively).",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),[ml] / [kg·min],33.29,89241,DB00586,Diclofenac
,2817851,clearance,"Diclofenac alone caused a significant decrease in indocyanine green clearance compared with clearance in controls (25.05 +/- 4.74 versus 33.29 +/- 7.52 ml/min per kg), and indocyanine green clearance appeared not significantly different from control values in animals receiving ceftriaxone plus diclofenac.",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),[ml] / [kg·min],25.05,89242,DB00586,Diclofenac
,2817851,clearance,"Diclofenac alone caused a significant decrease in indocyanine green clearance compared with clearance in controls (25.05 +/- 4.74 versus 33.29 +/- 7.52 ml/min per kg), and indocyanine green clearance appeared not significantly different from control values in animals receiving ceftriaxone plus diclofenac.",Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2817851/),[ml] / [kg·min],33.29,89243,DB00586,Diclofenac
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00586,Diclofenac
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00586,Diclofenac
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00586,Diclofenac
,17262954,zeta potential,The mean particle size of the diclofenac sodium liposomes was 226.5 nm with zeta potential of + 18.,[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),,18,93018,DB00586,Diclofenac
,17262954,entrapment efficiency,The entrapment efficiency reached 63%.,[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),%,63,93019,DB00586,Diclofenac
,17262954,Cmax,"Cmax of diclofenac sodium in aqueous humor instilled with liposome and eye-drop solution were (0.69 +/- 0.25) and (0.48 +/- 0.19) microg x mL(-1) and (36.68 +/- 11.7) and (21.82 +/- 8.6) microg x g(-1) in cornea, respectively.",[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),[μg] / [ml],0.69,93020,DB00586,Diclofenac
,17262954,Cmax,"Cmax of diclofenac sodium in aqueous humor instilled with liposome and eye-drop solution were (0.69 +/- 0.25) and (0.48 +/- 0.19) microg x mL(-1) and (36.68 +/- 11.7) and (21.82 +/- 8.6) microg x g(-1) in cornea, respectively.",[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),[μg] / [ml],0.48,93021,DB00586,Diclofenac
,17262954,Cmax,"Cmax of diclofenac sodium in aqueous humor instilled with liposome and eye-drop solution were (0.69 +/- 0.25) and (0.48 +/- 0.19) microg x mL(-1) and (36.68 +/- 11.7) and (21.82 +/- 8.6) microg x g(-1) in cornea, respectively.",[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),[μg] / [g],36.68,93022,DB00586,Diclofenac
,17262954,Cmax,"Cmax of diclofenac sodium in aqueous humor instilled with liposome and eye-drop solution were (0.69 +/- 0.25) and (0.48 +/- 0.19) microg x mL(-1) and (36.68 +/- 11.7) and (21.82 +/- 8.6) microg x g(-1) in cornea, respectively.",[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),[μg] / [g],21.82,93023,DB00586,Diclofenac
,17262954,o,The ocular bioavailability of liposome in aqueous humor was 211% compared with that of eyedrop.,[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),%,211,93024,DB00586,Diclofenac
,17262954,bioavailability,The ocular bioavailability of liposome in aqueous humor was 211% compared with that of eyedrop.,[Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17262954/),%,211,93025,DB00586,Diclofenac
,4095130,time at which 63.2%,"In vitro, the time at which 63.2% of the drug are liberated (tL) is 14, 20, 25, 14 and 3.5 min for the preparations A, B, C, D and E, respectively.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,14,93120,DB00586,Diclofenac
,4095130,time at which 63.2%,"In vitro, the time at which 63.2% of the drug are liberated (tL) is 14, 20, 25, 14 and 3.5 min for the preparations A, B, C, D and E, respectively.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,20,93121,DB00586,Diclofenac
,4095130,time at which 63.2%,"In vitro, the time at which 63.2% of the drug are liberated (tL) is 14, 20, 25, 14 and 3.5 min for the preparations A, B, C, D and E, respectively.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,25,93122,DB00586,Diclofenac
,4095130,time at which 63.2%,"In vitro, the time at which 63.2% of the drug are liberated (tL) is 14, 20, 25, 14 and 3.5 min for the preparations A, B, C, D and E, respectively.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,3.5,93123,DB00586,Diclofenac
,4095130,time of the concentration maximum (tmax),"In vivo, the time of the concentration maximum (tmax) in min is (mean +/- S mean): A = 68 +/- 18, B = 72 +/- 9, C = 120 +/- 22, D = 42 +/- 3, E = 24 +/- 0.5.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,68,93124,DB00586,Diclofenac
,4095130,time of the concentration maximum (tmax),"In vivo, the time of the concentration maximum (tmax) in min is (mean +/- S mean): A = 68 +/- 18, B = 72 +/- 9, C = 120 +/- 22, D = 42 +/- 3, E = 24 +/- 0.5.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,72,93125,DB00586,Diclofenac
,4095130,time of the concentration maximum (tmax),"In vivo, the time of the concentration maximum (tmax) in min is (mean +/- S mean): A = 68 +/- 18, B = 72 +/- 9, C = 120 +/- 22, D = 42 +/- 3, E = 24 +/- 0.5.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,120,93126,DB00586,Diclofenac
,4095130,time of the concentration maximum (tmax),"In vivo, the time of the concentration maximum (tmax) in min is (mean +/- S mean): A = 68 +/- 18, B = 72 +/- 9, C = 120 +/- 22, D = 42 +/- 3, E = 24 +/- 0.5.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,42,93127,DB00586,Diclofenac
,4095130,time of the concentration maximum (tmax),"In vivo, the time of the concentration maximum (tmax) in min is (mean +/- S mean): A = 68 +/- 18, B = 72 +/- 9, C = 120 +/- 22, D = 42 +/- 3, E = 24 +/- 0.5.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),min,24,93128,DB00586,Diclofenac
,4095130,tmax,"l-1 at tmax is (mean +/- S mean): A = 5.9 +/- 0.8, B = 3.9 +/- 0.3, C = 3.1 +/- 0.4, D = 5.7 +/- 0.6, and E = 5.5 +/- 0.8.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),1/[l],5.9,93129,DB00586,Diclofenac
,4095130,tmax,"l-1 at tmax is (mean +/- S mean): A = 5.9 +/- 0.8, B = 3.9 +/- 0.3, C = 3.1 +/- 0.4, D = 5.7 +/- 0.6, and E = 5.5 +/- 0.8.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),1/[l],3.9,93130,DB00586,Diclofenac
,4095130,tmax,"l-1 at tmax is (mean +/- S mean): A = 5.9 +/- 0.8, B = 3.9 +/- 0.3, C = 3.1 +/- 0.4, D = 5.7 +/- 0.6, and E = 5.5 +/- 0.8.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),1/[l],3.1,93131,DB00586,Diclofenac
,4095130,tmax,"l-1 at tmax is (mean +/- S mean): A = 5.9 +/- 0.8, B = 3.9 +/- 0.3, C = 3.1 +/- 0.4, D = 5.7 +/- 0.6, and E = 5.5 +/- 0.8.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),1/[l],5.7,93132,DB00586,Diclofenac
,4095130,tmax,"l-1 at tmax is (mean +/- S mean): A = 5.9 +/- 0.8, B = 3.9 +/- 0.3, C = 3.1 +/- 0.4, D = 5.7 +/- 0.6, and E = 5.5 +/- 0.8.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),,5.5,93133,DB00586,Diclofenac
,4095130,area under the curve (AUC),"The area under the curve (AUC) for all the preparations has found to be between 8.7 and 10,6 mumol . h . l-1.",[In vitro and in vivo studies of diclofenac suppositories in humans]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095130/),[h·μM] / [l],"8.7 and 10,6",93134,DB00586,Diclofenac
,29912563,half-life ( t1/2),"However, it hydrolyzed in human serum with a half-life ( t1/2) of 36 min, producing aceclofenac.","Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29912563/),min,36,93519,DB00586,Diclofenac
,7199303,t1/2e,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,1.98,93636,DB00586,Diclofenac
,7199303,tmax,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,2.2267,93637,DB00586,Diclofenac
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00586,Diclofenac
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00586,Diclofenac
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00586,Diclofenac
,19357794,lag time,The objective of this study was to develop and evaluate an oral chronomodulated drug delivery system (CDDS) for the treatment of rheumatoid arthritis with a distinct predetermined lag time of 6 h (+/- 0.25 h).,Development and evaluation of a time-specific pulsatile-release tablet of aceclofenac: a solution for morning pain in rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19357794/),h,6,95799,DB00586,Diclofenac
,14550741,terminal elimination half-life (t(1/2beta)),"The results obtained (median and range) were as follows: the terminal elimination half-life (t(1/2beta)) was 2.35 (1.90-2.73)h, total body clearance (Cl(T)) was 0.17 (0.16-0.21)lh kg(-1).",The disposition of diclofenac in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550741/),h,2.35,96012,DB00586,Diclofenac
,14550741,total body clearance (Cl(T)),"The results obtained (median and range) were as follows: the terminal elimination half-life (t(1/2beta)) was 2.35 (1.90-2.73)h, total body clearance (Cl(T)) was 0.17 (0.16-0.21)lh kg(-1).",The disposition of diclofenac in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550741/),[lh] / [kg],0.17,96013,DB00586,Diclofenac
,14550741,volume of distribution at steady state (V(SS)),"The volume of distribution at steady state (V(SS)) was 0.31 (0.21-0.39)l(-1)kg(-1), the volume of the central compartment of the two compartment pharmacokinetic model (V(C)) was 0.15 (0.11-0.17)l kg(-1).",The disposition of diclofenac in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550741/),1/[l],0.31,96014,DB00586,Diclofenac
,14550741,volume of the central compartment,"The volume of distribution at steady state (V(SS)) was 0.31 (0.21-0.39)l(-1)kg(-1), the volume of the central compartment of the two compartment pharmacokinetic model (V(C)) was 0.15 (0.11-0.17)l kg(-1).",The disposition of diclofenac in camels after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550741/),[l] / [kg],0.15,96015,DB00586,Diclofenac
,19825328,AUC yen,"Mean AUC yen was 798 +/- 281 ng x h/ml (mean +/- SD) for the film-coated and 776 +/- 249 ng x h/ml for the sugar-coated formulation, respectively.",Bioequivalence study of low-dose diclofenac potassium tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825328/),[h·ng] / [ml],798,96267,DB00586,Diclofenac
,19825328,AUC yen,"Mean AUC yen was 798 +/- 281 ng x h/ml (mean +/- SD) for the film-coated and 776 +/- 249 ng x h/ml for the sugar-coated formulation, respectively.",Bioequivalence study of low-dose diclofenac potassium tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825328/),[h·ng] / [ml],776,96268,DB00586,Diclofenac
,19825328,time to maximal plasma concentration,Both formulations were rapidly absorbed; median time to maximal plasma concentration was 35 min in each group.,Bioequivalence study of low-dose diclofenac potassium tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825328/),min,35,96269,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],20.5,96987,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],29.9,96988,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],30.0,96989,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],22.6,96990,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],23.5,96991,DB00586,Diclofenac
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],37.3,96992,DB00586,Diclofenac
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,18.1,99194,DB00586,Diclofenac
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,3.5,99195,DB00586,Diclofenac
,21783820,LD(50),"In a lethal dose study, diclofenac was shown to have an approximate intramuscular LD(50) of 9.8mg/kg in 18-week old layers.",Validating the domestic fowl as a model to investigate the pathophysiology of diclofenac in Gyps vultures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783820/),[mg] / [kg],9.8,99449,DB00586,Diclofenac
,21783820,half-life of elimination,"The pharmacokinetics after both the intramuscular and oral route showed that diclofenac had a short half-life of elimination of approximately 1h, a volume of distribution of 0.09-0.24l/kg and relative oral bioavailability of 50% compared to intramuscular administration.",Validating the domestic fowl as a model to investigate the pathophysiology of diclofenac in Gyps vultures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783820/),h,1,99450,DB00586,Diclofenac
,21783820,volume of distribution,"The pharmacokinetics after both the intramuscular and oral route showed that diclofenac had a short half-life of elimination of approximately 1h, a volume of distribution of 0.09-0.24l/kg and relative oral bioavailability of 50% compared to intramuscular administration.",Validating the domestic fowl as a model to investigate the pathophysiology of diclofenac in Gyps vultures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783820/),[l] / [kg],0.09-0.24,99451,DB00586,Diclofenac
,21783820,relative oral bioavailability,"The pharmacokinetics after both the intramuscular and oral route showed that diclofenac had a short half-life of elimination of approximately 1h, a volume of distribution of 0.09-0.24l/kg and relative oral bioavailability of 50% compared to intramuscular administration.",Validating the domestic fowl as a model to investigate the pathophysiology of diclofenac in Gyps vultures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21783820/),%,50,99452,DB00586,Diclofenac
,22314121,Tmax,Mean (± standard deviation) Tmax for nano-formulated diclofenac 18 (0.62 ± 0.35 h) and 35 mg (0.59 ± 0.20 h) demonstrated faster absorption than diclofenac 50 mg (0.80 ± 0.50 h).,"The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),h,0.62,100131,DB00586,Diclofenac
,22314121,Tmax,Mean (± standard deviation) Tmax for nano-formulated diclofenac 18 (0.62 ± 0.35 h) and 35 mg (0.59 ± 0.20 h) demonstrated faster absorption than diclofenac 50 mg (0.80 ± 0.50 h).,"The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),h,0.59,100132,DB00586,Diclofenac
,22314121,Tmax,Mean (± standard deviation) Tmax for nano-formulated diclofenac 18 (0.62 ± 0.35 h) and 35 mg (0.59 ± 0.20 h) demonstrated faster absorption than diclofenac 50 mg (0.80 ± 0.50 h).,"The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),h,0.80,100133,DB00586,Diclofenac
,22314121,T1/2,"The T1/2 was similar between nano-formulated diclofenac 35 mg and diclofenac 50 mg (1.85 ± 0.45 h vs 1.92 ± 0.38 h, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),h,1.85,100134,DB00586,Diclofenac
,22314121,T1/2,"The T1/2 was similar between nano-formulated diclofenac 35 mg and diclofenac 50 mg (1.85 ± 0.45 h vs 1.92 ± 0.38 h, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),h,1.92,100135,DB00586,Diclofenac
,22314121,Cmax,"The Cmax for nano-formulated diclofenac 35 mg and diclofenac 50 mg was comparable in fasted subjects (1347 ± 764 ng/mL vs 1316 ± 577 ng/mL, respectively), but lower in fed subjects (524 ± 222 ng/mL vs 951 ± 391 ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[ng] / [ml],1347,100136,DB00586,Diclofenac
,22314121,Cmax,"The Cmax for nano-formulated diclofenac 35 mg and diclofenac 50 mg was comparable in fasted subjects (1347 ± 764 ng/mL vs 1316 ± 577 ng/mL, respectively), but lower in fed subjects (524 ± 222 ng/mL vs 951 ± 391 ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[ng] / [ml],1316,100137,DB00586,Diclofenac
,22314121,Cmax,"The Cmax for nano-formulated diclofenac 35 mg and diclofenac 50 mg was comparable in fasted subjects (1347 ± 764 ng/mL vs 1316 ± 577 ng/mL, respectively), but lower in fed subjects (524 ± 222 ng/mL vs 951 ± 391 ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[ng] / [ml],524,100138,DB00586,Diclofenac
,22314121,Cmax,"The Cmax for nano-formulated diclofenac 35 mg and diclofenac 50 mg was comparable in fasted subjects (1347 ± 764 ng/mL vs 1316 ± 577 ng/mL, respectively), but lower in fed subjects (524 ± 222 ng/mL vs 951 ± 391 ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[ng] / [ml],951,100139,DB00586,Diclofenac
,22314121,AUC0(-∞),"As anticipated, there was a 19% reduction in drug exposure (AUC0(-∞)) when subjects received nano-formulated diclofenac 35 mg compared with diclofenac 50 mg under fasting conditions (1225 ± 322 h*ng/mL vs 1511 ± 389 h*ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[h·ng] / [ml],1225,100140,DB00586,Diclofenac
,22314121,AUC0(-∞),"As anticipated, there was a 19% reduction in drug exposure (AUC0(-∞)) when subjects received nano-formulated diclofenac 35 mg compared with diclofenac 50 mg under fasting conditions (1225 ± 322 h*ng/mL vs 1511 ± 389 h*ng/mL, respectively).","The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22314121/),[h·ng] / [ml],1511,100141,DB00586,Diclofenac
,19958362,dissociation equilibrium constant,The in vivo estimate of the dissociation equilibrium constant of the COX-2-lumiracoxib complex was 0.24 microg*mL(-1).,"Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19958362/),[μg] / [ml],0.24,102841,DB00586,Diclofenac
,24465044,Cmax,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],473.5,104701,DB00586,Diclofenac
,24465044,Cmax,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],546.6,104702,DB00586,Diclofenac
,24465044,AUC0-∞,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[h·ng] / [ml],3841.2,104703,DB00586,Diclofenac
,24465044,AUC0-∞,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[h·ng] / [ml],5019.1,104704,DB00586,Diclofenac
,24465044,Tmax,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,4.9,104705,DB00586,Diclofenac
,24465044,Tmax,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,4.3,104706,DB00586,Diclofenac
,24465044,t1/2,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,5.9,104707,DB00586,Diclofenac
,24465044,t1/2,"The pharmacokinetic parameters (mean [SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL; AUC0-∞ 3841.2 [1402.3], and 5019.1 [2,314.0] ng·h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5], and 6.0 [2.2] hours.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,6.0,104708,DB00586,Diclofenac
,24465044,"Cmax,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],525.6,104709,DB00586,Diclofenac
,24465044,"Cmax,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],650.5,104710,DB00586,Diclofenac
,24465044,"Cmin,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],33.9,104711,DB00586,Diclofenac
,24465044,"Cmin,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],62.9,104712,DB00586,Diclofenac
,24465044,AUCss,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[h·ng] / [ml],4316.3,104713,DB00586,Diclofenac
,24465044,AUCss,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[h·ng] / [ml],5335.1,104714,DB00586,Diclofenac
,24465044,"Cav,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],179.8,104715,DB00586,Diclofenac
,24465044,"Cav,ss","Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),[ng] / [ml],222.3,104716,DB00586,Diclofenac
,24465044,Tmax,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,5.1,104717,DB00586,Diclofenac
,24465044,Tmax,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,4.5,104718,DB00586,Diclofenac
,24465044,t1/2,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,5.2,104719,DB00586,Diclofenac
,24465044,t1/2,"Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4] and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1 [1291.9] ng·h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2 [2.9] and 5.5 [2.8] hours, respectively.","Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465044/),h,5.5,104720,DB00586,Diclofenac
,16621460,AUC(0-24),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),[min·μg] / [ml],3391.8,105360,DB00586,Diclofenac
,16621460,C(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),[μg] / [ml],17.3,105361,DB00586,Diclofenac
,16621460,C(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),[μg] / [ml],15.5,105362,DB00586,Diclofenac
,16621460,T(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),min,121.5,105363,DB00586,Diclofenac
,16621460,T(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),[min·μg] / [ml],2918.4,105364,DB00586,Diclofenac
,16621460,T(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),[μg] / [ml],15.5,105365,DB00586,Diclofenac
,16621460,T(max),"For Group 1, the mean (+/- standard deviation) AUC(0-24), C(max) and T(max) values were 3391.8+/-1186.7 microg min/mL, 17.3+/-6.5 microg /mL and 121.5+/-20.6 min, respectively; and for Group 2, the values were 2918.4+/-1024.8 microg min/mL, 15.5+/-5.8 microg /mL and 136.5+/-30.0 min, respectively.",Effect of sodium diclofenac on the bioavailability of amoxicillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621460/),min,136.5,105366,DB00586,Diclofenac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,249,106087,DB00586,Diclofenac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,950,106088,DB00586,Diclofenac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,834,106089,DB00586,Diclofenac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,286,106090,DB00586,Diclofenac
,15925259,flow rate,A C(18) 250 mm x 4mm column was used for the separation of analyte with a mobile phase consisting of 50% acetonitrile and 50% pH 3.0 of sodium 1-pentansulfonate solution at a flow rate of 1.0 mL/min.,"Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925259/),[ml] / [min],1.0,107268,DB00586,Diclofenac
,15925259,lower limit of detection (LOD),The lower limit of detection (LOD) was 0.5 ng/mL.,"Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925259/),[ng] / [ml],0.5,107269,DB00586,Diclofenac
,12711453,Steady state fluxes,"Steady state fluxes of 41.6 micro g/cm(2)/h (r=0.997) and 23.0 micro g/cm(2)/h (r=0.989) were obtained for granisetron and diclofenac, respectively.",Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711453/),[μg] / [cm(2)·h],41.6,108333,DB00586,Diclofenac
,12711453,Steady state fluxes,"Steady state fluxes of 41.6 micro g/cm(2)/h (r=0.997) and 23.0 micro g/cm(2)/h (r=0.989) were obtained for granisetron and diclofenac, respectively.",Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711453/),[μg] / [cm(2)·h],23.0,108334,DB00586,Diclofenac
,12711453,peak plasma level,"Similarly, application of granisetron patches (3% in crosslinked hydrogel) onto rats' abdominal skin pretreated with radiofrequency electrodes resulted in an averaged peak plasma level of 239.3+/-43.7 ng/ml after 12 h, which was about 30 times higher than the plasma levels obtained by 24-h passive diffusion of the applied drug.",Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711453/),[ng] / [ml],239.3,108335,DB00586,Diclofenac
,19203570,run time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,8.0,108772,DB00586,Diclofenac
,19203570,retention time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,6.0,108773,DB00586,Diclofenac
,19203570,retention time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,7.0,108774,DB00586,Diclofenac
,19203570,recovery,The mean recovery of diclofenac ranged from 88.76 to 99.14% and the limit of quantification was 50 ng/ml.,A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),%,88.76 to 99.14,108775,DB00586,Diclofenac
,28985539,drug,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,37.75,111364,DB00586,Diclofenac
,28985539,half-life,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,37.75,111365,DB00586,Diclofenac
,28985539,half-life,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,13.99,111366,DB00586,Diclofenac
,20863007,relative bioavailability,"The 90% confidence interval for the ratio of logarithmically transformed AUC(0-t), AUC(0-infinity) and Cmax were within the bioequivalence limit of 0.80-1.25 and the relative bioavailability of rabeprazole and diclofenac sodium were found to be 98.6% and 98.9% respectively in the test product.",Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863007/),%,98.6,111414,DB00586,Diclofenac
,20863007,relative bioavailability,"The 90% confidence interval for the ratio of logarithmically transformed AUC(0-t), AUC(0-infinity) and Cmax were within the bioequivalence limit of 0.80-1.25 and the relative bioavailability of rabeprazole and diclofenac sodium were found to be 98.6% and 98.9% respectively in the test product.",Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863007/),%,98.9,111415,DB00586,Diclofenac
,27382279,entrapment efficiency,"Particle size and entrapment efficiency of the optimized SLN ""S8"" were determined as 98.23 nm and 84.36%, respectively.",Development of transmucosal patch loaded with anesthetic and analgesic for dental procedures and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27382279/),%,84.36,111749,DB00586,Diclofenac
,7714752,flow rate,"The drugs were eluted from a 5 microns LC-8 column with a mobile phase consisting of acetonitrile/water (50/50 v/v) adjusted to pH 3.3 with glacial acetic acid, at a flow rate of 2 mL/min with UV detection at 280 nm for diclofenac and 275 nm for nitrofenac.",Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),[ml] / [min],2,112247,DB00586,Diclofenac
,7714752,detection limit,The detection limit for the drugs in plasma was 25 ng/mL.,Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),[ng] / [ml],25,112248,DB00586,Diclofenac
,7714752,mean residence time,"The peak concentration of nitrofenac was reached 7 h after drug administration, while with diclofenac we observed three peaks at 2, 5, and 10 h; the mean residence time and the elimination rate constant for nitrofenac were 6.18 +/- 0.09 h and 0.37 +/- 0.03 h-1 respectively, while those for diclofenac were 12.24 +/- 0.11 h and 0.11 +/- 0.04 h-1.",Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),h,6.18,112249,DB00586,Diclofenac
,7714752,mean residence time,"The peak concentration of nitrofenac was reached 7 h after drug administration, while with diclofenac we observed three peaks at 2, 5, and 10 h; the mean residence time and the elimination rate constant for nitrofenac were 6.18 +/- 0.09 h and 0.37 +/- 0.03 h-1 respectively, while those for diclofenac were 12.24 +/- 0.11 h and 0.11 +/- 0.04 h-1.",Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),h,12.24,112250,DB00586,Diclofenac
,7714752,elimination rate constant,"The peak concentration of nitrofenac was reached 7 h after drug administration, while with diclofenac we observed three peaks at 2, 5, and 10 h; the mean residence time and the elimination rate constant for nitrofenac were 6.18 +/- 0.09 h and 0.37 +/- 0.03 h-1 respectively, while those for diclofenac were 12.24 +/- 0.11 h and 0.11 +/- 0.04 h-1.",Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),1/[h],0.37,112251,DB00586,Diclofenac
,7714752,elimination rate constant,"The peak concentration of nitrofenac was reached 7 h after drug administration, while with diclofenac we observed three peaks at 2, 5, and 10 h; the mean residence time and the elimination rate constant for nitrofenac were 6.18 +/- 0.09 h and 0.37 +/- 0.03 h-1 respectively, while those for diclofenac were 12.24 +/- 0.11 h and 0.11 +/- 0.04 h-1.",Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714752/),1/[h],0.11,112252,DB00586,Diclofenac
,11240880,Cmax,Mean Cmax was 2.4+/-1.3 microg.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),μg,2.4,112268,DB00586,Diclofenac
,11240880,tmax,ml-1 and mean tmax was 2+/-0.5 h.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,2,112269,DB00586,Diclofenac
,11240880,Cmax,Eight of 10 children achieved Cmax of acetaminophen within the 10-20 microg.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),μg,10-20,112270,DB00586,Diclofenac
,11240880,tabs,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,0.7,112271,DB00586,Diclofenac
,11240880,Cmax,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),[μg] / [ml],12.7,112272,DB00586,Diclofenac
,11240880,tmax,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,1.4,112273,DB00586,Diclofenac
,21311716,maximum plasma concentration,"The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[μg] / [ml],1.30,112770,DB00586,Diclofenac
,21311716,maximum plasma concentration,"The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[μg] / [ml],0.93,112771,DB00586,Diclofenac
,21311716,time to reach maximum plasma concentration,"The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),h,0.50,112772,DB00586,Diclofenac
,21311716,time to reach maximum plasma concentration,"The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),h,1.08,112773,DB00586,Diclofenac
,21311716,areas under the curve from 0 to last measurable time point (AUC(0-t)),"The mean areas under the curve from 0 to last measurable time point (AUC(0-t)) for the test and reference formulations were 2.71 μg·h/mL and 2.73 μg·h/mL, respectively.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[h·μg] / [ml],2.71,112774,DB00586,Diclofenac
,21311716,areas under the curve from 0 to last measurable time point (AUC(0-t)),"The mean areas under the curve from 0 to last measurable time point (AUC(0-t)) for the test and reference formulations were 2.71 μg·h/mL and 2.73 μg·h/mL, respectively.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[h·μg] / [ml],2.73,112775,DB00586,Diclofenac
,21311716,AUCs from 0 to infinity (AUC(0-∞)),"The mean AUCs from 0 to infinity (AUC(0-∞)) for the test and reference formulations were 3.71 μg·h/mL and 3.75 μg·h/mL, respectively.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[h·μg] / [ml],3.71,112776,DB00586,Diclofenac
,21311716,AUCs from 0 to infinity (AUC(0-∞)),"The mean AUCs from 0 to infinity (AUC(0-∞)) for the test and reference formulations were 3.71 μg·h/mL and 3.75 μg·h/mL, respectively.",Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311716/),[h·μg] / [ml],3.75,112777,DB00586,Diclofenac
,1498266,availability,The extent of availability of diclofenac from the HGB capsule was only 59 per cent relative to that from the solution (p less than 0.05).,Effect of food and relative bioavailability following single doses of diclofenac 150 mg hydrogel bead (HGB) capsules in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1498266/),%,59,113679,DB00586,Diclofenac
,11204745,flow rate,"Both compounds were extracted from human plasma with ethyl acetate at pH 1 and were chromatographed using Shim-Pack GLC-CN column and a mobile phase consisting of acetonitrile and 20 mM ammonium acetate buffer solution pH 7, 4:1 (v/v) at a flow rate 1 ml min(-1).",High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),[ml] / [min],1,115645,DB00586,Diclofenac
,11204745,Detection limit,Detection limit for furosemide in plasma was 10 ng ml(-1).,High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),[ng] / [ml],10,115646,DB00586,Diclofenac
,11204745,extraction recovery percentages,The extraction recovery percentages of furosemide and IS from plasma were in the range 89.3-97.1%.,High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),%,89.3-97.1,115647,DB00586,Diclofenac
,9258981,Total plasma clearance,"Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),[ml] / [·1.73·m2·min],219,115847,DB00586,Diclofenac
,9258981,Total plasma clearance,"Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),[ml] / [·1.73·m2·min],212,115848,DB00586,Diclofenac
,9258981,renal clearance,"Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),[ml] / [·1.73·m2·min],97,115849,DB00586,Diclofenac
,9258981,renal clearance,"Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),[ml] / [·1.73·m2·min],96,115850,DB00586,Diclofenac
,9258981,terminal t1/2,"The terminal t1/2 of cloxacillin was 1.03 +/- 0.42 hr with placebo, and 1.12 +/- 0.37 with diclofenac (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),h,1.03,115851,DB00586,Diclofenac
,9258981,terminal t1/2,"The terminal t1/2 of cloxacillin was 1.03 +/- 0.42 hr with placebo, and 1.12 +/- 0.37 with diclofenac (ns).",No effect of diclofenac on the pharmacokinetics of cloxacillin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258981/),,1.12,115852,DB00586,Diclofenac
,10853880,apparent oral clearance,"For diclofenac, the following kinetic parameters were observed in the CYP2C9*1/*1 and CYP2C9*1/*3 subjects, respectively (mean +/- SD): apparent oral clearance (ml/kg/h) 355.8 +/- 56.9 and 484.4 +/- 155.3; area under plasma concentration time curve (microg h/ml) 2.7 +/- 0.7 and 1.9 +/- 0.6.",Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[ml] / [h·kg],355.8,117847,DB00586,Diclofenac
,10853880,apparent oral clearance,"For diclofenac, the following kinetic parameters were observed in the CYP2C9*1/*1 and CYP2C9*1/*3 subjects, respectively (mean +/- SD): apparent oral clearance (ml/kg/h) 355.8 +/- 56.9 and 484.4 +/- 155.3; area under plasma concentration time curve (microg h/ml) 2.7 +/- 0.7 and 1.9 +/- 0.6.",Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[ml] / [h·kg],484.4,117848,DB00586,Diclofenac
,10853880,area under plasma concentration time curve,"For diclofenac, the following kinetic parameters were observed in the CYP2C9*1/*1 and CYP2C9*1/*3 subjects, respectively (mean +/- SD): apparent oral clearance (ml/kg/h) 355.8 +/- 56.9 and 484.4 +/- 155.3; area under plasma concentration time curve (microg h/ml) 2.7 +/- 0.7 and 1.9 +/- 0.6.",Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[h·μg] / [ml],2.7,117849,DB00586,Diclofenac
,10853880,area under plasma concentration time curve,"For diclofenac, the following kinetic parameters were observed in the CYP2C9*1/*1 and CYP2C9*1/*3 subjects, respectively (mean +/- SD): apparent oral clearance (ml/kg/h) 355.8 +/- 56.9 and 484.4 +/- 155.3; area under plasma concentration time curve (microg h/ml) 2.7 +/- 0.7 and 1.9 +/- 0.6.",Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[h·μg] / [ml],1.9,117850,DB00586,Diclofenac
,10853880,formation clearance,The formation clearance of 4'-hydroxydiclofenac (ml/kg/h) was 63.6 +/- 19.1 in the CYP2C9*1/*1 subjects compared with 75.9 +/- 27.6 in the CYP2C9*1/*3 subjects.,Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[ml] / [h·kg],63.6,117851,DB00586,Diclofenac
,10853880,formation clearance,The formation clearance of 4'-hydroxydiclofenac (ml/kg/h) was 63.6 +/- 19.1 in the CYP2C9*1/*1 subjects compared with 75.9 +/- 27.6 in the CYP2C9*1/*3 subjects.,Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853880/),[ml] / [h·kg],75.9,117852,DB00586,Diclofenac
,16764589,terminal T(1/2lambda),Diclofenac is quickly eliminated from sheep with a terminal T(1/2lambda) of 2-3 hours for both routes of administration.,Pharmacokinetics of diclofenac in sheep following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764589/),h,2-3,119577,DB00586,Diclofenac
,16764589,Total,Total DCLF clearance after IV and IM administration was 87.86 +/- 24.10 and 85.69 +/- 40.76 mL kg(-1) hour(-1) respectively.,Pharmacokinetics of diclofenac in sheep following intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764589/),[ml] / [hour·kg],87.86,119578,DB00586,Diclofenac
,16764589,Total,Total DCLF clearance after IV and IM administration was 87.86 +/- 24.10 and 85.69 +/- 40.76 mL kg(-1) hour(-1) respectively.,Pharmacokinetics of diclofenac in sheep following intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764589/),[ml] / [hour·kg],85.69,119579,DB00586,Diclofenac
,16764589,absolute bioavailability,The absolute bioavailability of IM DCLF appears to be approximately 100%.,Pharmacokinetics of diclofenac in sheep following intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764589/),%,100,119580,DB00586,Diclofenac
,28351678,peak observed concentrations in the blood,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μg] / [ml],1.10,120584,DB00586,Diclofenac
,28351678,AUCinf,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μgh] / [ml],1.74,120585,DB00586,Diclofenac
,28351678,effective half-life,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),h,1.42,120586,DB00586,Diclofenac
,28351678,peak observed concentrations,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μg] / [ml],1.15,120587,DB00586,Diclofenac
,28351678,AUCinf,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μgh] / [ml],1.94,120588,DB00586,Diclofenac
,28351678,effective half-life,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),h,1.28,120589,DB00586,Diclofenac
,27540412,recovery,These revised processes allow clean extraction and near-quantitative recovery of analyte (approx. 89-95 %).,Determination of diclofenac concentrations in human plasma using a sensitive gas chromatography mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540412/),%,89-95,120842,DB00586,Diclofenac
,27540412,detection,"The detection and lower quantifiable limits were 0.125 and 0.25 ng/mL, respectively.",Determination of diclofenac concentrations in human plasma using a sensitive gas chromatography mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540412/),[ng] / [ml],0.125,120843,DB00586,Diclofenac
,19947166,AUC(0-24),"Oral administration of DFS resulted in AUC(0-24) and Cmax values of 20.4 microg h/mL and 3.04 microg/mL for microspheres and 33.5 microg h/mL and 5.59 microg/mL for Voltaren, respectively.",Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),[h·μg] / [ml],20.4,120946,DB00586,Diclofenac
,19947166,AUC(0-24),"Oral administration of DFS resulted in AUC(0-24) and Cmax values of 20.4 microg h/mL and 3.04 microg/mL for microspheres and 33.5 microg h/mL and 5.59 microg/mL for Voltaren, respectively.",Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),[h·μg] / [ml],33.5,120947,DB00586,Diclofenac
,19947166,Cmax,"Oral administration of DFS resulted in AUC(0-24) and Cmax values of 20.4 microg h/mL and 3.04 microg/mL for microspheres and 33.5 microg h/mL and 5.59 microg/mL for Voltaren, respectively.",Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),[μg] / [ml],3.04,120948,DB00586,Diclofenac
,19947166,Cmax,"Oral administration of DFS resulted in AUC(0-24) and Cmax values of 20.4 microg h/mL and 3.04 microg/mL for microspheres and 33.5 microg h/mL and 5.59 microg/mL for Voltaren, respectively.",Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),[μg] / [ml],5.59,120949,DB00586,Diclofenac
,19947166,Tmax,The Tmax was 3.0 h for both formulations.,Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),h,3.0,120950,DB00586,Diclofenac
,19947166,bioavailability,"The bioavailability of DFS in microspheres was about 61% that of Voltaren, for the parameters AUC and Cmax, and they are therefore not bioequivalent to Voltaren in relation to the extent of absorption.",Comparative in vitro and in vivo evaluations of oral sustained-release formulations of diclofenac sodium in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947166/),%,61,120951,DB00586,Diclofenac
,26633237,maximum plasma concentration (Cmax),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[μg] / [ml],1.73 to 2.91,122525,DB00586,Diclofenac
,26633237,area under the curve (AUC),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[g·h] / [ml],5.05 to 9.95,122526,DB00586,Diclofenac
,26633237,half life (T1/2),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),h,1.12 to 1.76,122527,DB00586,Diclofenac
,26633237,elimination rate constant (Kel ),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),1/[h],0.71 to 0.41,122528,DB00586,Diclofenac
,26633237,apparent oral clearance (CL/F),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[l] / [h],14.58 to 6.48,122529,DB00586,Diclofenac
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,3,123524,DB00586,Diclofenac
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.06,123525,DB00586,Diclofenac
,15655513,IC(50),"In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.14,123526,DB00586,Diclofenac
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.13,123527,DB00586,Diclofenac
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,67,123528,DB00586,Diclofenac
,15655513,selectivity ratio,"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),,515,123529,DB00586,Diclofenac
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],33,123530,DB00586,Diclofenac
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],0.24,123531,DB00586,Diclofenac
,29389580,m/z,"After protein precipitation extraction, the chromatographic separation of the analyte and internal standard (IS; diclofenac sodium) was performed on a reverse-phase Luna C18 column coupled with a Quattro Ultima triple quadruple mass spectrometer in the multiple-reaction monitoring mode using the transitions, m/z 347.31 → 75.09 for NC-8 and m/z 295.89 → 214.06 for the IS.",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),,347.31,123930,DB00586,Diclofenac
,29389580,m/z,"After protein precipitation extraction, the chromatographic separation of the analyte and internal standard (IS; diclofenac sodium) was performed on a reverse-phase Luna C18 column coupled with a Quattro Ultima triple quadruple mass spectrometer in the multiple-reaction monitoring mode using the transitions, m/z 347.31 → 75.09 for NC-8 and m/z 295.89 → 214.06 for the IS.",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),,75.09,123931,DB00586,Diclofenac
,29389580,m/z,"After protein precipitation extraction, the chromatographic separation of the analyte and internal standard (IS; diclofenac sodium) was performed on a reverse-phase Luna C18 column coupled with a Quattro Ultima triple quadruple mass spectrometer in the multiple-reaction monitoring mode using the transitions, m/z 347.31 → 75.09 for NC-8 and m/z 295.89 → 214.06 for the IS.",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),,295.89,123932,DB00586,Diclofenac
,29389580,m/z,"After protein precipitation extraction, the chromatographic separation of the analyte and internal standard (IS; diclofenac sodium) was performed on a reverse-phase Luna C18 column coupled with a Quattro Ultima triple quadruple mass spectrometer in the multiple-reaction monitoring mode using the transitions, m/z 347.31 → 75.09 for NC-8 and m/z 295.89 → 214.06 for the IS.",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),,214.06,123933,DB00586,Diclofenac
,29389580,linear scope,The linear scope of the standard curve was between 0.5 and 500 ng/mL.,Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),[ng] / [ml],0.5 and 500,123934,DB00586,Diclofenac
,29389580,Recoveries,"Recoveries ranged from 104% to 113.4%, and the matrix effects (absolute) were non-significant (CV ≤ 6%).",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),%,104,123935,DB00586,Diclofenac
,29389580,Recoveries,"Recoveries ranged from 104% to 113.4%, and the matrix effects (absolute) were non-significant (CV ≤ 6%).",Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389580/),%,113.4,123936,DB00586,Diclofenac
,15881815,bioavailability,"The in vivo availability study, reveled that the prepared beads filled in hard gelatin capsules had a 126.22% bioavailability relative to that of the commercial Voltaren tablets.",Evaluation of crosslinked chitosan hydrogel beads as a carrier for prolonged delivery of diclofenac sodium: in vitro and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881815/),%,126.22,124887,DB00586,Diclofenac
,3235214,peak serum concentration,The two brands did not significantly differ with respect to peak serum concentration (4.4 and 4.5 micrograms.,Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),μg,4.4,125504,DB00586,Diclofenac
,3235214,peak serum concentration,The two brands did not significantly differ with respect to peak serum concentration (4.4 and 4.5 micrograms.,Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),μg,4.5,125505,DB00586,Diclofenac
,3235214,lag time,"ml-1 for A and B, respectively) or to the lag time between dosing and the appearance of the drug in serum (1.06 and 0.88 h for A and B, respectively).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),h,1.06,125506,DB00586,Diclofenac
,3235214,lag time,"ml-1 for A and B, respectively) or to the lag time between dosing and the appearance of the drug in serum (1.06 and 0.88 h for A and B, respectively).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),h,0.88,125507,DB00586,Diclofenac
,3235214,area under serum concentration-time curve,"Further, the two brands were not found significantly different with respect to the extent of absorption as indicated by the area under serum concentration-time curve (6.31 and 5.91 micrograms.h.ml-1 for A and B, respectively).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),[h·μg] / [ml],6.31,125508,DB00586,Diclofenac
,3235214,area under serum concentration-time curve,"Further, the two brands were not found significantly different with respect to the extent of absorption as indicated by the area under serum concentration-time curve (6.31 and 5.91 micrograms.h.ml-1 for A and B, respectively).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),[h·μg] / [ml],5.91,125509,DB00586,Diclofenac
,3235214,time to attain peak serum concentration,"Brand B, however, exhibited a significantly earlier time to attain peak serum concentration (1.2 h) compared to brand A (2.4 h).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),h,1.2,125510,DB00586,Diclofenac
,3235214,time to attain peak serum concentration,"Brand B, however, exhibited a significantly earlier time to attain peak serum concentration (1.2 h) compared to brand A (2.4 h).",Comparative bioavailability and in vitro characterization of two brands of diclofenac sodium enteric-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235214/),h,2.4,125511,DB00586,Diclofenac
,8720309,tmax,"However, tmax differed significantly (p < 0.05) in case of rectal administration (0.625 +/- 0.065 h) compared to oral tablet (1.58 +/- 0.06 h).",Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720309/),h,0.625,128414,DB00586,Diclofenac
,8720309,tmax,"However, tmax differed significantly (p < 0.05) in case of rectal administration (0.625 +/- 0.065 h) compared to oral tablet (1.58 +/- 0.06 h).",Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720309/),h,1.58,128415,DB00586,Diclofenac
,8720309,relative rectal bioavailability,The relative rectal bioavailability was 107.19 +/- 3.2.,Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720309/),,107.19,128416,DB00586,Diclofenac
,17692878,elimination half-life (t(1/2beta)),"The elimination half-life (t(1/2beta)), area under concentration-time-curve (AUC), volume of distribution (Vd(area)), mean residence time (MRT) and total body clearance (Cl(B)) were 1.03+/-0.18h, 12.17+/-1.98microg h ml(-1), 0.14+/-0.02Lkg(-1), 1.36+/-0.16h and 0.10+/-0.02Lkg(-1)h(-1), respectively.",Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17692878/),h,1.03,129115,DB00586,Diclofenac
,17692878,total body clearance (Cl(B)),"The elimination half-life (t(1/2beta)), area under concentration-time-curve (AUC), volume of distribution (Vd(area)), mean residence time (MRT) and total body clearance (Cl(B)) were 1.03+/-0.18h, 12.17+/-1.98microg h ml(-1), 0.14+/-0.02Lkg(-1), 1.36+/-0.16h and 0.10+/-0.02Lkg(-1)h(-1), respectively.",Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17692878/),1/[lkg],0.10,129116,DB00586,Diclofenac
,17692878,t(1/2beta),"The t(1/2beta), AUC, Vd(area), MRT and Cl(B) were 1.33+/-0.10h, 7.32+/-1.01microg h mL(-1), 0.13+/-0.01Lkg(-1) and 0.07+/-0.01Lkg(-1)h(-1), respectively.",Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17692878/),h,1.33,129117,DB00586,Diclofenac
,17692878,Cl(B),"The t(1/2beta), AUC, Vd(area), MRT and Cl(B) were 1.33+/-0.10h, 7.32+/-1.01microg h mL(-1), 0.13+/-0.01Lkg(-1) and 0.07+/-0.01Lkg(-1)h(-1), respectively.",Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17692878/),1/[lkg],0.07,129118,DB00586,Diclofenac
,27610366,drug-loading rate,"The formulated Tongshu suppository had moderate hardness, a smooth surface with uniform color, and theoretical drug-loading rate of 8%.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),%,8,129376,DB00586,Diclofenac
,27610366,maximum concentrations (C max),"The concentration-time curves and drug release curves revealed that the maximum concentrations (C max) were 4.18 ± 1.03 μg·mL(-1) and 3.34 ± 0.41 μg·mL(-1) for the Tongshu and Aceclofenac suppositories, respectively, showing statistically insignificant difference, while the peak times were 34.87 ± 4.69 min and 34.76 ± 6.34 min, respectively, also showing statistically insignificant difference.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),[μg] / [ml],4.18,129377,DB00586,Diclofenac
,27610366,maximum concentrations (C max),"The concentration-time curves and drug release curves revealed that the maximum concentrations (C max) were 4.18 ± 1.03 μg·mL(-1) and 3.34 ± 0.41 μg·mL(-1) for the Tongshu and Aceclofenac suppositories, respectively, showing statistically insignificant difference, while the peak times were 34.87 ± 4.69 min and 34.76 ± 6.34 min, respectively, also showing statistically insignificant difference.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),[μg] / [ml],3.34,129378,DB00586,Diclofenac
,27610366,peak times,"The concentration-time curves and drug release curves revealed that the maximum concentrations (C max) were 4.18 ± 1.03 μg·mL(-1) and 3.34 ± 0.41 μg·mL(-1) for the Tongshu and Aceclofenac suppositories, respectively, showing statistically insignificant difference, while the peak times were 34.87 ± 4.69 min and 34.76 ± 6.34 min, respectively, also showing statistically insignificant difference.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),min,34.87,129379,DB00586,Diclofenac
,27610366,peak times,"The concentration-time curves and drug release curves revealed that the maximum concentrations (C max) were 4.18 ± 1.03 μg·mL(-1) and 3.34 ± 0.41 μg·mL(-1) for the Tongshu and Aceclofenac suppositories, respectively, showing statistically insignificant difference, while the peak times were 34.87 ± 4.69 min and 34.76 ± 6.34 min, respectively, also showing statistically insignificant difference.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),min,34.76,129380,DB00586,Diclofenac
,27610366,relative bioavailability,"Compared with the Aceclofenac suppository, the relative bioavailability of the Tongshu suppository was 104.4%, and the difference between them was statistically insignificant.",Preparation and In Vivo Pharmacokinetics of the Tongshu Suppository. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27610366/),%,104.4,129381,DB00586,Diclofenac
,23547761,drug fluxes,"The drug fluxes were 92.02 and 8.920 μg/cm(2)/h, respectively, for OV-3 and PV-1.","Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23547761/),[μg] / [cm(2)·h],92.02,130195,DB00586,Diclofenac
,23547761,drug fluxes,"The drug fluxes were 92.02 and 8.920 μg/cm(2)/h, respectively, for OV-3 and PV-1.","Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23547761/),[μg] / [cm(2)·h],8.920,130196,DB00586,Diclofenac
,23547761,Cmax,"The Cmax were 7.91 and 4.01 μg/ml at 4 and 6 h for OV-3 (2.5 mg) and PV-1 (10 mg), respectively.","Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23547761/),[μg] / [ml],7.91,130197,DB00586,Diclofenac
,23547761,Cmax,"The Cmax were 7.91 and 4.01 μg/ml at 4 and 6 h for OV-3 (2.5 mg) and PV-1 (10 mg), respectively.","Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23547761/),[μg] / [ml],4.01,130198,DB00586,Diclofenac
,8489569,peak plasma concentration,After administration of a diclofenac-sucralfate association diclofenac was quickly absorbed and the peak plasma concentration (0.773 +/- 0.08 microgram/ml) was achieved in about 1 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),[μg] / [ml],0.773,133557,DB00586,Diclofenac
,8489569,AUC(0-infinity),AUC(0-infinity) value was about 1.8 micrograms/ml/h and the mean elimination half-life was 1.20 +/- 0.12 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),[μg] / [h·ml],1.8,133558,DB00586,Diclofenac
,8489569,elimination half-life,AUC(0-infinity) value was about 1.8 micrograms/ml/h and the mean elimination half-life was 1.20 +/- 0.12 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),h,1.20,133559,DB00586,Diclofenac
,28402673,entrapment,"The entrapment and loading efficiency of MTX and ACL was calculated as 85-90% and 10-12%, respectively.",Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402673/),%,85-90,135156,DB00586,Diclofenac
,28402673,loading efficiency,"The entrapment and loading efficiency of MTX and ACL was calculated as 85-90% and 10-12%, respectively.",Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402673/),%,10-12,135157,DB00586,Diclofenac
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,39.0,138449,DB00586,Diclofenac
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,5.9,138450,DB00586,Diclofenac
,8225684,lag time,"The two products were not found to be statistically different with respect to the lag time between dosing and appearance of the drug in the serum (0.8 +/- 0.2 and 0.6 +/- 0.1 h for V and D, respectively), or in the time needed to attain the peak concentrations (4.5 +/- 0.8 and 4.1 +/- 0.9 h for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),h,0.8,138595,DB00586,Diclofenac
,8225684,lag time,"The two products were not found to be statistically different with respect to the lag time between dosing and appearance of the drug in the serum (0.8 +/- 0.2 and 0.6 +/- 0.1 h for V and D, respectively), or in the time needed to attain the peak concentrations (4.5 +/- 0.8 and 4.1 +/- 0.9 h for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),h,0.6,138596,DB00586,Diclofenac
,8225684,time needed to attain the peak concentrations,"The two products were not found to be statistically different with respect to the lag time between dosing and appearance of the drug in the serum (0.8 +/- 0.2 and 0.6 +/- 0.1 h for V and D, respectively), or in the time needed to attain the peak concentrations (4.5 +/- 0.8 and 4.1 +/- 0.9 h for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),h,4.5,138597,DB00586,Diclofenac
,8225684,time needed to attain the peak concentrations,"The two products were not found to be statistically different with respect to the lag time between dosing and appearance of the drug in the serum (0.8 +/- 0.2 and 0.6 +/- 0.1 h for V and D, respectively), or in the time needed to attain the peak concentrations (4.5 +/- 0.8 and 4.1 +/- 0.9 h for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),h,4.1,138598,DB00586,Diclofenac
,8225684,peak serum concentration,"The two products, however, varied in the peak serum concentration (736 +/- 125 and 536 +/- 63 ng.ml-1 for V and D, respectively), but this difference was not statistically significance.",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),[ng] / [ml],736,138599,DB00586,Diclofenac
,8225684,peak serum concentration,"The two products, however, varied in the peak serum concentration (736 +/- 125 and 536 +/- 63 ng.ml-1 for V and D, respectively), but this difference was not statistically significance.",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),[ng] / [ml],536,138600,DB00586,Diclofenac
,8225684,area under the concentration-time curve over 12 h,"In terms of the extent of absorption, assessed by estimating the area under the concentration-time curve over 12 h, the two products were not significantly different (3,340 +/- 270 and 3,045 +/- 294 ng.h.ml-1 for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),[h·ng] / [ml],"3,340",138601,DB00586,Diclofenac
,8225684,area under the concentration-time curve over 12 h,"In terms of the extent of absorption, assessed by estimating the area under the concentration-time curve over 12 h, the two products were not significantly different (3,340 +/- 270 and 3,045 +/- 294 ng.h.ml-1 for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),[h·ng] / [ml],"3,045",138602,DB00586,Diclofenac
,8225684,V,"In terms of the extent of absorption, assessed by estimating the area under the concentration-time curve over 12 h, the two products were not significantly different (3,340 +/- 270 and 3,045 +/- 294 ng.h.ml-1 for V and D, respectively).",A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225684/),[h·ng] / [ml],"3,045",138603,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,33.1,139253,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,31.7,139254,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,89.0,139255,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,86.6,139256,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.2,139257,DB00586,Diclofenac
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.0,139258,DB00586,Diclofenac
,18840026,apparent volume of distribution,"Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans.",Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),l,120,139735,DB00586,Diclofenac
,18840026,elimination half-life,The elimination half-life of approximately 20 hours in healthy subjects enables once-daily dosing.,Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),h,20,139736,DB00586,Diclofenac
,16236050,relative bioavailability,"The study was designed to evaluate the relative bioavailability of diclofenac in plasma, subcutaneous adipose and skeletal muscle tissue after repeated topical administration using MIKA Diclofenac Spray Gel (4%), a novel formulation, and after oral dosing using VOLTAREN 50 mg enteric coated tablets.",Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236050/),%,4,143040,DB00586,Diclofenac
,16236050,relative bioavailability,"The relative bioavailability of diclofenac in subcutaneous adipose and skeletal muscle tissue was substantially higher after topical compared with oral dosing (324% and 209%, respectively) whereas relative plasma bioavailability was 50-fold lower.",Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236050/),%,324,143041,DB00586,Diclofenac
,16236050,relative bioavailability,"The relative bioavailability of diclofenac in subcutaneous adipose and skeletal muscle tissue was substantially higher after topical compared with oral dosing (324% and 209%, respectively) whereas relative plasma bioavailability was 50-fold lower.",Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236050/),%,209,143042,DB00586,Diclofenac
,16236050,Plasma C(max),Plasma C(max) values were approximately 250-fold lower after topical compared with oral drug administration (i.e. median values = 4.89 ng mL(-1); 95% CI: 3.37-7.68 and 1240 ng mL(-1); 95% CI: 787-1389 ng mL(-1)).,Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236050/),[ng] / [ml],4.89,143043,DB00586,Diclofenac
,16236050,Plasma C(max),Plasma C(max) values were approximately 250-fold lower after topical compared with oral drug administration (i.e. median values = 4.89 ng mL(-1); 95% CI: 3.37-7.68 and 1240 ng mL(-1); 95% CI: 787-1389 ng mL(-1)).,Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236050/),[ng] / [ml],1240,143044,DB00586,Diclofenac
,30817844,t1/2β,"The main pharmacokinetic (PK) parameters after a single i.v. administration were as follows: t1/2β , 4.52 ± 1.71 h; AUC, 77.79 ± 16.76 h μg mL-1 ; mean residence time, 5.16 ± 1.11 h.",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),h,4.52,147314,DB00586,Diclofenac
,30817844,AUC,"The main pharmacokinetic (PK) parameters after a single i.v. administration were as follows: t1/2β , 4.52 ± 1.71 h; AUC, 77.79 ± 16.76 h μg mL-1 ; mean residence time, 5.16 ± 1.11 h.",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),[h·μg] / [ml],77.79,147315,DB00586,Diclofenac
,30817844,mean residence time,"The main pharmacokinetic (PK) parameters after a single i.v. administration were as follows: t1/2β , 4.52 ± 1.71 h; AUC, 77.79 ± 16.76 h μg mL-1 ; mean residence time, 5.16 ± 1.11 h.",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),h,5.16,147316,DB00586,Diclofenac
,30817844,Tmax,"The main PK parameters after a single i.m. administration were as follows: Tmax , 2.38 ± 1.19 h; Cmax , 7.46 ± 1.85 μg mL-1 ; t1/2β , 9.46 ± 2.86 h; AUC 67.57 ± 13.07 h μg mL-1 .",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),h,2.38,147317,DB00586,Diclofenac
,30817844,Cmax,"The main PK parameters after a single i.m. administration were as follows: Tmax , 2.38 ± 1.19 h; Cmax , 7.46 ± 1.85 μg mL-1 ; t1/2β , 9.46 ± 2.86 h; AUC 67.57 ± 13.07 h μg mL-1 .",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),[μg] / [ml],7.46,147318,DB00586,Diclofenac
,30817844,t1/2β,"The main PK parameters after a single i.m. administration were as follows: Tmax , 2.38 ± 1.19 h; Cmax , 7.46 ± 1.85 μg mL-1 ; t1/2β , 9.46 ± 2.86 h; AUC 67.57 ± 13.07 h μg mL-1 .",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),h,9.46,147319,DB00586,Diclofenac
,30817844,AUC,"The main PK parameters after a single i.m. administration were as follows: Tmax , 2.38 ± 1.19 h; Cmax , 7.46 ± 1.85 μg mL-1 ; t1/2β , 9.46 ± 2.86 h; AUC 67.57 ± 13.07 h μg mL-1 .",An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),[h·μg] / [ml],67.57,147320,DB00586,Diclofenac
,30817844,absolute bioavailability,The absolute bioavailability was 87.37 ± 5.96%.,An LC-MS/MS method for the quantification of diclofenac sodium in dairy cow plasma and its application in pharmacokinetics studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817844/),%,87.37,147321,DB00586,Diclofenac
,23475315,relative bioavailability,The calculated relative bioavailability of the aceclofenac DIA patch was 18.2 % compared to oral administration of the drug.,Formulation and biopharmaceutical evaluation of a transdermal patch containing aceclofenac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23475315/),%,18.2,149081,DB00586,Diclofenac
,19663688,Area under the plasma concentration-time curves (AUC(0-)(t)),"Area under the plasma concentration-time curves (AUC(0-)(t)) for the three formulations were between 577 and 585 ng-hr/mL and peak plasma concentrations (C(max)) were between 958 and 1087 ng/mL, with the DPSGC process B group having the highest C(max).",Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663688/),[ng-hr] / [ml],577 and 585,150000,DB00586,Diclofenac
,19663688,peak plasma concentrations (C(max)),"Area under the plasma concentration-time curves (AUC(0-)(t)) for the three formulations were between 577 and 585 ng-hr/mL and peak plasma concentrations (C(max)) were between 958 and 1087 ng/mL, with the DPSGC process B group having the highest C(max).",Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663688/),[ng] / [ml],958 and 1087,150001,DB00586,Diclofenac
below,19663688,times to C(max) (t(max)),"The times to C(max) (t(max)) were all below 30 minutes, with the liquid formulation producing the shortest t(max) (15 minutes).",Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663688/),min,30,150002,DB00586,Diclofenac
,19663688,t(max),"The times to C(max) (t(max)) were all below 30 minutes, with the liquid formulation producing the shortest t(max) (15 minutes).",Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663688/),min,15,150003,DB00586,Diclofenac
,24710899,IC50,"In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM).",In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710899/),μM,15.5,150775,DB00586,Diclofenac
,2737796,relative bioavailability,The relative bioavailability of the sustained-release formulation was found to be 53% compared with the conventional product.,A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737796/),%,53,153133,DB00586,Diclofenac
,2737796,Cmax,The Cmax for the sustained release formulation (0.54 +/- 0.29 micrograms ml-1) was significantly much lower than the corresponding value for the conventional formulation (4.12 +/- 0.91).,A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737796/),[μg] / [ml],0.54,153134,DB00586,Diclofenac
,2737796,Cmax,The Cmax for the sustained release formulation (0.54 +/- 0.29 micrograms ml-1) was significantly much lower than the corresponding value for the conventional formulation (4.12 +/- 0.91).,A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737796/),,4.12,153135,DB00586,Diclofenac
,2737796,tmax,"However, the tmax for the sustained release formulation (3.6 +/- 2.1 h) was not significantly different from the corresponding value for the conventional formulation (2.5 +/- 0.4 h).",A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737796/),h,3.6,153136,DB00586,Diclofenac
,2737796,tmax,"However, the tmax for the sustained release formulation (3.6 +/- 2.1 h) was not significantly different from the corresponding value for the conventional formulation (2.5 +/- 0.4 h).",A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737796/),h,2.5,153137,DB00586,Diclofenac
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],1137.2,155382,DB00586,Diclofenac
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],1326.7,155383,DB00586,Diclofenac
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],2200.4,155384,DB00586,Diclofenac
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],3,158705,DB00586,Diclofenac
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.4,158706,DB00586,Diclofenac
,18418582,detection limits,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.6,158707,DB00586,Diclofenac
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],3,158708,DB00586,Diclofenac
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.4,158709,DB00586,Diclofenac
,18418582,signal-to-noise ratio,"The detection limits of Mor in brain and blood microdialysates at a signal-to-noise ratio of 3 were 0.4 and 0.6 ng mL(-1), respectively.",Sensitive HPLC-fluorescence detection of morphine labeled with DIB-Cl in rat brain and blood microdialysates and its application to the preliminarily study of the pharmacokinetic interaction between morphine and diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18418582/),[ng] / [ml],0.6,158710,DB00586,Diclofenac
,28725140,f2,The in-vitro drug release of the prepared formulation showed similarity (f2 = 66.19) to the marketed product.,Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725140/),,66.19,158757,DB00586,Diclofenac
,28725140,AUC0-24,"The AUC0-24 values were 105.36 ± 83.3 and 92.87 ± 55.53 μg h/ml whereas the Cmax values were 11.25 ± 6.87 and 12.97 ± 8.45 μg/ml, for the test and reference, respectively.",Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725140/),[h·μg] / [ml],105.36,158758,DB00586,Diclofenac
,28725140,AUC0-24,"The AUC0-24 values were 105.36 ± 83.3 and 92.87 ± 55.53 μg h/ml whereas the Cmax values were 11.25 ± 6.87 and 12.97 ± 8.45 μg/ml, for the test and reference, respectively.",Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725140/),[h·μg] / [ml],92.87,158759,DB00586,Diclofenac
,28725140,Cmax,"The AUC0-24 values were 105.36 ± 83.3 and 92.87 ± 55.53 μg h/ml whereas the Cmax values were 11.25 ± 6.87 and 12.97 ± 8.45 μg/ml, for the test and reference, respectively.",Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725140/),[μg] / [ml],11.25,158760,DB00586,Diclofenac
,28725140,Cmax,"The AUC0-24 values were 105.36 ± 83.3 and 92.87 ± 55.53 μg h/ml whereas the Cmax values were 11.25 ± 6.87 and 12.97 ± 8.45 μg/ml, for the test and reference, respectively.",Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725140/),[μg] / [ml],12.97,158761,DB00586,Diclofenac
,27052193,maximum plasma concentration (Cmax),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (2.24-3.68 μg/mL, p < 0.05), area under the curve (AUC) (7.09-11.81 μg h/mL, p < 0.05), half-life (T1/2) (1.23-1.65 h, p < 0.05) and significantly decreased elimination rate constant (Kel) (0.62-0.41 h-1, p < 0.05), apparent oral clearance (CL/F) (7.57-4.52 L/h, p < 0.05) of DIC as compared to that of control phase.",Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052193/),[μg] / [ml],2.24-3.68,158818,DB00586,Diclofenac
,27052193,area under the curve (AUC),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (2.24-3.68 μg/mL, p < 0.05), area under the curve (AUC) (7.09-11.81 μg h/mL, p < 0.05), half-life (T1/2) (1.23-1.65 h, p < 0.05) and significantly decreased elimination rate constant (Kel) (0.62-0.41 h-1, p < 0.05), apparent oral clearance (CL/F) (7.57-4.52 L/h, p < 0.05) of DIC as compared to that of control phase.",Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052193/),[h·μg] / [ml],7.09-11.81,158819,DB00586,Diclofenac
,27052193,half-life (T1/2),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (2.24-3.68 μg/mL, p < 0.05), area under the curve (AUC) (7.09-11.81 μg h/mL, p < 0.05), half-life (T1/2) (1.23-1.65 h, p < 0.05) and significantly decreased elimination rate constant (Kel) (0.62-0.41 h-1, p < 0.05), apparent oral clearance (CL/F) (7.57-4.52 L/h, p < 0.05) of DIC as compared to that of control phase.",Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052193/),h,1.23-1.65,158820,DB00586,Diclofenac
,27052193,elimination rate constant (Kel),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (2.24-3.68 μg/mL, p < 0.05), area under the curve (AUC) (7.09-11.81 μg h/mL, p < 0.05), half-life (T1/2) (1.23-1.65 h, p < 0.05) and significantly decreased elimination rate constant (Kel) (0.62-0.41 h-1, p < 0.05), apparent oral clearance (CL/F) (7.57-4.52 L/h, p < 0.05) of DIC as compared to that of control phase.",Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052193/),1/[h],0.62-0.41,158821,DB00586,Diclofenac
,27052193,apparent oral clearance (CL/F),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (2.24-3.68 μg/mL, p < 0.05), area under the curve (AUC) (7.09-11.81 μg h/mL, p < 0.05), half-life (T1/2) (1.23-1.65 h, p < 0.05) and significantly decreased elimination rate constant (Kel) (0.62-0.41 h-1, p < 0.05), apparent oral clearance (CL/F) (7.57-4.52 L/h, p < 0.05) of DIC as compared to that of control phase.",Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052193/),[l] / [h],7.57-4.52,158822,DB00586,Diclofenac
,1815046,bioavailability,"After oral dosing, an early peak was also observed, but it was lower than that obtained after intraduodenal dosing: 71% diclofenac bioavailability was found in bile duct-cannulated rats intraduodenally dosed, whereas in normal animals dosed by mouth a bioavailability of 79% was obtained.",Pharmacokinetics and bioavailability of diclofenac in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815046/),%,71,160875,DB00586,Diclofenac
,1815046,bioavailability,"After oral dosing, an early peak was also observed, but it was lower than that obtained after intraduodenal dosing: 71% diclofenac bioavailability was found in bile duct-cannulated rats intraduodenally dosed, whereas in normal animals dosed by mouth a bioavailability of 79% was obtained.",Pharmacokinetics and bioavailability of diclofenac in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815046/),%,79,160876,DB00586,Diclofenac
,1815046,apparent bioavailability,"In normal animals intraduodenally dosed, an apparent bioavailability of 106% was observed.",Pharmacokinetics and bioavailability of diclofenac in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815046/),%,106,160877,DB00586,Diclofenac
,1932158,limit of detection,"The limit of detection of plasma levels of diclofenac is 2 ng ml-1, which renders the method useful for clinical studies on oral, intravenous and rectal administration of the drug.",Determination of diclofenac in human plasma by selected ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932158/),[ng] / [ml],2,161507,DB00586,Diclofenac
,1932158,area under curve,"Pharmacokinetic parameters (area under curve = 1.8 +/- 0.26 microgram h ml-1, tmax = 1.5 +/- 0.5 h, Cmax = 734 +/- 82 ng ml-1 and terminal half-life = 0.88 +/- 0.52 h) determined from the plasma decay of diclofenac in three healthy subjects given a single oral dose of diclofenac were in good agreement with those reported in the literature.",Determination of diclofenac in human plasma by selected ion monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932158/),[h·μg] / [ml],1.8,161508,DB00586,Diclofenac
,1932158,tmax,"Pharmacokinetic parameters (area under curve = 1.8 +/- 0.26 microgram h ml-1, tmax = 1.5 +/- 0.5 h, Cmax = 734 +/- 82 ng ml-1 and terminal half-life = 0.88 +/- 0.52 h) determined from the plasma decay of diclofenac in three healthy subjects given a single oral dose of diclofenac were in good agreement with those reported in the literature.",Determination of diclofenac in human plasma by selected ion monitoring. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932158/),h,1.5,161509,DB00586,Diclofenac
,1932158,Cmax,"Pharmacokinetic parameters (area under curve = 1.8 +/- 0.26 microgram h ml-1, tmax = 1.5 +/- 0.5 h, Cmax = 734 +/- 82 ng ml-1 and terminal half-life = 0.88 +/- 0.52 h) determined from the plasma decay of diclofenac in three healthy subjects given a single oral dose of diclofenac were in good agreement with those reported in the literature.",Determination of diclofenac in human plasma by selected ion monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932158/),[ng] / [ml],734,161510,DB00586,Diclofenac
,1932158,terminal half-life,"Pharmacokinetic parameters (area under curve = 1.8 +/- 0.26 microgram h ml-1, tmax = 1.5 +/- 0.5 h, Cmax = 734 +/- 82 ng ml-1 and terminal half-life = 0.88 +/- 0.52 h) determined from the plasma decay of diclofenac in three healthy subjects given a single oral dose of diclofenac were in good agreement with those reported in the literature.",Determination of diclofenac in human plasma by selected ion monitoring. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932158/),h,0.88,161511,DB00586,Diclofenac
,23166444,maximum concentration [C(max)],"Peak systemic exposure of diclofenac was very low by dermal application compared with oral administration (maximum concentration [C(max)] values of 3.5 vs 9640 ng/mL, respectively).",Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166444/),[ng] / [ml],3.5,163675,DB00586,Diclofenac
,23166444,maximum concentration [C(max)],"Peak systemic exposure of diclofenac was very low by dermal application compared with oral administration (maximum concentration [C(max)] values of 3.5 vs 9640 ng/mL, respectively).",Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166444/),[ng] / [ml],9640,163676,DB00586,Diclofenac
,23166444,C(max),"Concentrations of diclofenac in muscles beneath the patch application site were similar to corresponding tissues after oral administration (C(max) values of 879 and 1160 ng/mL, respectively).",Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166444/),[ng] / [ml],879,163677,DB00586,Diclofenac
,23166444,C(max),"Concentrations of diclofenac in muscles beneath the patch application site were similar to corresponding tissues after oral administration (C(max) values of 879 and 1160 ng/mL, respectively).",Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166444/),[ng] / [ml],1160,163678,DB00586,Diclofenac
,8573422,absolute bioavailability,An absolute bioavailability of approximately 6% has been reported with large inter- and intra-subject variability.,Human pharmacokinetics of tiludronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),%,6,165181,DB00586,Diclofenac
,8573422,elimination half-life,"The elimination half-life in patients with normal renal function is approximately 40-60 h, but is significantly increased in subjects with severe renal impairment.",Human pharmacokinetics of tiludronate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),h,40-60,165182,DB00586,Diclofenac
,8573422,renal clearance,The renal clearance (0.7 L/h) is independent of dose and suggests that glomerular filtration is the mechanism responsible for elimination.,Human pharmacokinetics of tiludronate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),[l] / [h],0.7,165183,DB00586,Diclofenac
,9532613,Cmax,"A peak analgesic effect was observed between 60 and 120 min, while Cmax (10.6 +/- 3.8 micrograms/ml) of nimesulide was reached at 60 min (Tmax).",Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9532613/),[μg] / [ml],10.6,165992,DB00586,Diclofenac
,9532613,T,"A peak analgesic effect was observed between 60 and 120 min, while Cmax (10.6 +/- 3.8 micrograms/ml) of nimesulide was reached at 60 min (Tmax).",Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9532613/),min,60,165993,DB00586,Diclofenac
,12603175,area under the concentration-time curve over the dosage interval (AUC(tau)),"For diclofenac, area under the concentration-time curve over the dosage interval (AUC(tau)) was larger in young subjects (3.2 +/- 1.0 mg * h/L) than in older individuals (2.4 +/- 0.4 mg * h/L; p < 0.05).",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],3.2,166277,DB00586,Diclofenac
,12603175,area under the concentration-time curve over the dosage interval (AUC(tau)),"For diclofenac, area under the concentration-time curve over the dosage interval (AUC(tau)) was larger in young subjects (3.2 +/- 1.0 mg * h/L) than in older individuals (2.4 +/- 0.4 mg * h/L; p < 0.05).",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],2.4,166278,DB00586,Diclofenac
,12603175,terminal half-life (t((1/2)Z)),"As the terminal half-life (t((1/2)Z)) was very similar in both groups (3.9 +/- 4.4 vs 3.5 +/- 3.3 hours), either less complete absorption in the elderly or their higher bodyweight could account for the difference.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,3.9,166279,DB00586,Diclofenac
,12603175,terminal half-life (t((1/2)Z)),"As the terminal half-life (t((1/2)Z)) was very similar in both groups (3.9 +/- 4.4 vs 3.5 +/- 3.3 hours), either less complete absorption in the elderly or their higher bodyweight could account for the difference.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,3.5,166280,DB00586,Diclofenac
,12603175,AUC(tau),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],5.8,166281,DB00586,Diclofenac
,12603175,AUC(tau),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],5.6,166282,DB00586,Diclofenac
,12603175,t((1/2)z),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,11.8,166283,DB00586,Diclofenac
,12603175,t((1/2)z),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,11.2,166284,DB00586,Diclofenac
,7981929,tlag,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),h,0.454,167374,DB00586,Diclofenac
,7981929,tlag,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),h,0.998,167375,DB00586,Diclofenac
,7981929,tmax,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),h,1.41,167376,DB00586,Diclofenac
,7981929,tmax,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),h,2.56,167377,DB00586,Diclofenac
,7981929,peak concentrations (Cmax,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),[μg] / [ml],1.64,167378,DB00586,Diclofenac
,7981929,peak concentrations (Cmax,"Diclofenac was significantly faster absorbed from the resinate than from the enteric coated formulation (tlag = 0.454 h vs. 0.998 h, tmax = 1.41 h vs. 2.56 h) and reached lower peak concentrations (Cmax = 1.64 micrograms/ml vs. 2.59 micrograms/ml).",The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981929/),[μg] / [ml],2.59,167379,DB00586,Diclofenac
,10997932,V(max),The formation of codeine-6-glucuronide exhibited single enzyme Michaelis-Menten kinetics with an average V(max) of 93.6 +/- 35.3 pmol/mg/min.,In vitro interaction of codeine and diclofenac. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),[pM] / [mg·min],93.6,167800,DB00586,Diclofenac
,10997932,K(i),A noncompetitive inhibition of codeine-6-glucuronidation by diclofenac was observed with an average K(i) of 7.9 microM.,In vitro interaction of codeine and diclofenac. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),μM,7.9,167801,DB00586,Diclofenac
,21219996,AUC((0 → 24)),"The AUC((0 → 24)) of the immediate release pellets, the two matrix pellets and the reference were 304.4, 87.7, 204.1 and 179.1 μg h/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[h·μg] / [ml],304.4,168949,DB00586,Diclofenac
,21219996,AUC((0 → 24)),"The AUC((0 → 24)) of the immediate release pellets, the two matrix pellets and the reference were 304.4, 87.7, 204.1 and 179.1 μg h/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[h·μg] / [ml],87.7,168950,DB00586,Diclofenac
,21219996,AUC((0 → 24)),"The AUC((0 → 24)) of the immediate release pellets, the two matrix pellets and the reference were 304.4, 87.7, 204.1 and 179.1 μg h/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[h·μg] / [ml],204.1,168951,DB00586,Diclofenac
,21219996,AUC((0 → 24)),"The AUC((0 → 24)) of the immediate release pellets, the two matrix pellets and the reference were 304.4, 87.7, 204.1 and 179.1 μg h/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[h·μg] / [ml],179.1,168952,DB00586,Diclofenac
,21219996,C(max),"The C(max) of the formulations mentioned above were 46.3, 13.0, 33.6 and 32.1 μg/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[μg] / [ml],46.3,168953,DB00586,Diclofenac
,21219996,C(max),"The C(max) of the formulations mentioned above were 46.3, 13.0, 33.6 and 32.1 μg/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[μg] / [ml],13.0,168954,DB00586,Diclofenac
,21219996,C(max),"The C(max) of the formulations mentioned above were 46.3, 13.0, 33.6 and 32.1 μg/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[μg] / [ml],33.6,168955,DB00586,Diclofenac
,21219996,C(max),"The C(max) of the formulations mentioned above were 46.3, 13.0, 33.6 and 32.1 μg/ml, respectively.",Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219996/),[μg] / [ml],32.1,168956,DB00586,Diclofenac
,9342419,Retention times,"Retention times for diclofenac and the internal standard (naproxen) were 3.5 and 6 min, respectively.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),min,3.5,169052,DB00586,Diclofenac
,9342419,Retention times,"Retention times for diclofenac and the internal standard (naproxen) were 3.5 and 6 min, respectively.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),min,6,169053,DB00586,Diclofenac
,9342419,detection limit,"The method was linear in the range of 25 to 2000 ng/ml and the detection limit of the method was 10 ng/ml, using 100 microliters of whole blood sample.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),[ng] / [ml],10,169054,DB00586,Diclofenac
,9342419,half-life,Then concentration decayed with a half-life of about 15 h.,Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),h,15,169055,DB00586,Diclofenac
,21999217,lag times,Their corresponding estimated in vivo lag times for appearance of the drugs in the deeper probes were 1.1 min for diclofenac and 30 min for nicotine.,Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999217/),min,1.1,169176,DB00586,Diclofenac
,21999217,lag times,Their corresponding estimated in vivo lag times for appearance of the drugs in the deeper probes were 1.1 min for diclofenac and 30 min for nicotine.,Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999217/),min,30,169177,DB00586,Diclofenac
,18293616,maximum (Cmax),Plasma oxytetracycline concentration showed a maximum (Cmax) of 3.89 +/- 1.48 microg/ml and a prolonged elimination half-life (T1/2beta: 47.73 +/- 18.33 h).,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),[μg] / [ml],3.89,170809,DB00586,Diclofenac
,18293616,elimination half-life (T1/2beta,Plasma oxytetracycline concentration showed a maximum (Cmax) of 3.89 +/- 1.48 microg/ml and a prolonged elimination half-life (T1/2beta: 47.73 +/- 18.33 h).,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,47.73,170810,DB00586,Diclofenac
,18293616,Cmax,"The diclofenac plasma profile showed high Cmax (577.62 +/- 238.40 ng/ml), and its T1/2beta was also prolonged (30.48 +/- 9.42 h).",Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),[ng] / [ml],577.62,170811,DB00586,Diclofenac
,18293616,T1/2beta,"The diclofenac plasma profile showed high Cmax (577.62 +/- 238.40 ng/ml), and its T1/2beta was also prolonged (30.48 +/- 9.42 h).",Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,30.48,170812,DB00586,Diclofenac
,18293616,T1/2beta,The long elimination half-life of diclofenac was an unexpected finding; its T1/2beta in humans is 1.1 h.,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,1.1,170813,DB00586,Diclofenac
,7192104,plasma half-life,The plasma half-life of diclofenac was 1.3 h in dogs.,Disposition and enterohepatic circulation of diclofenac in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192104/),h,1.3,171068,DB00586,Diclofenac
,26268443,area under the concentration-time-curve (AUC,"Although area under the concentration-time-curve (AUC, 187.97 ± 315.92 vs. 22.92 ± 42.44 ng*min/ml) and maximum concentration (Cmax, 2.06 ± 3.79 vs. 0.22 ± 0.41 ng/ml) values showed a numerically clear trend for higher values with iontophoresis compared to passive diffusion, no significant difference could be found due to high inter-individual variability.",Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268443/),[min·ng] / [ml],187.97,172478,DB00586,Diclofenac
,26268443,area under the concentration-time-curve (AUC,"Although area under the concentration-time-curve (AUC, 187.97 ± 315.92 vs. 22.92 ± 42.44 ng*min/ml) and maximum concentration (Cmax, 2.06 ± 3.79 vs. 0.22 ± 0.41 ng/ml) values showed a numerically clear trend for higher values with iontophoresis compared to passive diffusion, no significant difference could be found due to high inter-individual variability.",Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268443/),[min·ng] / [ml],22.92,172479,DB00586,Diclofenac
,26268443,maximum concentration (Cmax,"Although area under the concentration-time-curve (AUC, 187.97 ± 315.92 vs. 22.92 ± 42.44 ng*min/ml) and maximum concentration (Cmax, 2.06 ± 3.79 vs. 0.22 ± 0.41 ng/ml) values showed a numerically clear trend for higher values with iontophoresis compared to passive diffusion, no significant difference could be found due to high inter-individual variability.",Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268443/),[ng] / [ml],2.06,172480,DB00586,Diclofenac
,26268443,maximum concentration (Cmax,"Although area under the concentration-time-curve (AUC, 187.97 ± 315.92 vs. 22.92 ± 42.44 ng*min/ml) and maximum concentration (Cmax, 2.06 ± 3.79 vs. 0.22 ± 0.41 ng/ml) values showed a numerically clear trend for higher values with iontophoresis compared to passive diffusion, no significant difference could be found due to high inter-individual variability.",Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268443/),[ng] / [ml],0.22,172481,DB00586,Diclofenac
,27020304,IC50,"Compound 4f showed an IC50 of 123nM for inhibition of PGE2-induced TNFα reduction in an ex vivo LPS-stimulated human whole blood assay (showing >10-fold increase over clinical compound CJ-023,423).",Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020304/),nM,123,172539,DB00586,Diclofenac
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.3,175652,DB00586,Diclofenac
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,2.0,175653,DB00586,Diclofenac
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.1,175654,DB00586,Diclofenac
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.8,175655,DB00586,Diclofenac
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.5,175656,DB00586,Diclofenac
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.9,175657,DB00586,Diclofenac
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.53,175748,DB00586,Diclofenac
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.28,175749,DB00586,Diclofenac
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,2.76,175750,DB00586,Diclofenac
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,1.16,175751,DB00586,Diclofenac
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],11.3,176452,DB00586,Diclofenac
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],13.6,176453,DB00586,Diclofenac
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],8.06,176454,DB00586,Diclofenac
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],15.2,176455,DB00586,Diclofenac
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],435,176456,DB00586,Diclofenac
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],367,176457,DB00586,Diclofenac
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],540,176458,DB00586,Diclofenac
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],329,176459,DB00586,Diclofenac
,9835504,steady-state plasma panipenem concentration,"VPA (50 mg/kg of body weight) or diclofenac (10 mg/kg of body weight) was administered intravenously under the steady-state plasma panipenem concentration of 4 microgram/ml, which had been achieved by a constant infusion rate.",Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835504/),[μg] / [ml],4,176569,DB00586,Diclofenac
,15139795,terminal elimination half-life,Lumiracoxib was rapidly absorbed (peak plasma concentration at 2 hours) and the terminal elimination half-life in plasma was short (6 hours).,Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),h,6,177383,DB00586,Diclofenac
,15139795,steady-state trough concentration,"The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 microg/L) was approximately three times higher than the mean value in plasma (155 microg/L), and the area under the concentration-time curve from 12 to 24 hours after administration was 2.6-fold higher for synovial fluid than for plasma.",Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),[μg] / [l],454,177384,DB00586,Diclofenac
,15139795,steady-state trough concentration,"The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 microg/L) was approximately three times higher than the mean value in plasma (155 microg/L), and the area under the concentration-time curve from 12 to 24 hours after administration was 2.6-fold higher for synovial fluid than for plasma.",Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),[μg] / [l],155,177385,DB00586,Diclofenac
,15139795,protein binding,Median lumiracoxib protein binding was similar in plasma and synovial fluid (range 97.9-98.3%).,Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),%,97.9-98.3,177386,DB00586,Diclofenac
,25546369,tmax,"When taken under fed conditions, the oral solution resulted in an approximately 80% faster median tmax (0.17 vs 1.25 hours, P = .00015) and a 21% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 835 ± 449, P = .00061) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,0.17,178335,DB00586,Diclofenac
,25546369,tmax,"When taken under fed conditions, the oral solution resulted in an approximately 80% faster median tmax (0.17 vs 1.25 hours, P = .00015) and a 21% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 835 ± 449, P = .00061) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,1.25,178336,DB00586,Diclofenac
,25546369,Cmax,"When taken under fed conditions, the oral solution resulted in an approximately 80% faster median tmax (0.17 vs 1.25 hours, P = .00015) and a 21% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 835 ± 449, P = .00061) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],506,178337,DB00586,Diclofenac
,25546369,Cmax,"When taken under fed conditions, the oral solution resulted in an approximately 80% faster median tmax (0.17 vs 1.25 hours, P = .00015) and a 21% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 835 ± 449, P = .00061) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],835,178338,DB00586,Diclofenac
,25546369,tmax,"When taken under fasting conditions, the oral solution exhibited a 50% faster median tmax (0.25 vs 0.50 hours, P = .00035) to achieve a 77% higher Cmax (mean ± SD, ng/mL: 1620 ± 538 vs 1160 ± 452, P = .00032) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,0.25,178339,DB00586,Diclofenac
,25546369,tmax,"When taken under fasting conditions, the oral solution exhibited a 50% faster median tmax (0.25 vs 0.50 hours, P = .00035) to achieve a 77% higher Cmax (mean ± SD, ng/mL: 1620 ± 538 vs 1160 ± 452, P = .00032) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,0.50,178340,DB00586,Diclofenac
,25546369,Cmax,"When taken under fasting conditions, the oral solution exhibited a 50% faster median tmax (0.25 vs 0.50 hours, P = .00035) to achieve a 77% higher Cmax (mean ± SD, ng/mL: 1620 ± 538 vs 1160 ± 452, P = .00032) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],1620,178341,DB00586,Diclofenac
,25546369,Cmax,"When taken under fasting conditions, the oral solution exhibited a 50% faster median tmax (0.25 vs 0.50 hours, P = .00035) to achieve a 77% higher Cmax (mean ± SD, ng/mL: 1620 ± 538 vs 1160 ± 452, P = .00032) compared with the tablet.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],1160,178342,DB00586,Diclofenac
,25546369,tmax,"When taken under fed conditions, the oral solution resulted in a similar median tmax (0.17 vs 0.25 hours, P = .185) and 64% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 1620 ± 538, P < .00001) compared with fasting conditions.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,0.17,178343,DB00586,Diclofenac
,25546369,tmax,"When taken under fed conditions, the oral solution resulted in a similar median tmax (0.17 vs 0.25 hours, P = .185) and 64% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 1620 ± 538, P < .00001) compared with fasting conditions.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),h,0.25,178344,DB00586,Diclofenac
,25546369,Cmax,"When taken under fed conditions, the oral solution resulted in a similar median tmax (0.17 vs 0.25 hours, P = .185) and 64% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 1620 ± 538, P < .00001) compared with fasting conditions.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],506,178345,DB00586,Diclofenac
,25546369,Cmax,"When taken under fed conditions, the oral solution resulted in a similar median tmax (0.17 vs 0.25 hours, P = .185) and 64% lower Cmax (mean ± SD, ng/mL: 506 ± 305 vs 1620 ± 538, P < .00001) compared with fasting conditions.",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],1620,178346,DB00586,Diclofenac
,25546369,tmax,"In comparison, the tablets under fed conditions resulted in a statistically significantly delayed median tmax (1.25 vs 0.50, P = .00143) and ∼30% lower Cmax (mean ± SD, ng/mL: 835 ± 449 vs 1160 ± 452, P = .00377).",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),,1.25,178347,DB00586,Diclofenac
,25546369,tmax,"In comparison, the tablets under fed conditions resulted in a statistically significantly delayed median tmax (1.25 vs 0.50, P = .00143) and ∼30% lower Cmax (mean ± SD, ng/mL: 835 ± 449 vs 1160 ± 452, P = .00377).",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),,0.50,178348,DB00586,Diclofenac
,25546369,Cmax,"In comparison, the tablets under fed conditions resulted in a statistically significantly delayed median tmax (1.25 vs 0.50, P = .00143) and ∼30% lower Cmax (mean ± SD, ng/mL: 835 ± 449 vs 1160 ± 452, P = .00377).",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],835,178349,DB00586,Diclofenac
,25546369,Cmax,"In comparison, the tablets under fed conditions resulted in a statistically significantly delayed median tmax (1.25 vs 0.50, P = .00143) and ∼30% lower Cmax (mean ± SD, ng/mL: 835 ± 449 vs 1160 ± 452, P = .00377).",Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546369/),[ng] / [ml],1160,178350,DB00586,Diclofenac
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.39,178926,DB00586,Diclofenac
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.49,178927,DB00586,Diclofenac
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178928,DB00586,Diclofenac
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178929,DB00586,Diclofenac
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178930,DB00586,Diclofenac
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178931,DB00586,Diclofenac
,29105638,injection volume,"The injection volume was 20μL, detected at 274 nm; flow rate: 1mL/min.",Development & validation of reversed phase HPLC method for quantification of water insoluble API. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105638/),μl,20,179794,DB00586,Diclofenac
,29105638,flow rate,"The injection volume was 20μL, detected at 274 nm; flow rate: 1mL/min.",Development & validation of reversed phase HPLC method for quantification of water insoluble API. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105638/),[ml] / [min],1,179795,DB00586,Diclofenac
,1931476,Cmax,Peak serum drug concentrations as well as the area under the drug concentration-time curve were significantly less during the night compared with the day (Cmax: 1886 +/- s.d 901 vs 2791 +/- 1565 ng ml-1 and AUC: 2807 +/- 1376 vs 3681 +/- 1986 ng ml-1 h).,The relative bioavailability of diclofenac with respect to time of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931476/),[ng] / [ml],1886,179950,DB00586,Diclofenac
,1931476,Cmax,Peak serum drug concentrations as well as the area under the drug concentration-time curve were significantly less during the night compared with the day (Cmax: 1886 +/- s.d 901 vs 2791 +/- 1565 ng ml-1 and AUC: 2807 +/- 1376 vs 3681 +/- 1986 ng ml-1 h).,The relative bioavailability of diclofenac with respect to time of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931476/),[ng] / [ml],2791,179951,DB00586,Diclofenac
,1931476,AUC,Peak serum drug concentrations as well as the area under the drug concentration-time curve were significantly less during the night compared with the day (Cmax: 1886 +/- s.d 901 vs 2791 +/- 1565 ng ml-1 and AUC: 2807 +/- 1376 vs 3681 +/- 1986 ng ml-1 h).,The relative bioavailability of diclofenac with respect to time of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931476/),[h·ng] / [ml],2807,179952,DB00586,Diclofenac
,1931476,AUC,Peak serum drug concentrations as well as the area under the drug concentration-time curve were significantly less during the night compared with the day (Cmax: 1886 +/- s.d 901 vs 2791 +/- 1565 ng ml-1 and AUC: 2807 +/- 1376 vs 3681 +/- 1986 ng ml-1 h).,The relative bioavailability of diclofenac with respect to time of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931476/),[h·ng] / [ml],3681,179953,DB00586,Diclofenac
,24736104,half lives,"The ester's half lives were found to be 8 h, 47 h and 21 min in pH 1, pH 7.4 and plasma, respectively.","Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonylmorpholine Ester of Diclofenac as a Prodrug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24736104/),h,8,181291,DB00586,Diclofenac
,24736104,half lives,"The ester's half lives were found to be 8 h, 47 h and 21 min in pH 1, pH 7.4 and plasma, respectively.","Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonylmorpholine Ester of Diclofenac as a Prodrug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24736104/),h,47,181292,DB00586,Diclofenac
,24736104,half lives,"The ester's half lives were found to be 8 h, 47 h and 21 min in pH 1, pH 7.4 and plasma, respectively.","Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonylmorpholine Ester of Diclofenac as a Prodrug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24736104/),min,21,181293,DB00586,Diclofenac
,12487149,plasma clearance,"In contrast, allometric scaling using in vivo data from the mouse, rat, and rabbit predicted a plasma clearance of 3.5 mL/min/kg, similar to that observed in patients (3.7 mL/min/kg).","Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12487149/),[ml] / [kg·min],3.5,181457,DB00586,Diclofenac
,12487149,plasma clearance,"In contrast, allometric scaling using in vivo data from the mouse, rat, and rabbit predicted a plasma clearance of 3.5 mL/min/kg, similar to that observed in patients (3.7 mL/min/kg).","Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12487149/),[ml] / [kg·min],3.7,181458,DB00586,Diclofenac
below,30445374,half-life,"Following a pharmacokinetic analysis, the drug was well absorbed and distributed in the pigeons with a half-life below 6 h.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),h,6,182110,DB00586,Diclofenac
above,30445374,half-life,"A toxicokinetic evaluation in quails showed poisoning was due to metabolic constraint, with a half-life and mean residence time above 6 h and 8 h respectively resulting in death.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),h,6,182111,DB00586,Diclofenac
,30445374,mean residence time,"A toxicokinetic evaluation in quails showed poisoning was due to metabolic constraint, with a half-life and mean residence time above 6 h and 8 h respectively resulting in death.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),h,8,182112,DB00586,Diclofenac
,30445374,half-life,Toxicity seen in the ducks was however not related to metabolic constraint but hyperuricemia as metabolism was rapid [half-life (1-2 h) and mean residence time (2-3 h)] irrespective of survival or death.,Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),h,1-2,182113,DB00586,Diclofenac
,30445374,mean residence time,Toxicity seen in the ducks was however not related to metabolic constraint but hyperuricemia as metabolism was rapid [half-life (1-2 h) and mean residence time (2-3 h)] irrespective of survival or death.,Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),h,2-3,182114,DB00586,Diclofenac
,30445374,oral median lethal dose (LD50),"Despite succumbing to diclofenac, the established oral median lethal dose (LD50) of 405.42 mg/kg and 189.92 mg/kg in Japanese quails and Muscovy ducks respectively from this study were substantially higher than those reported for Gyps vultures (0.098 mg/kg) which is as a result of the rapid elimination of the drug from the body in the former species.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),[mg] / [kg],405.42,182115,DB00586,Diclofenac
,30445374,oral median lethal dose (LD50),"Despite succumbing to diclofenac, the established oral median lethal dose (LD50) of 405.42 mg/kg and 189.92 mg/kg in Japanese quails and Muscovy ducks respectively from this study were substantially higher than those reported for Gyps vultures (0.098 mg/kg) which is as a result of the rapid elimination of the drug from the body in the former species.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),[mg] / [kg],189.92,182116,DB00586,Diclofenac
,30445374,oral median lethal dose (LD50),"Despite succumbing to diclofenac, the established oral median lethal dose (LD50) of 405.42 mg/kg and 189.92 mg/kg in Japanese quails and Muscovy ducks respectively from this study were substantially higher than those reported for Gyps vultures (0.098 mg/kg) which is as a result of the rapid elimination of the drug from the body in the former species.",Could the environmental toxicity of diclofenac in vultures been predictable if preclinical testing methodology were applied? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30445374/),[mg] / [kg],0.098,182117,DB00586,Diclofenac
,7742793,total clearance (CL),"In the group without EHC by means of bile cannulation, the total clearance (CL) markedly decreased by CCl4-intoxication from 0.7 l/h/kg down to 0.1 l/h/kg, and mean residence time (MRT) increased from 0.29 h up to 2.8 h.",Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),[l] / [h·kg],0.7,182266,DB00586,Diclofenac
,7742793,total clearance (CL),"In the group without EHC by means of bile cannulation, the total clearance (CL) markedly decreased by CCl4-intoxication from 0.7 l/h/kg down to 0.1 l/h/kg, and mean residence time (MRT) increased from 0.29 h up to 2.8 h.",Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),[l] / [h·kg],0.1,182267,DB00586,Diclofenac
,7742793,mean residence time (MRT),"In the group without EHC by means of bile cannulation, the total clearance (CL) markedly decreased by CCl4-intoxication from 0.7 l/h/kg down to 0.1 l/h/kg, and mean residence time (MRT) increased from 0.29 h up to 2.8 h.",Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),h,0.29,182268,DB00586,Diclofenac
,7742793,mean residence time (MRT),"In the group without EHC by means of bile cannulation, the total clearance (CL) markedly decreased by CCl4-intoxication from 0.7 l/h/kg down to 0.1 l/h/kg, and mean residence time (MRT) increased from 0.29 h up to 2.8 h.",Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),h,2.8,182269,DB00586,Diclofenac
,7742793,bile excretion ratio,The bile excretion ratio of diclofenac markedly decreased by CCl4-intoxication from 43% down to 13%.,Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),%,43,182270,DB00586,Diclofenac
,7742793,bile excretion ratio,The bile excretion ratio of diclofenac markedly decreased by CCl4-intoxication from 43% down to 13%.,Influence of laparotomy on disposition kinetics of diclofenac in CCl4-intoxicated rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742793/),%,13,182271,DB00586,Diclofenac
,23057661,EE%,"Maximum EE% of 95%, 94% and 93% were obtained for SLMs formulated with SRMS 1:1, 2:1 and 1:2, respectively.",Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23057661/),%,95,183092,DB00586,Diclofenac
,23057661,EE%,"Maximum EE% of 95%, 94% and 93% were obtained for SLMs formulated with SRMS 1:1, 2:1 and 1:2, respectively.",Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23057661/),%,94,183093,DB00586,Diclofenac
,23057661,EE%,"Maximum EE% of 95%, 94% and 93% were obtained for SLMs formulated with SRMS 1:1, 2:1 and 1:2, respectively.",Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23057661/),%,93,183094,DB00586,Diclofenac
>,15100180,mean plasma concentrations,"Lumiracoxib was rapidly absorbed, achieving mean plasma concentrations >1 microg/ml within 1 h of dosing.",Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),[μg] / [ml],1,183734,DB00586,Diclofenac
,15100180,terminal half-life,The terminal half-life of lumiracoxib in plasma was 6.5 h.,Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),h,6.5,183735,DB00586,Diclofenac
,15624028,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 1503.9 ng/ml (diclofenac alone) and 1742.5 ng/ml (diclofenac and ranitidine).",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[ng] / [ml],1503.9,184954,DB00586,Diclofenac
,15624028,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 1503.9 ng/ml (diclofenac alone) and 1742.5 ng/ml (diclofenac and ranitidine).",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[ng] / [ml],1742.5,184955,DB00586,Diclofenac
,15624028,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 0.85 hrs, and 0.82 hrs, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),h,0.85,184956,DB00586,Diclofenac
,15624028,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 0.85 hrs, and 0.82 hrs, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),h,0.82,184957,DB00586,Diclofenac
,15624028,areas under the curve (AUC0-6),"The areas under the curve (AUC0-6) were 1479.9 ng x hr/ml and 1650.3 ng x hr/ml, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[h·ng] / [ml],1479.9,184958,DB00586,Diclofenac
,15624028,areas under the curve (AUC0-6),"The areas under the curve (AUC0-6) were 1479.9 ng x hr/ml and 1650.3 ng x hr/ml, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[h·ng] / [ml],1650.3,184959,DB00586,Diclofenac
,22677306,Cmax,"However, the geometric mean Cmax for the 25 mg liquid capsule was almost double that of 2 × 12.5 mg tablets (1,058.2 vs. 564.5 ng/ml), while the median tmax was 5 minutes faster with the 25 mg liquid capsule and the geometric mean AUCtmax ref for the 25 mg liquid capsule (133.0 ng×h/ml) was much higher than for 2 × 12.5 mg tablets (91.6 ng×h/ml).","Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677306/),[ng] / [ml],"1,058.2",185120,DB00586,Diclofenac
,22677306,Cmax,"However, the geometric mean Cmax for the 25 mg liquid capsule was almost double that of 2 × 12.5 mg tablets (1,058.2 vs. 564.5 ng/ml), while the median tmax was 5 minutes faster with the 25 mg liquid capsule and the geometric mean AUCtmax ref for the 25 mg liquid capsule (133.0 ng×h/ml) was much higher than for 2 × 12.5 mg tablets (91.6 ng×h/ml).","Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677306/),[ng] / [ml],564.5,185121,DB00586,Diclofenac
,22677306,AUCtmax ref,"However, the geometric mean Cmax for the 25 mg liquid capsule was almost double that of 2 × 12.5 mg tablets (1,058.2 vs. 564.5 ng/ml), while the median tmax was 5 minutes faster with the 25 mg liquid capsule and the geometric mean AUCtmax ref for the 25 mg liquid capsule (133.0 ng×h/ml) was much higher than for 2 × 12.5 mg tablets (91.6 ng×h/ml).","Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677306/),[h·ng] / [ml],133.0,185122,DB00586,Diclofenac
,22677306,AUCtmax ref,"However, the geometric mean Cmax for the 25 mg liquid capsule was almost double that of 2 × 12.5 mg tablets (1,058.2 vs. 564.5 ng/ml), while the median tmax was 5 minutes faster with the 25 mg liquid capsule and the geometric mean AUCtmax ref for the 25 mg liquid capsule (133.0 ng×h/ml) was much higher than for 2 × 12.5 mg tablets (91.6 ng×h/ml).","Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677306/),[h·ng] / [ml],91.6,185123,DB00586,Diclofenac
,22677306,AUCtmax ref ratio,"The estimated AUCtmax ref ratio of 25 mg liquid capsule to 2 × 12.5 mg tablets was 143.1%, indicating much higher early exposure to diclofenac from the 25 mg liquid capsule.","Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677306/),%,143.1,185124,DB00586,Diclofenac
,34191301,IC50,In vitro studies with rat blood brain endothelial cells (RBE4) that express MCT1 indicated that diclofenac can inhibit GHB transport with an IC50 of 10.6 μM at pH 7.4.,Drug-drug interaction between diclofenac and gamma-hydroxybutyric acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34191301/),μM,10.6,189209,DB00586,Diclofenac
,23744759,Cmax,"Study 2: Cmax for diclofenac was 2904 and 6031 ng/ml after the first IV dose of 18.75 and 37.5 mg HPβCD-diclofenac, respectively, and was 3090 and 5617 ng/ml after the fourth dose, indicating no accumulation.",Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23744759/),[ng] / [ml],2904,191971,DB00586,Diclofenac
,23744759,Cmax,"Study 2: Cmax for diclofenac was 2904 and 6031 ng/ml after the first IV dose of 18.75 and 37.5 mg HPβCD-diclofenac, respectively, and was 3090 and 5617 ng/ml after the fourth dose, indicating no accumulation.",Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23744759/),[ng] / [ml],6031,191972,DB00586,Diclofenac
,23744759,Cmax,"Study 2: Cmax for diclofenac was 2904 and 6031 ng/ml after the first IV dose of 18.75 and 37.5 mg HPβCD-diclofenac, respectively, and was 3090 and 5617 ng/ml after the fourth dose, indicating no accumulation.",Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23744759/),[ng] / [ml],3090,191973,DB00586,Diclofenac
,23744759,Cmax,"Study 2: Cmax for diclofenac was 2904 and 6031 ng/ml after the first IV dose of 18.75 and 37.5 mg HPβCD-diclofenac, respectively, and was 3090 and 5617 ng/ml after the fourth dose, indicating no accumulation.",Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23744759/),[ng] / [ml],5617,191974,DB00586,Diclofenac
,32767766,time to maximum concentration,Diclofenac was rapidly absorbed with a median time to maximum concentration of 15 minutes and a mean peak plasma concentration of 1412 (±846.2) ng/mL.,An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32767766/),min,15,193141,DB00586,Diclofenac
,32767766,peak plasma concentration,Diclofenac was rapidly absorbed with a median time to maximum concentration of 15 minutes and a mean peak plasma concentration of 1412 (±846.2) ng/mL.,An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32767766/),[ng] / [ml],1412,193142,DB00586,Diclofenac
,32767766,half-life,Diclofenac had a half-life of 66.8 (±9.2) minutes.,An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32767766/),min,66.8,193143,DB00586,Diclofenac
,32767766,area under the concentration-time curve from zero to the last measurable time point,"The mean area under the concentration-time curve from zero to the last measurable time point was 82,920.0 (±25,327.6) minutes × ng/mL, and the mean area under the concentration-time curve from time zero to infinity was 84,388.8 (±25,993.6) minutes × ng/mL.",An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32767766/),[min·ng] / [ml],"82,920.0",193144,DB00586,Diclofenac
,32767766,area under the concentration-time curve from time zero to infinity,"The mean area under the concentration-time curve from zero to the last measurable time point was 82,920.0 (±25,327.6) minutes × ng/mL, and the mean area under the concentration-time curve from time zero to infinity was 84,388.8 (±25,993.6) minutes × ng/mL.",An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32767766/),[min·ng] / [ml],"84,388.8",193145,DB00586,Diclofenac
,8058639,absolute bioavailability,"The absolute bioavailability after oral administration of 50 mL buffer, 50 mL water, and 200 mL water solutions were 107, 97, and 109%, respectively, compared to approximately 50% in man.",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),%,107,193640,DB00586,Diclofenac
,8058639,absolute bioavailability,"The absolute bioavailability after oral administration of 50 mL buffer, 50 mL water, and 200 mL water solutions were 107, 97, and 109%, respectively, compared to approximately 50% in man.",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),%,97,193641,DB00586,Diclofenac
,8058639,absolute bioavailability,"The absolute bioavailability after oral administration of 50 mL buffer, 50 mL water, and 200 mL water solutions were 107, 97, and 109%, respectively, compared to approximately 50% in man.",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),%,109,193642,DB00586,Diclofenac
,8058639,absolute bioavailability,"The absolute bioavailability after oral administration of 50 mL buffer, 50 mL water, and 200 mL water solutions were 107, 97, and 109%, respectively, compared to approximately 50% in man.",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),%,50,193643,DB00586,Diclofenac
,8058639,total plasma clearance,The total plasma clearance in minipigs was fivefold slower than in humans (57 +/- 17 vs 252 +/- 54 mL/hr/kg).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),[ml] / [h·kg],57,193644,DB00586,Diclofenac
,8058639,total plasma clearance,The total plasma clearance in minipigs was fivefold slower than in humans (57 +/- 17 vs 252 +/- 54 mL/hr/kg).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),[ml] / [h·kg],252,193645,DB00586,Diclofenac
,8058639,volume of distribution of the central compartment,The volume of distribution of the central compartment was 40% less in humans than in pigs (39 vs 67 mL/kg).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),[ml] / [kg],39,193646,DB00586,Diclofenac
,8058639,volume of distribution of the central compartment,The volume of distribution of the central compartment was 40% less in humans than in pigs (39 vs 67 mL/kg).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),[ml] / [kg],67,193647,DB00586,Diclofenac
,8058639,terminal half-lives,The terminal half-lives of the parent drug were similar in pigs (2.4 hr) and humans (1.8 hr).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),h,2.4,193648,DB00586,Diclofenac
,8058639,terminal half-lives,The terminal half-lives of the parent drug were similar in pigs (2.4 hr) and humans (1.8 hr).,Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),h,1.8,193649,DB00586,Diclofenac
,8058639,Ka,"The rate of oral drug absorption increased in the order of 50 mL aqueous, 200 mL aqueous, and 50 mL buffered solutions (Ka = 0.52 +/- 0.11, 0.59 +/- 0.13, and 1.2 +/- 0.7 hr-1, respectively).",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),1/[h],0.52,193650,DB00586,Diclofenac
,8058639,Ka,"The rate of oral drug absorption increased in the order of 50 mL aqueous, 200 mL aqueous, and 50 mL buffered solutions (Ka = 0.52 +/- 0.11, 0.59 +/- 0.13, and 1.2 +/- 0.7 hr-1, respectively).",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),1/[h],0.59,193651,DB00586,Diclofenac
,8058639,Ka,"The rate of oral drug absorption increased in the order of 50 mL aqueous, 200 mL aqueous, and 50 mL buffered solutions (Ka = 0.52 +/- 0.11, 0.59 +/- 0.13, and 1.2 +/- 0.7 hr-1, respectively).",Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058639/),1/[h],1.2,193652,DB00586,Diclofenac
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],3890,195143,DB00586,Diclofenac
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],233,195144,DB00586,Diclofenac
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],807,195145,DB00586,Diclofenac
,26096889,AUC0-inf,Mean AUC0-inf values for a 50-mg oral tablet and an 18.75-mg intravenous formulation were similar (1308.9 [393.0]) vs 1232.4 [147.6]).,"Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel-group, single-center study in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096889/),,1308.9,195705,DB00586,Diclofenac
,26096889,AUC0-inf,Mean AUC0-inf values for a 50-mg oral tablet and an 18.75-mg intravenous formulation were similar (1308.9 [393.0]) vs 1232.4 [147.6]).,"Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel-group, single-center study in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096889/),,1232.4,195706,DB00586,Diclofenac
,20840388,T(max),"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1,196332,DB00586,Diclofenac
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.70,196333,DB00586,Diclofenac
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.79,196334,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,55.5,196771,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,5.56,196772,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,15.3,196773,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,30.7,196774,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,7.45,196775,DB00586,Diclofenac
,24796327,half-maximal inhibitory concentration (IC50),"The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively.",Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24796327/),nM,20.4,196776,DB00586,Diclofenac
,15569270,AUC ratio,"Concerning the relative extent of absorption, assessed by the AUC ratio (Inflaban/Voltaren) for 12 hr, the average value was found to be 1.00+/-0.09 with a 95% confidence limits (C.L.) of 0.82-1.18.",A two-way cross-over bioequivalence study comparing two products of diclofenac sodium suppositories in healthy human volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569270/),,1.00,197227,DB00586,Diclofenac
,10709153,AUC,"Cirrhotics had a mean +/- SD diclofenac AUC value (19,114 +/- 6806 ng.h/ml) significantly different (p < 0.02) from hepatitis patients (6071 +/- 1867 ng.h/ml) and healthy subjects (7008 +/- 2006 ng.h/ml), whereas healthy subjects and hepatitis patients had similar values.",Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709153/),[h·ng] / [ml],"19,114",198275,DB00586,Diclofenac
,10709153,AUC,"Cirrhotics had a mean +/- SD diclofenac AUC value (19,114 +/- 6806 ng.h/ml) significantly different (p < 0.02) from hepatitis patients (6071 +/- 1867 ng.h/ml) and healthy subjects (7008 +/- 2006 ng.h/ml), whereas healthy subjects and hepatitis patients had similar values.",Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709153/),[h·ng] / [ml],6071,198276,DB00586,Diclofenac
,10709153,AUC,"Cirrhotics had a mean +/- SD diclofenac AUC value (19,114 +/- 6806 ng.h/ml) significantly different (p < 0.02) from hepatitis patients (6071 +/- 1867 ng.h/ml) and healthy subjects (7008 +/- 2006 ng.h/ml), whereas healthy subjects and hepatitis patients had similar values.",Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709153/),[h·ng] / [ml],7008,198277,DB00586,Diclofenac
,26280282,flow rate,"Separation was achieved using a Shimadzu liquid chromatography system with a C18 column and mobile phase acetonitrile/water (60:40 and 70:30 for flavones A and B, respectively) containing 0.2% acetic acid and 0.05% triethylamine at a flow rate of 0.4mL/min and detection at 245nm.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [min],0.4,200441,DB00586,Diclofenac
,26280282,Recovery,"Recovery of concentrations 250, 1000, 2500, 5000, and 100,000ng/mL ranged from 87 to 116% and 84 to 103% (n=3) for flavone A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),%,87 to 116,200442,DB00586,Diclofenac
,26280282,Recovery,"Recovery of concentrations 250, 1000, 2500, 5000, and 100,000ng/mL ranged from 87 to 116% and 84 to 103% (n=3) for flavone A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),%,84 to 103,200443,DB00586,Diclofenac
≥,26280282,peak ratio,Stability of both flavones after a freezing/thawing cycle yielded a mean peak ratio ≥0.92 when compared to freshly extracted samples.,Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),,0.92,200444,DB00586,Diclofenac
,26280282,half-lives,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),min,83.68,200445,DB00586,Diclofenac
,26280282,half-lives,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),min,107.45,200446,DB00586,Diclofenac
,26280282,clearance,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [kg·min],12.99,200447,DB00586,Diclofenac
,26280282,clearance,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [kg·min],80.79,200448,DB00586,Diclofenac
,30782291,withdrawal time,"After a single dose of 2.5 mg/kg body weight per day for continuous 3 days, the withdrawal time in the tissues of liver, kidney, sebum, muscle and administration site were 9.892 days, 5.116 days, 14.205 days, 5.444 days and 8.818 days, respectively.",Pharmacokinetics and residues elimination of diclofenac sodium administration in pigs by a new HPLC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782291/),d,9.892,200456,DB00586,Diclofenac
,30782291,withdrawal time,"After a single dose of 2.5 mg/kg body weight per day for continuous 3 days, the withdrawal time in the tissues of liver, kidney, sebum, muscle and administration site were 9.892 days, 5.116 days, 14.205 days, 5.444 days and 8.818 days, respectively.",Pharmacokinetics and residues elimination of diclofenac sodium administration in pigs by a new HPLC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782291/),d,5.116,200457,DB00586,Diclofenac
,30782291,withdrawal time,"After a single dose of 2.5 mg/kg body weight per day for continuous 3 days, the withdrawal time in the tissues of liver, kidney, sebum, muscle and administration site were 9.892 days, 5.116 days, 14.205 days, 5.444 days and 8.818 days, respectively.",Pharmacokinetics and residues elimination of diclofenac sodium administration in pigs by a new HPLC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782291/),d,14.205,200458,DB00586,Diclofenac
,30782291,withdrawal time,"After a single dose of 2.5 mg/kg body weight per day for continuous 3 days, the withdrawal time in the tissues of liver, kidney, sebum, muscle and administration site were 9.892 days, 5.116 days, 14.205 days, 5.444 days and 8.818 days, respectively.",Pharmacokinetics and residues elimination of diclofenac sodium administration in pigs by a new HPLC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782291/),d,5.444,200459,DB00586,Diclofenac
,30782291,withdrawal time,"After a single dose of 2.5 mg/kg body weight per day for continuous 3 days, the withdrawal time in the tissues of liver, kidney, sebum, muscle and administration site were 9.892 days, 5.116 days, 14.205 days, 5.444 days and 8.818 days, respectively.",Pharmacokinetics and residues elimination of diclofenac sodium administration in pigs by a new HPLC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782291/),d,8.818,200460,DB00586,Diclofenac
,19375262,low flow rate,"A simple mobile phase consisting of 0.1M formic acid, acetonitrile and methanol (43:52:5) was pumped at a low flow rate of 0.3 ml/min through a reverse phase Phenomenex Luna C(18) (2) (5 microm, 150 mm x 2.0mm i.d.) column maintained at 40 degrees C.",Rapid method for the quantitative determination of efavirenz in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19375262/),[ml] / [min],0.3,201343,DB00586,Diclofenac
,19375262,recovery,"Mean recovery based on high, medium and low quality control standards ranged between 92.7 and 94.1% with %RSD values better than 3%.",Rapid method for the quantitative determination of efavirenz in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19375262/),%,92.7 and 94.1,201344,DB00586,Diclofenac
,19516015,settling velocity,The estimated settling velocity of the suspension in the vitreous humor was 3 cm/h.,Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19516015/),[cm] / [h],3,201467,DB00586,Diclofenac
,19516015,elimination half-life,"The elimination half-life of diclofenac suspension was 24 and 18 days in vitreous and retina-choroid, respectively, compared to 2.9 and 0.9 hours observed with diclofenac sodium.",Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19516015/),d,24,201468,DB00586,Diclofenac
,19516015,elimination half-life,"The elimination half-life of diclofenac suspension was 24 and 18 days in vitreous and retina-choroid, respectively, compared to 2.9 and 0.9 hours observed with diclofenac sodium.",Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19516015/),d,18,201469,DB00586,Diclofenac
,19516015,elimination half-life,"The elimination half-life of diclofenac suspension was 24 and 18 days in vitreous and retina-choroid, respectively, compared to 2.9 and 0.9 hours observed with diclofenac sodium.",Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19516015/),h,2.9,201470,DB00586,Diclofenac
,19516015,elimination half-life,"The elimination half-life of diclofenac suspension was 24 and 18 days in vitreous and retina-choroid, respectively, compared to 2.9 and 0.9 hours observed with diclofenac sodium.",Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19516015/),h,0.9,201471,DB00586,Diclofenac
,9056060,"AUC(0,8 h)","Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[h·ng] / [ml],2265,201717,DB00586,Diclofenac
,9056060,"AUC(0,8 h)","Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[h·ng] / [ml],1821,201718,DB00586,Diclofenac
,9056060,Cmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[ng] / [ml],1135,201719,DB00586,Diclofenac
,9056060,Cmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[ng] / [ml],70,201720,DB00586,Diclofenac
,9056060,tmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),h,1.0,201721,DB00586,Diclofenac
,9056060,tmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),h,1.0,201722,DB00586,Diclofenac
,3596865,plasma clearance,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),[ml] / [kg·min],2.85,202817,DB00586,Diclofenac
,3596865,plasma clearance,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),[ml] / [kg·min],3.39,202818,DB00586,Diclofenac
,3596865,plasma terminal half-life of elimination,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),h,0.61,202819,DB00586,Diclofenac
,3596865,plasma terminal half-life of elimination,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),h,0.71,202820,DB00586,Diclofenac
,3596865,apparent volume of distribution,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),[l] / [kg],0.15,202821,DB00586,Diclofenac
,3596865,apparent volume of distribution,"Diclofenac was found to have a plasma clearance of 2.85 +/- 1.03 (s.d.) and 3.39 +/- 1.43 ml min-1 kg-1, a plasma terminal half-life of elimination of 0.61 +/- 0.25 and 0.71 +/- 0.39 h, and an apparent volume of distribution of 0.15 +/- 0.10 and 0.21 +/- 0.13 l kg-1 (the values obtained with the Ciba-Geigy preparation being shown before the Istituto Biochimico Italiano preparation in each case).",Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596865/),[l] / [kg],0.21,202822,DB00586,Diclofenac
,19032726,CL/F,The estimates of CL/F and V(D)/F were 53.98 l h(-1) 70 kg(-1) and 4.84 l 70 kg(-1) respectively.,Population pharmacokinetics of oral diclofenac for acute pain in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032726/),[l] / [70·h·kg],53.98,203105,DB00586,Diclofenac
,19032726,V(D)/F,The estimates of CL/F and V(D)/F were 53.98 l h(-1) 70 kg(-1) and 4.84 l 70 kg(-1) respectively.,Population pharmacokinetics of oral diclofenac for acute pain in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032726/),[l] / [70·kg],4.84,203106,DB00586,Diclofenac
,21682990,limits of detection,"The limits of detection and quantification of diclofenac were 25 and 75 ng/mL, respectively.",HPLC method for determination of diclofenac in human plasma and its application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682990/),[ng] / [ml],25,203905,DB00586,Diclofenac
,21682990,limits of detection,"The limits of detection and quantification of diclofenac were 25 and 75 ng/mL, respectively.",HPLC method for determination of diclofenac in human plasma and its application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682990/),[ng] / [ml],75,203906,DB00586,Diclofenac
,29626440,Michaels-Menten,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼30,208233,DB00586,Diclofenac
,29626440,constant Km,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼30,208234,DB00586,Diclofenac
,29626440,constant Km,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼120,208235,DB00586,Diclofenac
,26497615,total amounts,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[μg] / [cm(2],60.81,212723,DB00586,Diclofenac
,26497615,total amounts,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[μg] / [cm(2],60.86,212724,DB00586,Diclofenac
,26497615,total amounts,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[μg] / [cm(2],27.00,212725,DB00586,Diclofenac
,26497615,maximum plasma concentrations,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[ng] / [ml],275.57,212726,DB00586,Diclofenac
,26497615,maximum plasma concentrations,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[ng] / [ml],281.31,212727,DB00586,Diclofenac
,26497615,maximum plasma concentrations,"In vitro release results, in vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester- over polysorbate-based microemulsions (total amounts of aceclofenac penetrated 60.81±5.97 and 60.86±3.67 vs. 27.00±5.09μg/cm(2), and its maximum plasma concentrations 275.57±109.49 and 281.31±76.76 vs. 150.23±69.74ng/ml for sucrose laurate- and myristate- vs. polysorbate 80-based microemulsions, respectively).",Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497615/),[ng] / [ml],150.23,212728,DB00586,Diclofenac
,27119581,time to achieve peak plasma concentrations,"The median time to achieve peak plasma concentrations of diclofenac was 0.5, 0.25, and 0.75 hours with the softgel capsule, oral solution, and tablet formulations, respectively.",Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27119581/),h,0.5,212779,DB00586,Diclofenac
,27119581,time to achieve peak plasma concentrations,"The median time to achieve peak plasma concentrations of diclofenac was 0.5, 0.25, and 0.75 hours with the softgel capsule, oral solution, and tablet formulations, respectively.",Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27119581/),h,0.25,212780,DB00586,Diclofenac
,27119581,time to achieve peak plasma concentrations,"The median time to achieve peak plasma concentrations of diclofenac was 0.5, 0.25, and 0.75 hours with the softgel capsule, oral solution, and tablet formulations, respectively.",Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27119581/),h,0.75,212781,DB00586,Diclofenac
,19922894,AUC,"The mean (SD) AUC values for the fasted and fed states were 691 (195) and 680 (184) ng x h/mL, respectively, with the 25-mg dose, and 1521 (377) and 1416 (366) ng . h/mL, respectively, with the 50-mg dose, suggesting that the extent of absorption was similar with both dietary conditions at each dose.","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[h·ng] / [ml],691,213923,DB00586,Diclofenac
,19922894,AUC,"The mean (SD) AUC values for the fasted and fed states were 691 (195) and 680 (184) ng x h/mL, respectively, with the 25-mg dose, and 1521 (377) and 1416 (366) ng . h/mL, respectively, with the 50-mg dose, suggesting that the extent of absorption was similar with both dietary conditions at each dose.","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[h·ng] / [ml],680,213924,DB00586,Diclofenac
,19922894,AUC,"The mean (SD) AUC values for the fasted and fed states were 691 (195) and 680 (184) ng x h/mL, respectively, with the 25-mg dose, and 1521 (377) and 1416 (366) ng . h/mL, respectively, with the 50-mg dose, suggesting that the extent of absorption was similar with both dietary conditions at each dose.","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[h·ng] / [ml],1521,213925,DB00586,Diclofenac
,19922894,AUC,"The mean (SD) AUC values for the fasted and fed states were 691 (195) and 680 (184) ng x h/mL, respectively, with the 25-mg dose, and 1521 (377) and 1416 (366) ng . h/mL, respectively, with the 50-mg dose, suggesting that the extent of absorption was similar with both dietary conditions at each dose.","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[h·ng] / [ml],1416,213926,DB00586,Diclofenac
,19922894,C(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[ng] / [ml],1156,213927,DB00586,Diclofenac
,19922894,C(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[ng] / [ml],686,213928,DB00586,Diclofenac
,19922894,C(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[ng] / [ml],2365,213929,DB00586,Diclofenac
,19922894,C(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),[ng] / [ml],1154,213930,DB00586,Diclofenac
,19922894,T(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),h,0.49,213931,DB00586,Diclofenac
,19922894,T(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),h,1.02,213932,DB00586,Diclofenac
,19922894,T(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),h,0.51,213933,DB00586,Diclofenac
,19922894,T(max),"Food intake was associated with decreases in C(max) by nearly half in the 25-mg group (fasted vs fed, 1156 [482] vs 686 [411] ng/mL, respectively; P < 0.05) and the 50-mg group (2365 [1034] vs 1154 [592 ng/mL; P < 0.05) and delayed T(max) in the 25-mg group (0.49 [0.16] vs 1.02 [0.55] hours; P < 0.05) and 50-mg group (0.51 [0.19] vs 1.28 [0.71] hours; P < 0.05).","Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922894/),h,1.28,213934,DB00586,Diclofenac
,10714612,terminal half-life,"Pharmacokinetics of fast release diclofenac were best described by a two-compartment population model, with an estimated terminal half-life of 1.2 hours.",Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714612/),h,1.2,214227,DB00586,Diclofenac
,7785828,half-life,The half-life after single IV or IM administration was around 4.0 hours.,High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785828/),h,4.0,214404,DB00586,Diclofenac
,7785828,half-life,"The half-life, determined between 48 and 96 hours after the last dose, was approximately 26 hours in both groups, and flunixin could be detected in plasma up to 8 days, on average.",High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785828/),h,26,214405,DB00586,Diclofenac
,29914211,IC50,"Honokiol and magnolol inhibited in vitro CYP1A activity (probe substrate: phenacetin) more potently than CYP2C activity (probe substrate: diclofenac): The mean IC50 values of honokiol for the metabolism of phenacetin and diclofenac were 8.59 μM and 44.7 μM, while those of magnolol were 19.0 μM and 47.3 μM, respectively.",Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914211/),μM,8.59,214914,DB00586,Diclofenac
,29914211,IC50,"Honokiol and magnolol inhibited in vitro CYP1A activity (probe substrate: phenacetin) more potently than CYP2C activity (probe substrate: diclofenac): The mean IC50 values of honokiol for the metabolism of phenacetin and diclofenac were 8.59 μM and 44.7 μM, while those of magnolol were 19.0 μM and 47.3 μM, respectively.",Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914211/),μM,44.7,214915,DB00586,Diclofenac
,29914211,IC50,"Honokiol and magnolol inhibited in vitro CYP1A activity (probe substrate: phenacetin) more potently than CYP2C activity (probe substrate: diclofenac): The mean IC50 values of honokiol for the metabolism of phenacetin and diclofenac were 8.59 μM and 44.7 μM, while those of magnolol were 19.0 μM and 47.3 μM, respectively.",Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914211/),μM,19.0,214916,DB00586,Diclofenac
,29914211,IC50,"Honokiol and magnolol inhibited in vitro CYP1A activity (probe substrate: phenacetin) more potently than CYP2C activity (probe substrate: diclofenac): The mean IC50 values of honokiol for the metabolism of phenacetin and diclofenac were 8.59 μM and 44.7 μM, while those of magnolol were 19.0 μM and 47.3 μM, respectively.",Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914211/),μM,47.3,214917,DB00586,Diclofenac
,15324530,oral bioavailability,"Oxaprozin has a high oral bioavailability (95%), with peak plasma concentrations at 3 to 5 hours after dosing.",Oxaprozin: kinetic and dynamic profile in the treatment of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15324530/),%,95,215232,DB00586,Diclofenac
,22164964,Cmax,"For the test and reference formulation, mean Cmax values were 2257.3 (ng/ml) and 2156 (ng/ml), respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[ng] / [ml],2257.3,217633,DB00586,Diclofenac
,22164964,Cmax,"For the test and reference formulation, mean Cmax values were 2257.3 (ng/ml) and 2156 (ng/ml), respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[ng] / [ml],2156,217634,DB00586,Diclofenac
,22164964,AUC(0)tau,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5726.1,217635,DB00586,Diclofenac
,22164964,AUC(0)tau,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5689.9,217636,DB00586,Diclofenac
,22164964,AUC(0)infinity,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5917.8,217637,DB00586,Diclofenac
,22164964,AUC(0)infinity,"The mean AUC(0)tau and AUC(0)infinity were 5726.1 (ng x h/ml) and 5917.8 (ng x h/ml) for the test and 5689.9 (ng x h/ml) and 5967.4 (ng x h/ml) for the reference formulation, respectively.",Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22164964/),[h·ng] / [ml],5967.4,217638,DB00586,Diclofenac
,19299212,Extraction recoveries,Extraction recoveries were 85% for rhein and 70% for aceclofenac.,Simultaneous HPLC-UV determination of rhein and aceclofenac in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299212/),%,85,217701,DB00586,Diclofenac
,19299212,Extraction recoveries,Extraction recoveries were 85% for rhein and 70% for aceclofenac.,Simultaneous HPLC-UV determination of rhein and aceclofenac in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299212/),%,70,217702,DB00586,Diclofenac
,9204774,friability,Hard spherical beads of aluminum alginate and aluminum carboxymethylcellulose with a narrow particle size distribution (1.60 +/- 0.12 and 3.10 +/- 0.20 mm) and low friability (0.5 and 1.4%) respectively were obtained with high yield (80-90%) and a drug content approaching 70-80%.,Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,0.5,218180,DB00586,Diclofenac
,9204774,friability,Hard spherical beads of aluminum alginate and aluminum carboxymethylcellulose with a narrow particle size distribution (1.60 +/- 0.12 and 3.10 +/- 0.20 mm) and low friability (0.5 and 1.4%) respectively were obtained with high yield (80-90%) and a drug content approaching 70-80%.,Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,1.4,218181,DB00586,Diclofenac
,9204774,Kel,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.02,218182,DB00586,Diclofenac
,9204774,Kel,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.3,218183,DB00586,Diclofenac
,9204774,t1/2,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),,34.65,218184,DB00586,Diclofenac
,9204774,t1/2,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),,27.70,218185,DB00586,Diclofenac
,9204774,mean residence time (MRT),"They also showed mean residence time (MRT) values of 9.56 +/- 2.5 and 7.86 +/- 0.54 h, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,9.56,218186,DB00586,Diclofenac
,9204774,mean residence time (MRT),"They also showed mean residence time (MRT) values of 9.56 +/- 2.5 and 7.86 +/- 0.54 h, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,7.86,218187,DB00586,Diclofenac
,9204774,relative bioavailability,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,59.01,218188,DB00586,Diclofenac
,9204774,relative bioavailability,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,47.96,218189,DB00586,Diclofenac
,9204774,Kel,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.044,218190,DB00586,Diclofenac
,9204774,t1/2,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,15.75,218191,DB00586,Diclofenac
,9204774,MRT,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,7.45,218192,DB00586,Diclofenac
,26418414,Cmax,"The Cmax, AUC0-t, and Tmax of CAPSULE were 1.01±0.52 μg/mL, 1.54±0.18 μg·h/mL, and 1.50±1.31 h, respectively.",Pharmacokinetic Study of a Diclofenac Sodium Capsule Filled with Enteric-coated Pellets in Healthy Chinese Volunteers by Liquid Chromatography-electrospray Ionization-tandem Mass Spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26418414/),[μg] / [ml],1.01,220155,DB00586,Diclofenac
,26418414,AUC0-t,"The Cmax, AUC0-t, and Tmax of CAPSULE were 1.01±0.52 μg/mL, 1.54±0.18 μg·h/mL, and 1.50±1.31 h, respectively.",Pharmacokinetic Study of a Diclofenac Sodium Capsule Filled with Enteric-coated Pellets in Healthy Chinese Volunteers by Liquid Chromatography-electrospray Ionization-tandem Mass Spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26418414/),[h·μg] / [ml],1.54,220156,DB00586,Diclofenac
,26418414,Tmax,"The Cmax, AUC0-t, and Tmax of CAPSULE were 1.01±0.52 μg/mL, 1.54±0.18 μg·h/mL, and 1.50±1.31 h, respectively.",Pharmacokinetic Study of a Diclofenac Sodium Capsule Filled with Enteric-coated Pellets in Healthy Chinese Volunteers by Liquid Chromatography-electrospray Ionization-tandem Mass Spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26418414/),h,1.50,220157,DB00586,Diclofenac
,28561421,Cmax,"After the first patch, Cmax was 0.81 ± 0.11 (mean ± S.E.M.) ng/mL (reached 12 hr after patch removal) for diclofenac and 31.3 ± 3.8 ng/mL for flufenamic acid (reached at patch removal), the main metabolite of etofenamate.",Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),[ng] / [ml],0.81,220965,DB00586,Diclofenac
,28561421,Cmax,"After the first patch, Cmax was 0.81 ± 0.11 (mean ± S.E.M.) ng/mL (reached 12 hr after patch removal) for diclofenac and 31.3 ± 3.8 ng/mL for flufenamic acid (reached at patch removal), the main metabolite of etofenamate.",Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),[ng] / [ml],31.3,220966,DB00586,Diclofenac
,28561421,trough plasma concentrations,"After repetitive dosing, trough plasma concentrations after the eighth dose were 1.72 ± 0.32 ng/mL for diclofenac and 48.7 ± 6.6 ng/mL for flufenamic acid.",Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),[ng] / [ml],1.72,220967,DB00586,Diclofenac
,28561421,trough plasma concentrations,"After repetitive dosing, trough plasma concentrations after the eighth dose were 1.72 ± 0.32 ng/mL for diclofenac and 48.7 ± 6.6 ng/mL for flufenamic acid.",Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),[ng] / [ml],48.7,220968,DB00586,Diclofenac
,28561421,Bioavailabilities,Bioavailabilities (single dose) relative to i.m. applications were 0.22 ± 0.04% for diclofenac and 1.15 ± 0.06% for flufenamic acid.,Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),%,0.22,220969,DB00586,Diclofenac
,28561421,Bioavailabilities,Bioavailabilities (single dose) relative to i.m. applications were 0.22 ± 0.04% for diclofenac and 1.15 ± 0.06% for flufenamic acid.,Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561421/),%,1.15,220970,DB00586,Diclofenac
,34011257,globule size,"The optimized formulation exhibited good physical stability, ideal globule size (156±0.4 nm), quick release, better therapeutics, and safety, increase in LD50 (221.9 mg/kg) to that of the commercial counterpart (109.9 mg/kg).",Novel Self-Micro Emulsifying Drug Delivery System for safe intra muscular delivery with improved pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011257/),nm,156,223433,DB00586,Diclofenac
,34011257,LD50,"The optimized formulation exhibited good physical stability, ideal globule size (156±0.4 nm), quick release, better therapeutics, and safety, increase in LD50 (221.9 mg/kg) to that of the commercial counterpart (109.9 mg/kg).",Novel Self-Micro Emulsifying Drug Delivery System for safe intra muscular delivery with improved pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011257/),[mg] / [kg],221.9,223434,DB00586,Diclofenac
,34011257,LD50,"The optimized formulation exhibited good physical stability, ideal globule size (156±0.4 nm), quick release, better therapeutics, and safety, increase in LD50 (221.9 mg/kg) to that of the commercial counterpart (109.9 mg/kg).",Novel Self-Micro Emulsifying Drug Delivery System for safe intra muscular delivery with improved pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011257/),[mg] / [kg],109.9,223435,DB00586,Diclofenac
,11270806,tmax,The corresponding value for tmax was 0.75 (0.00 to approximately 1.00).,Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270806/),,0.75,223989,DB00586,Diclofenac
,22964950,peak concentration,"Immediate release tablets showed rapid genistein absorption, with mean peak concentration of 726 ± 199 ng/mL reached at 0.2 ± 0.0 h.",Oral pharmacokinetic comparison of different genistein tablets in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22964950/),[ng] / [ml],726,224603,DB00586,Diclofenac
,22964950,relative bioavailability,The relative bioavailability of the extended release tablet over the immediate release formulation was estimated to be 134 ± 47% based on the AUCInf values from non-compartmental analysis.,Oral pharmacokinetic comparison of different genistein tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22964950/),%,134,224604,DB00586,Diclofenac
,7667194,hepatic extraction ratio in,"By comparing the reabsorbed amounts in the portal system and in the systemic circulation, the hepatic extraction ratio in vivo (FH) of diclofenac was estimated to be 63%.",Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667194/),%,63,225395,DB00586,Diclofenac
less,1439623,elimination half-lives,Both drugs have elimination half-lives of less than 2 hours and do not accumulate in plasma after recommended doses.,"Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439623/),h,2,225682,DB00586,Diclofenac
,8070327,recirculation ratio (Fc),"In the nonanesthetized group, the recirculation ratio (Fc) and the mean recirculation time (tc) of diclofenac were estimated to be 21.1% and 4.5 hr, respectively.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),%,21.1,226834,DB00586,Diclofenac
,8070327,recirculation time (tc),"In the nonanesthetized group, the recirculation ratio (Fc) and the mean recirculation time (tc) of diclofenac were estimated to be 21.1% and 4.5 hr, respectively.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),h,4.5,226835,DB00586,Diclofenac
,8070327,absorption ratio (Fa),"The absorption ratio (Fa) and the mean absorption time (ta) from the intestinal tract were 52.2% and 4.29 hr, respectively.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),%,52.2,226836,DB00586,Diclofenac
,8070327,mean absorption time (ta),"The absorption ratio (Fa) and the mean absorption time (ta) from the intestinal tract were 52.2% and 4.29 hr, respectively.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),h,4.29,226837,DB00586,Diclofenac
,8070327,total amounts excreted,"The experiments using bile duct cannulation revealed that the total amounts excreted into the bile were 14.4% in the anesthetized group and 40.4% in the nonanesthetized group of rats, and that diclofenac was excreted 95% as the glucuronide form and 5% as the intact form in both groups.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),%,14.4,226838,DB00586,Diclofenac
,8070327,total amounts excreted,"The experiments using bile duct cannulation revealed that the total amounts excreted into the bile were 14.4% in the anesthetized group and 40.4% in the nonanesthetized group of rats, and that diclofenac was excreted 95% as the glucuronide form and 5% as the intact form in both groups.",A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070327/),%,40.4,226839,DB00586,Diclofenac
,24959939,polydispersity index,"The optimized formulation (SLM-4) had particle size of 79.40 ± 0.31 µm, polydispersity index of 0.633 ± 0.190, zeta potential of -63.20 ± 0.12 mV and encapsulation efficiency of 91.2 ± 0.1% with good stability after 8 months of storage.",Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24959939/),,0.633,227553,DB00586,Diclofenac
,24959939,zeta potential,"The optimized formulation (SLM-4) had particle size of 79.40 ± 0.31 µm, polydispersity index of 0.633 ± 0.190, zeta potential of -63.20 ± 0.12 mV and encapsulation efficiency of 91.2 ± 0.1% with good stability after 8 months of storage.",Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24959939/),mv,-,227554,DB00586,Diclofenac
,24959939,zeta potential,"The optimized formulation (SLM-4) had particle size of 79.40 ± 0.31 µm, polydispersity index of 0.633 ± 0.190, zeta potential of -63.20 ± 0.12 mV and encapsulation efficiency of 91.2 ± 0.1% with good stability after 8 months of storage.",Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24959939/),mv,63.20,227555,DB00586,Diclofenac
,24959939,encapsulation efficiency,"The optimized formulation (SLM-4) had particle size of 79.40 ± 0.31 µm, polydispersity index of 0.633 ± 0.190, zeta potential of -63.20 ± 0.12 mV and encapsulation efficiency of 91.2 ± 0.1% with good stability after 8 months of storage.",Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24959939/),%,91.2,227556,DB00586,Diclofenac
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,26,228719,DB00586,Diclofenac
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,0. 5,228720,DB00586,Diclofenac
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],180,228721,DB00586,Diclofenac
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],15.6,228722,DB00586,Diclofenac
,17828713,t(1/2),"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),min,43.83,230476,DB00586,Diclofenac
,17828713,V(d),"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[l] / [kg],0.37,230477,DB00586,Diclofenac
,17828713,Cl,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[ml] / [kg·min],129.21,230478,DB00586,Diclofenac
,17828713,AUC,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[μg] / [min·ml],25.62,230479,DB00586,Diclofenac
,17828713,AUC,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),,20.21,230480,DB00586,Diclofenac
,17828713,t(1/2),"One day after intoxication, when the liver was damaged and regenerating, the metabolism was decreased: diclofenac t(1/2) was increased to 258.21 +/- 30.80 min but V(d) did not change significantly, therefore Cl was reduced to 32.81 +/- 3.38 ml/min kg.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),min,258.21,230481,DB00586,Diclofenac
,17828713,Cl,"One day after intoxication, when the liver was damaged and regenerating, the metabolism was decreased: diclofenac t(1/2) was increased to 258.21 +/- 30.80 min but V(d) did not change significantly, therefore Cl was reduced to 32.81 +/- 3.38 ml/min kg.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[ml] / [kg·min],32.81,230482,DB00586,Diclofenac
,11596282,recovery,The recovery of aceclofenac was 91.3%-96.9%.,[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),%,91.,230940,DB00586,Diclofenac
,11596282,detection limit,The detection limit of the method is 10 ng.,[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),ng,10,230941,DB00586,Diclofenac
,11596282,T1/2 alpha,The mean value of T1/2 alpha and T1/2 beta for aceclofenac were 2.5 min and 137 min respectively.,[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),min,2.5,230942,DB00586,Diclofenac
,11596282,T1/2 beta,The mean value of T1/2 alpha and T1/2 beta for aceclofenac were 2.5 min and 137 min respectively.,[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),min,137,230943,DB00586,Diclofenac
,11596282,Cmax,"Plasma diclofenac concentration, a major metabolite of aceclofenac, reached its maximum at about 110 min, the mean Cmax for diclofenac was 3.2 micrograms.",[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),μg,3.2,230944,DB00586,Diclofenac
,11596282,terminal elimination half-life,The mean terminal elimination half-life for diclofenac was 140 min.,[High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596282/),min,140,230945,DB00586,Diclofenac
,28749581,IC50,Physiologically based pharmacokinetic (PBPK) modeling reproduced the renal clearance of baricitinib and the inhibitory effect of probenecid using the in vitro IC50 value of 4.4 μM.,Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231753,DB00586,Diclofenac
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231754,DB00586,Diclofenac
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,3.8,231755,DB00586,Diclofenac
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.2,231756,DB00586,Diclofenac
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.0,231757,DB00586,Diclofenac
,30905704,diameters,"The average diameters for DFEE-PBCL-TM and DFEE-PCL-TM were 37.2 ± 0.06 and 45.1 ± 0.06 nm, respectively.",Delivery and Biodistribution of Traceable Polymeric Micellar Diclofenac in the Rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30905704/),nm,37.2,231837,DB00586,Diclofenac
,30905704,diameters,"The average diameters for DFEE-PBCL-TM and DFEE-PCL-TM were 37.2 ± 0.06 and 45.1 ± 0.06 nm, respectively.",Delivery and Biodistribution of Traceable Polymeric Micellar Diclofenac in the Rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30905704/),nm,45.1,231838,DB00586,Diclofenac
less,10325547,Plasma levels,Plasma levels were very low (less than 0.1 microg/ml) in all experimental groups.,The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325547/),[μg] / [ml],0,232704,DB00586,Diclofenac
,15153204,formation clearance,"The formation clearance to 4'-hydroxydiclofenac (% CV) and to 5'-hydroxydiclofenac were 8.41 (8.1) and 3.41 (113) l.h(-1) respectively, standardized to a 70 kg person using allometric '1/4 power' models.",Diclofenac and metabolite pharmacokinetics in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [h],8.41,234637,DB00586,Diclofenac
,15153204,formation clearance,"The formation clearance to 4'-hydroxydiclofenac (% CV) and to 5'-hydroxydiclofenac were 8.41 (8.1) and 3.41 (113) l.h(-1) respectively, standardized to a 70 kg person using allometric '1/4 power' models.",Diclofenac and metabolite pharmacokinetics in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [h],3.41,234638,DB00586,Diclofenac
,15153204,Clearance,Clearance by other routes contributed 33.0 (64) l.h(-1) 70 kg(-1).,Diclofenac and metabolite pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [70·h·kg],33.0,234639,DB00586,Diclofenac
,15153204,Elimination clearance,Elimination clearance of hydroxyl metabolites was fixed at 27.5 l.h(-1) 70 kg(-1).,Diclofenac and metabolite pharmacokinetics in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [70·h·kg],27.5,234640,DB00586,Diclofenac
,15153204,volumes of distribution,The volumes of distribution of parent diclofenac and its hydroxyl metabolite were 22.8 (19.0) and 45.3 (l.70) kg(-1).,Diclofenac and metabolite pharmacokinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),1/[kg],22.8,234641,DB00586,Diclofenac
,15153204,volumes of distribution,The volumes of distribution of parent diclofenac and its hydroxyl metabolite were 22.8 (19.0) and 45.3 (l.70) kg(-1).,Diclofenac and metabolite pharmacokinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),1/[kg],45.3,234642,DB00586,Diclofenac
,15153204,absorption half-life,The suppository formulation had an absorption half-life of 0.613 (33.2) h with a lag time of 0.188 (24.9) h.,Diclofenac and metabolite pharmacokinetics in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),h,0.613,234643,DB00586,Diclofenac
,15153204,lag time,The suppository formulation had an absorption half-life of 0.613 (33.2) h with a lag time of 0.188 (24.9) h.,Diclofenac and metabolite pharmacokinetics in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),h,0.188,234644,DB00586,Diclofenac
,15153204,relative bioavailability,The relative bioavailability of the suppository compared with an enteric-coated tablet was 1.26.,Diclofenac and metabolite pharmacokinetics in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),,1.26,234645,DB00586,Diclofenac
,15153204,formation clearance,The formation clearance of the active metabolite 4'-hydroxydiclofenac contributed 19% of total clearance (44.82 l.h(-1) 70 kg(-1)).,Diclofenac and metabolite pharmacokinetics in children. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [70·h·kg],44.82,234646,DB00586,Diclofenac
,15153204,total clearance,The formation clearance of the active metabolite 4'-hydroxydiclofenac contributed 19% of total clearance (44.82 l.h(-1) 70 kg(-1)).,Diclofenac and metabolite pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),[l] / [70·h·kg],44.82,234647,DB00586,Diclofenac
,15153204,maximum concentration,The rectum is a suitable route for administration of diclofenac in children 2-8 year of age and was associated with a higher relative bioavailabilty than enteric-coated tablets and an earlier maximum concentration (50 vs. 108 min).,Diclofenac and metabolite pharmacokinetics in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),min,50,234648,DB00586,Diclofenac
,15153204,maximum concentration,The rectum is a suitable route for administration of diclofenac in children 2-8 year of age and was associated with a higher relative bioavailabilty than enteric-coated tablets and an earlier maximum concentration (50 vs. 108 min).,Diclofenac and metabolite pharmacokinetics in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15153204/),min,108,234649,DB00586,Diclofenac
,17386653,flow rate,"The mobile phase used was methanol-triethylamine (pH 7.0; 0.3% v/v in Milli-Q water) (60:40%, v/v) at a flow rate of 1.0 mL min(-1).",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),[ml] / [min],1.0,235092,DB00586,Diclofenac
,17386653,recovery,"The mean recovery of aceclofenac and IS were 84.62+/-3.23 and 89.19+/-1.57%, respectively and the method was found to be precise, accurate, and specific during the study.",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),%,84.62,235093,DB00586,Diclofenac
,17386653,recovery,"The mean recovery of aceclofenac and IS were 84.62+/-3.23 and 89.19+/-1.57%, respectively and the method was found to be precise, accurate, and specific during the study.",High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386653/),%,89.19,235094,DB00586,Diclofenac
,6361986,Maximum concentrations,"Maximum concentrations ranged from 0.79 to 4.25 micrograms/ml, and were found between 0.5 and 2 hours.",Treatment of juvenile rheumatoid arthritis with diclofenac sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361986/),[μg] / [ml],0.79 to 4.25,236071,DB00586,Diclofenac
,6361986,Renal elimination,Renal elimination of total diclofenac ranged from 5.4 to 10.2% of the oral dose in 6 of the 7 patients.,Treatment of juvenile rheumatoid arthritis with diclofenac sodium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361986/),%,5.4 to 10.2,236072,DB00586,Diclofenac
,21882209,recovery,"The recovery was 90.3-94.7% and 83.3% for fenofibric acid and IS, respectively.",Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),%,90.3-94.7,236086,DB00586,Diclofenac
,21882209,recovery,"The recovery was 90.3-94.7% and 83.3% for fenofibric acid and IS, respectively.",Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),%,83.3,236087,DB00586,Diclofenac
,21882209,Total run time,Total run time for each sample analysis was 2.5 min.,Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),min,2.5,236088,DB00586,Diclofenac
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00586,Diclofenac
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00586,Diclofenac
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00586,Diclofenac
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00586,Diclofenac
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00586,Diclofenac
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00586,Diclofenac
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00586,Diclofenac
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00586,Diclofenac
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00586,Diclofenac
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00586,Diclofenac
,11097147,tmax,"DIC-effervesc shows no lag time, a tmax within 30 min and a double peak of Cmax in 15/24 subjects.",Bioavailability of a new effervescent tablet of diclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097147/),min,30,238303,DB00586,Diclofenac
,11097147,Cmax (arithm,The mean Cmax (arithm. mean +/- SD) for DIC-effervesc is 950+/-341 ng/ml (first Cmax) and for DIC-enteric 1364+/-335 ng/ml.,Bioavailability of a new effervescent tablet of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097147/),[ng] / [ml],950,238304,DB00586,Diclofenac
,11097147,Cmax (arithm,The mean Cmax (arithm. mean +/- SD) for DIC-effervesc is 950+/-341 ng/ml (first Cmax) and for DIC-enteric 1364+/-335 ng/ml.,Bioavailability of a new effervescent tablet of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097147/),[ng] / [ml],1364,238305,DB00586,Diclofenac
,11097147,"AUC0-infinity,","The mean AUC0-infinity, (arithm. mean +/- SD) amounts to 1097+/-210 ng/ml x h for DIC-effervesc and 1262+/-220 ng/ml x h for DIC-enteric.",Bioavailability of a new effervescent tablet of diclofenac. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097147/),[ng] / [h·ml],1097,238306,DB00586,Diclofenac
,11097147,"AUC0-infinity,","The mean AUC0-infinity, (arithm. mean +/- SD) amounts to 1097+/-210 ng/ml x h for DIC-effervesc and 1262+/-220 ng/ml x h for DIC-enteric.",Bioavailability of a new effervescent tablet of diclofenac. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097147/),[ng] / [h·ml],1262,238307,DB00586,Diclofenac
,33602085,Percent relative bioavailability,"Percent relative bioavailability of ACF-l-CYS NG and ACF-UREA NG cocrystals in Wistar rats was found to be 242.05 ± 65.27and 178.93 ± 45.21 respectively, which were significantly higher (ANOVA, P < 0.05) than that of pure ACF.",Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602085/),,242.05,238582,DB00586,Diclofenac
,33602085,Percent relative bioavailability,"Percent relative bioavailability of ACF-l-CYS NG and ACF-UREA NG cocrystals in Wistar rats was found to be 242.05 ± 65.27and 178.93 ± 45.21 respectively, which were significantly higher (ANOVA, P < 0.05) than that of pure ACF.",Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602085/),,178.93,238583,DB00586,Diclofenac
,12833392,flow rate,"The analytes were separated using an acetonitrile-phosphate buffer gradient at a flow rate of 1 mL/min, and UV detection at 282 nm.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),[ml] / [min],1,239549,DB00586,Diclofenac
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,69.1,239550,DB00586,Diclofenac
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,60.9,239551,DB00586,Diclofenac
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,46.9,239552,DB00586,Diclofenac
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,28.4,239553,DB00586,Diclofenac
,12833392,retention times,"The retention times for aceclofenac, diclofenac, 4'-hydroxy-aceclofenac, 4'-hydroxy-diclofenac and ketoprofen (internal standard) were 69.1, 60.9, 46.9, 28.4 and 21.2 min, respectively.",Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12833392/),min,21.2,239554,DB00586,Diclofenac
,531447,terminal elimination half-life,"The investigations on young volunteers show that when the enteric-coated tablets are taken there is a delay in the onset of absorption but thereafter absorption and elimination are rapid, with a terminal elimination half-life of 1.2 hours.",Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/531447/),h,1.2,240699,DB00586,Diclofenac
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],2.07,241166,DB00586,Diclofenac
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],3.21,241167,DB00586,Diclofenac
,32454668,lag phase,"DMP-1 and DMP-2 pellets had 2 hr of drug release and pulsatile, controlled-release pellets had a 6 hr lag phase followed by 12 hr controlled release.",Biopharmaceutical Process of Diclofenac Multi-particulate Systems for Chronotherapy of Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32454668/),h,6,241522,DB00586,Diclofenac
,32454668,maximum concentration,The maximum concentration of DC in plasma was 400.8 ng/mL at 5 hr for DMP-2 and 381.1 ng/mL at 14 hr for DMPP-5.,Biopharmaceutical Process of Diclofenac Multi-particulate Systems for Chronotherapy of Rheumatoid Arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32454668/),[ng] / [ml],400.8,241523,DB00586,Diclofenac
,32454668,maximum concentration,The maximum concentration of DC in plasma was 400.8 ng/mL at 5 hr for DMP-2 and 381.1 ng/mL at 14 hr for DMPP-5.,Biopharmaceutical Process of Diclofenac Multi-particulate Systems for Chronotherapy of Rheumatoid Arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32454668/),[ng] / [ml],381.1,241524,DB00586,Diclofenac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB00586,Diclofenac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB00586,Diclofenac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB00586,Diclofenac
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],234,245012,DB00586,Diclofenac
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],73,245013,DB00586,Diclofenac
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],201,245014,DB00586,Diclofenac
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],4.1,245015,DB00586,Diclofenac
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1670,245385,DB00586,Diclofenac
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1817,245386,DB00586,Diclofenac
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245387,DB00586,Diclofenac
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245388,DB00586,Diclofenac
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,116,245389,DB00586,Diclofenac
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,100,245390,DB00586,Diclofenac
,16300171,tmax,The corresponding value for tmax was 0.75 (0.00 to 1.00).,Bioequivalence of diclofenac injection formulations assessed in Korean males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300171/),,0.75,247888,DB00586,Diclofenac
,15606444,times to maximal plasma concentration (t(max)),Mean (+/- SD) times to maximal plasma concentration (t(max)) of diclofenac were 0.48 +/- 0.28 h (12.5 mg) and 0.93 +/- 0.96 h (25 mg).,Bioavailability of diclofenac potassium at low doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606444/),h,0.48,248547,DB00586,Diclofenac
,15606444,times to maximal plasma concentration (t(max)),Mean (+/- SD) times to maximal plasma concentration (t(max)) of diclofenac were 0.48 +/- 0.28 h (12.5 mg) and 0.93 +/- 0.96 h (25 mg).,Bioavailability of diclofenac potassium at low doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606444/),h,0.93,248548,DB00586,Diclofenac
,15606444,absolute bioavailability,"The absolute bioavailability of diclofenac-K after oral administration did not differ significantly in the 12.5-mg and 25-mg dose group (63.1 +/- 12.6%vs. 65.1 +/- 19.4%, respectively).",Bioavailability of diclofenac potassium at low doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606444/),%,63.1,248549,DB00586,Diclofenac
,15606444,absolute bioavailability,"The absolute bioavailability of diclofenac-K after oral administration did not differ significantly in the 12.5-mg and 25-mg dose group (63.1 +/- 12.6%vs. 65.1 +/- 19.4%, respectively).",Bioavailability of diclofenac potassium at low doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606444/),%,65.1,248550,DB00586,Diclofenac
,29721588,maximum blood concentrations,Diclofenac reached maximum blood concentrations of 2.43 ± 0.9 µg/mL (n = 3) at 0.25 h post-dose with an AUCinf of 3.67 µg h/mL and an effective half-life of 0.86 h (n = 2).,The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[μg] / [ml],2.43,248787,DB00586,Diclofenac
,29721588,AUCinf,Diclofenac reached maximum blood concentrations of 2.43 ± 0.9 µg/mL (n = 3) at 0.25 h post-dose with an AUCinf of 3.67 µg h/mL and an effective half-life of 0.86 h (n = 2).,The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[h·μg] / [ml],3.67,248788,DB00586,Diclofenac
,29721588,effective half-life,Diclofenac reached maximum blood concentrations of 2.43 ± 0.9 µg/mL (n = 3) at 0.25 h post-dose with an AUCinf of 3.67 µg h/mL and an effective half-life of 0.86 h (n = 2).,The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),h,0.86,248789,DB00586,Diclofenac
,29721588,maximum blood concentrations,"In the murinized animals, maximum blood concentrations were determined as 3.86 ± 2.31 µg/mL at 0.25 h post-dose with an AUCinf of 4.94 ± 2.93 µg h/mL and a half-life of 0.52 ± 0.03 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[μg] / [ml],3.86,248790,DB00586,Diclofenac
,29721588,AUCinf,"In the murinized animals, maximum blood concentrations were determined as 3.86 ± 2.31 µg/mL at 0.25 h post-dose with an AUCinf of 4.94 ± 2.93 µg h/mL and a half-life of 0.52 ± 0.03 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[h·μg] / [ml],4.94,248791,DB00586,Diclofenac
,29721588,half-life,"In the murinized animals, maximum blood concentrations were determined as 3.86 ± 2.31 µg/mL at 0.25 h post-dose with an AUCinf of 4.94 ± 2.93 µg h/mL and a half-life of 0.52 ± 0.03 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),h,0.52,248792,DB00586,Diclofenac
,29721588,peak blood concentrations,"In C57BL/6J mice, mean peak blood concentrations of 2.31 ± 0.53 µg/mL were seen 0.25 h post-dose with a mean AUCinf of 2.10 ± 0.49 µg h/mL and a half-life of 0.51 ± 0.49 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[μg] / [ml],2.31,248793,DB00586,Diclofenac
,29721588,AUCinf,"In C57BL/6J mice, mean peak blood concentrations of 2.31 ± 0.53 µg/mL were seen 0.25 h post-dose with a mean AUCinf of 2.10 ± 0.49 µg h/mL and a half-life of 0.51 ± 0.49 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),[h·μg] / [ml],2.10,248794,DB00586,Diclofenac
,29721588,half-life,"In C57BL/6J mice, mean peak blood concentrations of 2.31 ± 0.53 µg/mL were seen 0.25 h post-dose with a mean AUCinf of 2.10 ± 0.49 µg h/mL and a half-life of 0.51 ± 0.49 h (n = 3).",The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721588/),h,0.51,248795,DB00586,Diclofenac
,3369245,lag-time,72.9% of the oral dose was absorbed with an average lag-time of 2.2 h.,[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),h,2.2,248942,DB00586,Diclofenac
,3369245,Peak plasma concentrations,"Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg.",[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),[μg] / [ml],2.9,248943,DB00586,Diclofenac
,3369245,Peak plasma concentrations,"Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg.",[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),[μg] / [ml],2.15,248944,DB00586,Diclofenac
,3369245,half-life,Diclofenac sodium was excreted with an average half-life of 1.15 h.,[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),h,1.15,248945,DB00586,Diclofenac
,18498912,C(max),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[μg] / [ml],10.57,249119,DB00586,Diclofenac
,18498912,C(max),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[μg] / [ml],9.79,249120,DB00586,Diclofenac
,18498912,AUC(0-t),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[h·μg] / [ml],19.95,249121,DB00586,Diclofenac
,18498912,AUC(0-t),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[h·μg] / [ml],19.93,249122,DB00586,Diclofenac
,18498912,AUC(0-infinity),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[h·μg] / [ml],20.75,249123,DB00586,Diclofenac
,18498912,AUC(0-infinity),"No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratios for these parameters as follows: C(max), 10.57 versus 9.79 microg/mL (0.961-1.225); AUC(0-t), 19.95 versus 19.93 microg x h/mL (0.937-1.037); and AUC(0-infinity), 20.75 versus 20.48 microg x h/mL (0.949-1.049).","Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498912/),[h·μg] / [ml],20.48,249124,DB00586,Diclofenac
,23879789,AUC,"The AUC of diclofenac from DICCIC (53.7± 5.8 ug/mL.min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (885.9 ± 124,8 ug/mL.min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ug] / [min·ml],53.7,249456,DB00586,Diclofenac
,23879789,AUC,"The AUC of diclofenac from DICCIC (53.7± 5.8 ug/mL.min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (885.9 ± 124,8 ug/mL.min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ug] / [min·ml],885.9,249457,DB00586,Diclofenac
,23879789,Terminal half-life,"Terminal half-life of diclofenac from DICCIC (50.1 ± 17.2 min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (247.4 ± 100.9 min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),min,50.1,249458,DB00586,Diclofenac
,23879789,Terminal half-life,"Terminal half-life of diclofenac from DICCIC (50.1 ± 17.2 min) was significantly less (Mann Whitney test, p<0.05) than that of diclofenac from diclofenac administration (247.4 ± 100.9 min).",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),min,247.4,249459,DB00586,Diclofenac
,23879789,clearance,"Still the parameters clearance and distribution volume were calculated for diclofenac from diclofenac, whose results were 9.2 ±1.2 mL/min.kg and 3.3 ±1.2 L/kg, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ml] / [kg·min],9.2,249460,DB00586,Diclofenac
,23879789,distribution volume,"Still the parameters clearance and distribution volume were calculated for diclofenac from diclofenac, whose results were 9.2 ±1.2 mL/min.kg and 3.3 ±1.2 L/kg, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],3.3,249461,DB00586,Diclofenac
,23879789,DICCIC,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249462,DB00586,Diclofenac
,23879789,clearance,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[ml] / [kg·min],108.9,249463,DB00586,Diclofenac
,23879789,clearance,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249464,DB00586,Diclofenac
,23879789,distribution volume,"The results of DICCIC from DICCIC administration were 108.9 ± 19.6 mL/min.kg and 7.8 ± 2.4 L/kg for clearance and distribution volume, respectively.",Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879789/),[l] / [kg],7.8,249465,DB00586,Diclofenac
,25311913,T(max),"The T(max) of DF and SMM were reached 1.5 and 5.6 hr after they have been orally administered, respectively, and this was followed by their slow elimination.","Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311913/),h,1.5,249651,DB00586,Diclofenac
,25311913,T(max),"The T(max) of DF and SMM were reached 1.5 and 5.6 hr after they have been orally administered, respectively, and this was followed by their slow elimination.","Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311913/),h,5.6,249652,DB00586,Diclofenac
,25311913,mean absorption times (MATs),"The mean absorption times (MATs) of DF and SMM were 6 and 15 hr, respectively.","Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311913/),h,6,249653,DB00586,Diclofenac
,25311913,mean absorption times (MATs),"The mean absorption times (MATs) of DF and SMM were 6 and 15 hr, respectively.","Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311913/),h,15,249654,DB00586,Diclofenac
,9794502,Topical absorption,Topical absorption was 6.6% of applied dose.,In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9794502/),%,6.6,250362,DB00586,Diclofenac
,9794502,Skin surface residue,Skin surface residue at 24 h was 26 +/- 9.5% dose (remainder assumed lost to clothing and bedding).,In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9794502/),%,26,250363,DB00586,Diclofenac
,27891231,Km,The Km for the dehydrogenation pathway was determined in mouse (Km = 29.5 ± 10.0 μmol/L) and human (Km = 12.7 ± 4.8 μmol/L) liver microsomes.,A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891231/),[μM] / [l],29.5,251074,DB00586,Diclofenac
,27891231,Km,The Km for the dehydrogenation pathway was determined in mouse (Km = 29.5 ± 10.0 μmol/L) and human (Km = 12.7 ± 4.8 μmol/L) liver microsomes.,A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891231/),[μM] / [l],12.7,251075,DB00586,Diclofenac
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB00586,Diclofenac
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB00586,Diclofenac
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00586,Diclofenac
,25499666,T(max),"Median T(max) values were similar between the low-dose SoluMatrix diclofenac 35-mg capsules and the diclofenac potassium IR 50-mg tablets (both, ~1.0 hour).",Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25499666/),h,1.0,253705,DB00586,Diclofenac
,25499666,maximum plasma concentration (C(max)),The mean maximum plasma concentration (C(max)) after the administration of low-dose SoluMatrix diclofenac 35-mg capsules was 26% lower than that with diclofenac potassium IR 50-mg tablets under fasting conditions (868.72 vs 1194.21 ng/mL).,Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25499666/),[ng] / [ml],868.72,253706,DB00586,Diclofenac
,25499666,maximum plasma concentration (C(max)),The mean maximum plasma concentration (C(max)) after the administration of low-dose SoluMatrix diclofenac 35-mg capsules was 26% lower than that with diclofenac potassium IR 50-mg tablets under fasting conditions (868.72 vs 1194.21 ng/mL).,Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25499666/),[ng] / [ml],1194.21,253707,DB00586,Diclofenac
,527637,half-lives,"Individual drug profiles were described by a triexponential function and mean half-lives of the three exponential phases were 0.05, 0.26 and 1.1 h.",The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),h,0.05,253807,DB00586,Diclofenac
,527637,half-lives,"Individual drug profiles were described by a triexponential function and mean half-lives of the three exponential phases were 0.05, 0.26 and 1.1 h.",The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),h,0.26,253808,DB00586,Diclofenac
,527637,half-lives,"Individual drug profiles were described by a triexponential function and mean half-lives of the three exponential phases were 0.05, 0.26 and 1.1 h.",The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),h,1.1,253809,DB00586,Diclofenac
,527637,lag time,"After oral doses of enteric-coated tablets, the lag time between dosing and the appearance of drug in plasma varied between 1.0 and 4.5 h.",The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),h,1.0 and 4.5,253810,DB00586,Diclofenac
,527637,Peak plasma diclofenac levels,Peak plasma diclofenac levels ranged from 1.4 to 3.0 microgram .,The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),μg,1.4 to 3.0,253811,DB00586,Diclofenac
,527637,terminal drug half-life,The mean terminal drug half-life in plasma was 1.8 h after oral doses.,The pharmacokinetics of diclofenac sodium following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/527637/),h,1.8,253812,DB00586,Diclofenac
,23503706,time to maximum concentration (tmax),The time to maximum concentration (tmax) varied from 0.5 to 24 hours (median 12 hours) according to which peak predominated.,The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),h,12,254654,DB00586,Diclofenac
,23503706,maximum concentration (Cmax),"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.22,254655,DB00586,Diclofenac
,23503706,maximum individual Cmax,"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.44,254656,DB00586,Diclofenac
,1626168,lag time (tlag),"The lag time (tlag) for DR is 0.4 h, shorter than for D (2.2 h), which indicates a faster absorption in the upper sections of the gastrointestinal tract.",[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,0.4,254682,DB00586,Diclofenac
,1626168,lag time (tlag),"The lag time (tlag) for DR is 0.4 h, shorter than for D (2.2 h), which indicates a faster absorption in the upper sections of the gastrointestinal tract.",[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,2.2,254683,DB00586,Diclofenac
,1626168,tmax,Also tmax was shorter for Dr (1.9 h) than for D (4.3 h).,[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,1.9,254684,DB00586,Diclofenac
,1626168,tmax,Also tmax was shorter for Dr (1.9 h) than for D (4.3 h).,[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,4.3,254685,DB00586,Diclofenac
,1626168,t1/2 beta,"The diclofenac sodium elimination process from plasma is significantly slower with DR than with D (t1/2 beta = 18.1 h and 2.5 h, respectively).",[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,18.1,254686,DB00586,Diclofenac
,1626168,t1/2 beta,"The diclofenac sodium elimination process from plasma is significantly slower with DR than with D (t1/2 beta = 18.1 h and 2.5 h, respectively).",[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),h,2.5,254687,DB00586,Diclofenac
,1626168,Absolute bioavailability,"Absolute bioavailability of both preparations is about 80%, with great interindividual variations.",[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),%,80,254688,DB00586,Diclofenac
,1626168,Relative bioavailability,Relative bioavailability between DR and D was 91.5%.,[Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1626168/),%,91.5,254689,DB00586,Diclofenac
,8376509,retention times,"The retention times of diclofenac and the internal standard (4'-methoxydiclofenac, CGP-4287) are 6.4 and 7.6 min, respectively.",High-performance liquid chromatographic determination of diclofenac in human plasma using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376509/),min,6.4,255309,DB00586,Diclofenac
,8376509,retention times,"The retention times of diclofenac and the internal standard (4'-methoxydiclofenac, CGP-4287) are 6.4 and 7.6 min, respectively.",High-performance liquid chromatographic determination of diclofenac in human plasma using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376509/),min,7.6,255310,DB00586,Diclofenac
below,8376509,detection limit,The peak height versus plasma concentration is linear over the range 5.0-2000 ng/ml with a detection limit below 2.5 ng/ml.,High-performance liquid chromatographic determination of diclofenac in human plasma using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376509/),,2,255311,DB00586,Diclofenac
,8376509,absolute recovery,The mean absolute recovery of diclofenac using the described assay is 96.5% (n = 24).,High-performance liquid chromatographic determination of diclofenac in human plasma using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376509/),%,96.5,255312,DB00586,Diclofenac
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.094,255638,DB00586,Diclofenac
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.237,255639,DB00586,Diclofenac
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.336,255640,DB00586,Diclofenac
,23735902,Transdermal elimination half-life,"Transdermal elimination half-life was significantly increased from the true value of 3.2h due to depot formation, prolonging complete absorption of the drug.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),h,3.2,255641,DB00586,Diclofenac
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB00586,Diclofenac
,28860715,minimum particle size (PS),"The minimum particle size (PS) and polydispersity index was found to be 112±2.01 nm and 0.165, respectively, using hydroxypropyl methylcellulose (1%, w/w), polyvinylpyrrolidone K30 (1%, w/w) and sodium lauryl sulfate (0.12%, w/w).","Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: formulation optimization, characterization, analgesic and acute toxicity studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28860715/),nm,112,256396,DB00586,Diclofenac
,28860715,polydispersity index,"The minimum particle size (PS) and polydispersity index was found to be 112±2.01 nm and 0.165, respectively, using hydroxypropyl methylcellulose (1%, w/w), polyvinylpyrrolidone K30 (1%, w/w) and sodium lauryl sulfate (0.12%, w/w).","Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: formulation optimization, characterization, analgesic and acute toxicity studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28860715/),,0.165,256397,DB00586,Diclofenac
,28781777,terminal elimination rate constant (λz),"Following i.v. administration of DIC, the terminal elimination rate constant (λz), apparent terminal elimination half-life (t½), area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞), clearance (CL), apparent volume of distribution (Vz), mean residence time (MRT), and apparent volume of distribution at steady state (Vss) were 0.57±0.05 l/h, 1.22±0.11 h, 3356±238 h × ng/ml, 0.60±0.04 l/h, 1.05±0.10 l, 1.05±0.07 h and 0.63±0.07 l, respectively.",A pharmacokinetic study of diclofenac sodium in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28781777/),[l] / [h],0.57,256408,DB00586,Diclofenac
,28781777,apparent volume of distribution at steady state (Vss),"Following i.v. administration of DIC, the terminal elimination rate constant (λz), apparent terminal elimination half-life (t½), area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞), clearance (CL), apparent volume of distribution (Vz), mean residence time (MRT), and apparent volume of distribution at steady state (Vss) were 0.57±0.05 l/h, 1.22±0.11 h, 3356±238 h × ng/ml, 0.60±0.04 l/h, 1.05±0.10 l, 1.05±0.07 h and 0.63±0.07 l, respectively.",A pharmacokinetic study of diclofenac sodium in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28781777/),h,1.05,256409,DB00586,Diclofenac
,28781777,apparent volume of distribution at steady state (Vss),"Following i.v. administration of DIC, the terminal elimination rate constant (λz), apparent terminal elimination half-life (t½), area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞), clearance (CL), apparent volume of distribution (Vz), mean residence time (MRT), and apparent volume of distribution at steady state (Vss) were 0.57±0.05 l/h, 1.22±0.11 h, 3356±238 h × ng/ml, 0.60±0.04 l/h, 1.05±0.10 l, 1.05±0.07 h and 0.63±0.07 l, respectively.",A pharmacokinetic study of diclofenac sodium in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28781777/),l,0.63,256410,DB00586,Diclofenac
,28781777,λz,"Following p.o. administration of DIC, the λz, t½, Cmax, tmax, AUC0-∞, CL, Vz, MRT were: 0.63±0.12 l/h, 1.12±0.18 h, 1272±112 ng/ml, 0.19±0.04 h, 2501±303 h × ng/ml, 0.81±0.10 l/h, 1.29±0.12 l, and 2.70±0.18 h, respectively.",A pharmacokinetic study of diclofenac sodium in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28781777/),[l] / [h],0.63,256411,DB00586,Diclofenac
,28781777,MRT,"Following p.o. administration of DIC, the λz, t½, Cmax, tmax, AUC0-∞, CL, Vz, MRT were: 0.63±0.12 l/h, 1.12±0.18 h, 1272±112 ng/ml, 0.19±0.04 h, 2501±303 h × ng/ml, 0.81±0.10 l/h, 1.29±0.12 l, and 2.70±0.18 h, respectively.",A pharmacokinetic study of diclofenac sodium in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28781777/),h,2.70,256412,DB00586,Diclofenac
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],1051.8,256545,DB00586,Diclofenac
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],335.9,256546,DB00586,Diclofenac
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],11150,256547,DB00586,Diclofenac
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,4,256548,DB00586,Diclofenac
,26512724,Tmax,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,5.3,256549,DB00586,Diclofenac
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,13.3,256550,DB00586,Diclofenac
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,1.8,256551,DB00586,Diclofenac
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,18.7,256552,DB00586,Diclofenac
,9333105,AUC,"In those experiments where concentration versus time profiles were obtained for both probes mean AUC was 532 +/- 197 microg x min x ml(-1) for superficial layers, and 438 +/- 249 microg x min x ml(-1) for deep layers.",Diclofenac concentrations in defined tissue layers after topical administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333105/),[min·μg] / [ml],532,257060,DB00586,Diclofenac
,9333105,AUC,"In those experiments where concentration versus time profiles were obtained for both probes mean AUC was 532 +/- 197 microg x min x ml(-1) for superficial layers, and 438 +/- 249 microg x min x ml(-1) for deep layers.",Diclofenac concentrations in defined tissue layers after topical administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333105/),[min·μg] / [ml],438,257061,DB00586,Diclofenac
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],17.2,258185,DB00586,Diclofenac
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],10.4,258186,DB00586,Diclofenac
,3410601,maximal plasma concentration (Cmax),"After a single oral dose of 100 mg Effekton-100, a mean maximal plasma concentration (Cmax) of 497 +/- 120 ng/ml was obtained after 7.4 h (tmax).",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410601/),[ng] / [ml],497,258330,DB00586,Diclofenac
,3410601,tmax,"After a single oral dose of 100 mg Effekton-100, a mean maximal plasma concentration (Cmax) of 497 +/- 120 ng/ml was obtained after 7.4 h (tmax).",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410601/),h,7.4,258331,DB00586,Diclofenac
,3410601,peak plasma concentration,"After an identical dose of Voltaren-Retard, a peak plasma concentration of 654 +/- 329 ng/ml was obtained after 6.4 h.",Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410601/),[ng] / [ml],654,258332,DB00586,Diclofenac
,3410601,bioavailability,The mean bioavailability of diclofenac from Effekton-100 was 0.97 +/- 0.28 relative to that of Voltaren-Retard.,Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410601/),,0.97,258333,DB00586,Diclofenac
,2281031,lag time,"Finally, the lag time between gastric emptying of the EC tablet and the onset of drug absorption was consistently at 1 hr for all subjects.",Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281031/),h,1,259003,DB00586,Diclofenac
,14730924,delayed-release time T0.1,"In vitro, the delayed-release time T0.1 was 3.1 h, and the pulsed-release time T0.1-0.2 was 1.2 h.",[Studies on diclofenac sodium pulsatile release pellets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730924/),h,3.1,259031,DB00586,Diclofenac
,14730924,pulsed-release time T0.1-0.2,"In vitro, the delayed-release time T0.1 was 3.1 h, and the pulsed-release time T0.1-0.2 was 1.2 h.",[Studies on diclofenac sodium pulsatile release pellets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730924/),h,1.2,259032,DB00586,Diclofenac
,14730924,delayed-release time Tlag,"In vivo, the delayed-release time Tlag was 2.8 h, and the bioavailability was (91 +/- 12)%.",[Studies on diclofenac sodium pulsatile release pellets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730924/),h,2.8,259033,DB00586,Diclofenac
,14730924,bioavailability,"In vivo, the delayed-release time Tlag was 2.8 h, and the bioavailability was (91 +/- 12)%.",[Studies on diclofenac sodium pulsatile release pellets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730924/),%,91,259034,DB00586,Diclofenac
,29128828,half-life,The half-life of betamethasone was 8.5days.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),d,8.5,259718,DB00586,Diclofenac
,29128828,elimination rate constant,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),1/[h],2.49,259719,DB00586,Diclofenac
,29128828,clearance,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),[l] / [d],4.72,259720,DB00586,Diclofenac
,16354407,ED50,"The value of the 50% effective dose for the anti-inflammatory effect of diclofenac sodium (ED50 = 1.14 +/- 0.23 mg kg(-1)) using carrageenan-induced rat paw oedema model, was not modified by the concomitant administration of 30 or 100 mg kg(-1) of CME.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[mg] / [kg],1.14,260480,DB00586,Diclofenac
,16354407,Cmax,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[μg] / [ml],7.08,260481,DB00586,Diclofenac
,16354407,AUC,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),[h·μg] / [ml],12.67,260482,DB00586,Diclofenac
,16354407,tmax,"It was observed that the simultaneous administration of diclofenac sodium and 300 mg kg(-1) of CME decreased significantly the values of Cmax (7.08 +/- 1.42 microg mL(-1)) and AUC (12.67 +/- 2.97 microg h mL(-1)), but not the value of tmax (0.13 (0.1-0.25)h) obtained with the administration of diclofenac alone.",Gastroprotection and effect of the simultaneous administration of Cuachalalate (Amphipterygium adstringens) on the pharmacokinetics and anti-inflammatory activity of diclofenac in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354407/),h,0.13,260483,DB00586,Diclofenac
,18096348,limits of detection,The limits of detection were 2 ng/mL for aceclofenac and 0.2 ng/mL for both diclofenac and 4'-OH-diclofenac.,Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18096348/),[ng] / [ml],2,260658,DB00586,Diclofenac
,18096348,limits of detection,The limits of detection were 2 ng/mL for aceclofenac and 0.2 ng/mL for both diclofenac and 4'-OH-diclofenac.,Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18096348/),[ng] / [ml],0.2,260659,DB00586,Diclofenac
,23567284,flow rate,"The mobile phase was a mixture of acetonitrile and methanol (70:30, v/v) at a flow rate of 1.0 ml/min.",A RP-HPLC method for quantification of diclofenac sodium released from biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23567284/),[ml] / [min],1.0,261140,DB00586,Diclofenac
,23567284,extraction recovery,The extraction recovery of diclofenac sodium in plasma of three quality control (QC) samples was ranged from 81.52% to 95.29%.,A RP-HPLC method for quantification of diclofenac sodium released from biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23567284/),%,81.52,261141,DB00586,Diclofenac
,23567284,extraction recovery,The extraction recovery of diclofenac sodium in plasma of three quality control (QC) samples was ranged from 81.52% to 95.29%.,A RP-HPLC method for quantification of diclofenac sodium released from biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23567284/),%,95.29,261142,DB00586,Diclofenac
,22677305,Cmax,"However, the mean Cmax for the liquid capsules (1,090 ng/ml) was almost double that of the tablets (583 ng/ml) (mean Cmax ratio = 196%, 2-sided 90% CI = (169%, 227%)).","Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),[ng] / [ml],"1,090",262305,DB00586,Diclofenac
,22677305,Cmax,"However, the mean Cmax for the liquid capsules (1,090 ng/ml) was almost double that of the tablets (583 ng/ml) (mean Cmax ratio = 196%, 2-sided 90% CI = (169%, 227%)).","Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),[ng] / [ml],583,262306,DB00586,Diclofenac
,22677305,tmax,Median tmax was ~ 10 min faster with the liquid capsules (0.42 h) compared with the tablets (0.58 h) and AUCtmax ref for the liquid capsules (294 ng×h/ml) was almost double the value for the tablets (158 ng×h/ml).,"Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),h,0.42,262307,DB00586,Diclofenac
,22677305,tmax,Median tmax was ~ 10 min faster with the liquid capsules (0.42 h) compared with the tablets (0.58 h) and AUCtmax ref for the liquid capsules (294 ng×h/ml) was almost double the value for the tablets (158 ng×h/ml).,"Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),h,0.58,262308,DB00586,Diclofenac
,22677305,AUCtmax ref,Median tmax was ~ 10 min faster with the liquid capsules (0.42 h) compared with the tablets (0.58 h) and AUCtmax ref for the liquid capsules (294 ng×h/ml) was almost double the value for the tablets (158 ng×h/ml).,"Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),[h·ng] / [ml],294,262309,DB00586,Diclofenac
,22677305,AUCtmax ref,Median tmax was ~ 10 min faster with the liquid capsules (0.42 h) compared with the tablets (0.58 h) and AUCtmax ref for the liquid capsules (294 ng×h/ml) was almost double the value for the tablets (158 ng×h/ml).,"Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677305/),[h·ng] / [ml],158,262310,DB00586,Diclofenac
,1748542,tmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),h,0.8,262921,DB00586,Diclofenac
,1748542,tmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),h,2.4,262922,DB00586,Diclofenac
,1748542,Cmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [ml],"1,125",262923,DB00586,Diclofenac
,1748542,Cmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [ml],434,262924,DB00586,Diclofenac
,1748542,AUC,"The AUC is not influenced (without food: 1,217 +/- 368 ng/ml x h; with food: 1,037 +/- 267 ng/ml x h).",The influence of food on the absorption of diclofenac as a pure substance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [h·ml],"1,217",262925,DB00586,Diclofenac
,1748542,AUC,"The AUC is not influenced (without food: 1,217 +/- 368 ng/ml x h; with food: 1,037 +/- 267 ng/ml x h).",The influence of food on the absorption of diclofenac as a pure substance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [h·ml],"1,037",262926,DB00586,Diclofenac
,19531931,peak plasma concentrations (Cmax),"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng] / [ml],302,263308,DB00586,Diclofenac
,19531931,peak plasma concentrations (Cmax),"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng] / [ml],749,263309,DB00586,Diclofenac
,19531931,peak plasma concentrations (Cmax),"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng] / [ml],1006,263310,DB00586,Diclofenac
,19531931,peak plasma concentrations (Cmax),"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng] / [ml],902,263311,DB00586,Diclofenac
,19531931,area under the plasma concentration curve,"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng-hour] / [ml],316,263312,DB00586,Diclofenac
,19531931,area under the plasma concentration curve,"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng-hour] / [ml],595,263313,DB00586,Diclofenac
,19531931,area under the plasma concentration curve,"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng-hour] / [ml],1029,263314,DB00586,Diclofenac
,19531931,area under the plasma concentration curve,"PK data for ProSorb-D 12.5-mg liquid, DPSGC 25 mg, DPSGC 50 mg, and diclofenac potassium 50-mg tablet revealed mean peak plasma concentrations (Cmax) of 302, 749, 1006, and 902 ng/mL, respectively, whereas area under the plasma concentration curve values were 316, 595, 1029, and 1166 ng-hour/mL, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),[ng-hour] / [ml],1166,263315,DB00586,Diclofenac
,19531931,times to Cmax (tmax),"Mean times to Cmax (tmax) were 0.49, 0.63, 0.95, and 1.26 h, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),h,0.49,263316,DB00586,Diclofenac
,19531931,times to Cmax (tmax),"Mean times to Cmax (tmax) were 0.49, 0.63, 0.95, and 1.26 h, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),h,0.63,263317,DB00586,Diclofenac
,19531931,times to Cmax (tmax),"Mean times to Cmax (tmax) were 0.49, 0.63, 0.95, and 1.26 h, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),h,0.95,263318,DB00586,Diclofenac
,19531931,times to Cmax (tmax),"Mean times to Cmax (tmax) were 0.49, 0.63, 0.95, and 1.26 h, respectively.",A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531931/),h,1.26,263319,DB00586,Diclofenac
,9200563,onset of action,The onset of action of DFU (about 30 min) is in good agreement with the pharmacokinetic profile of this compound in squirrel monkeys.,A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200563/),min,30,265113,DB00586,Diclofenac
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],95.6,267028,DB00586,Diclofenac
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],160.4,267029,DB00586,Diclofenac
,8513853,maximum plasma concentration,The maximum plasma concentration of isradipine was increased 19.6% during co-administration from 5.06 to 6.05 ng.,Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513853/),ng,5.06,267151,DB00586,Diclofenac
,8513853,maximum plasma concentration,The maximum plasma concentration of isradipine was increased 19.6% during co-administration from 5.06 to 6.05 ng.,Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513853/),ng,6.05,267152,DB00586,Diclofenac
,25362603,peaks,The optimized test tablets (F-2) significantly (p<0.05) exhibited peaks plasma concentration (cmax=237.66±1.98) and extended the peak time (tmax=4.63±0.24).,A simple and rapid approach to evaluate the in vitro in vivo role of release controlling agent ethyl cellulose ether derivative polymer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362603/),,237.66,267572,DB00586,Diclofenac
,25362603,peak time (tmax,The optimized test tablets (F-2) significantly (p<0.05) exhibited peaks plasma concentration (cmax=237.66±1.98) and extended the peak time (tmax=4.63±0.24).,A simple and rapid approach to evaluate the in vitro in vivo role of release controlling agent ethyl cellulose ether derivative polymer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362603/),,4.63,267573,DB00586,Diclofenac
,28744125,polydispersity index (PDI),The optimized nanocrystals had a particle size of 484.7±54.12 nm with a polydispersity index (PDI) of 0.108±0.009.,A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744125/),,0.108,267689,DB00586,Diclofenac
,28744125,Cmax,The in vivo pharmacokinetic data generated showed a statistically significant increase in the Cmax for aceclofenac nanocrystals of 3.75±0.28 µg/mL (for pure unmilled aceclofenac Cmax was 1.96±0.17 µg/mL).,A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744125/),[μg] / [ml],3.75,267690,DB00586,Diclofenac
,28744125,Cmax,The in vivo pharmacokinetic data generated showed a statistically significant increase in the Cmax for aceclofenac nanocrystals of 3.75±0.28 µg/mL (for pure unmilled aceclofenac Cmax was 1.96±0.17 µg/mL).,A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744125/),[μg] / [ml],1.96,267691,DB00586,Diclofenac
,31269359,elimination half-time (T1/2β),"After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),h,1.32,268410,DB00586,Diclofenac
,31269359,area under the curve (AUC),"After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),[h·μg] / [ml],55.50,268411,DB00586,Diclofenac
,31269359,mean residence time (MRT),"After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),h,1.60,268412,DB00586,Diclofenac
,31269359,apparent volume of distribution (Vd),"After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),[l] / [kg],0.50,268413,DB00586,Diclofenac
,31269359,body clearance (CLB),"After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),[l] / [h·kg],0.26,268414,DB00586,Diclofenac
,31269359,peak time (Tmax),"After the single i.m. administration, the pharmacokinetic parameters were as follows: peak time (Tmax) was 1.19±0.26 h; and peak concentration (Cmax) was 11.61±5.99 μg mL-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),h,1.19,268415,DB00586,Diclofenac
,31269359,peak concentration (Cmax),"After the single i.m. administration, the pharmacokinetic parameters were as follows: peak time (Tmax) was 1.19±0.26 h; and peak concentration (Cmax) was 11.61±5.99 μg mL-1.",Pharmacokinetics of diclofenac sodium injection in swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269359/),[μg] / [ml],11.61,268416,DB00586,Diclofenac
,15712910,flow rate,The flow rate was 1.0 mL/min.,[Determination of aceclofenac in human plasma by reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15712910/),[ml] / [min],1.0,270443,DB00586,Diclofenac
,15712910,absolute recovery,The mean absolute recovery was 82.5% and the mean relative recovery was 100.3%.,[Determination of aceclofenac in human plasma by reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15712910/),%,82.5,270444,DB00586,Diclofenac
,15712910,relative recovery,The mean absolute recovery was 82.5% and the mean relative recovery was 100.3%.,[Determination of aceclofenac in human plasma by reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15712910/),%,100.3,270445,DB00586,Diclofenac
,20006565,absolute recovery,The mean absolute recovery for all tested molecules was always found to be close to 100%.,HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006565/),%,100,270692,DB00586,Diclofenac
,11745779,maximum plasma concentration,"The maximum plasma concentration of sodium diclofenac was achieved within 1 h of iontophoresis, and the delivery was proportional to applied current density (371 +/- 141 and 132 +/- 62 microg/L at 0.5 and 0.2 mA/cm(2), respectively).",Pharmacokinetic and local tissue disposition of [14C]sodium diclofenac following iontophoresis and systemic administration in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745779/),[μg] / [l],371,272718,DB00586,Diclofenac
,11745779,maximum plasma concentration,"The maximum plasma concentration of sodium diclofenac was achieved within 1 h of iontophoresis, and the delivery was proportional to applied current density (371 +/- 141 and 132 +/- 62 microg/L at 0.5 and 0.2 mA/cm(2), respectively).",Pharmacokinetic and local tissue disposition of [14C]sodium diclofenac following iontophoresis and systemic administration in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745779/),[μg] / [l],132,272719,DB00586,Diclofenac
,11745779,delivery efficiency,The in vivo delivery efficiency for diclofenac in rabbit was 0.15 mg/mA.h.,Pharmacokinetic and local tissue disposition of [14C]sodium diclofenac following iontophoresis and systemic administration in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745779/),[mg] / [h·ma],0.15,272720,DB00586,Diclofenac
,23829165,absolute bioavailability (F),3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),%,21,273116,DB00586,Diclofenac
<,23829165,t1/2,3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),h,1,273117,DB00586,Diclofenac
,29789008,maximum concentration,"In the pharmacokinetic study, the DF concentration in the synovium after SI-613 administration reached its maximum concentration of 311.6 ng/g on day 1, and gradually declined to 10 ng/g by day 28.","Pharmacological effects of N-[2-[[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]ethyl]hyaluronamide (diclofenac Etalhyaluronate, SI-613), a novel sodium hyaluronate derivative chemically linked with diclofenac. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29789008/),[ng] / [g],311.6,274108,DB00586,Diclofenac
